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Abstract 
Lingli Lu 
Novel Ferrocenyl Peptide Bioconjugates as Anti-Cancer Agents 
 
The aim of this project was to explore the structure-activity relationship (SAR) of novel ferrocenyl 
based anti-cancer bioconjugates. A series of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N- (1’-
ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters and a series of N-
(ferrocenylmethylamino acid)-fluorinated-benzene carboxamide derivatives have been synthesized, 
characterized and biologically evaluated for their anti-proliferative activity on various cancer cell 
lines. 
 
The synthesis of each series of compounds was achieved by coupling the free N-terminus of various 
amino acid and dipeptide esters to the carboxyl group of methyl and ethyl ferrocenyl naphthoic acid 
or the free N-terminus of the ferrocenylmethylamine to the carboxylic acid group of the N-
(fluorobenzoyl)-amino acid using the conventional N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) coupling protocol. All 
compounds were fully characterized by a combination of spectroscopic techniques, including 1H, 13C 
and 19F NMR, IR, UV-Vis and MS.  
 
Biological evaluation was performed in vitro against the human cervical carcinoma cells (ATCC 
HTB-35, SiHa) and human liver cells (ATCC CCL-13, Chang liver, HeLa markers) for N-(1’-alkyl-
6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters and vincristine.  N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester had an IC50 of 8.75 μM on cervical cancer 
cells, which is significantly more cytotoxic than chemotherapeutic medication vincristine. And it has 
low toxicity against Chang liver cells. The results can suggest that there are differences in 
susceptibilities to novel ferrocenyl amino acid and dipeptide bioconjugates toxicity between cervical 
carcinoma and liver cells. Therefore N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl 
ester is a potential anti-cancer agent with selectivity.  
 
Another series of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives 
were tested on the estrogen positive (ER+) breast cancer cell line, MCF-7. N-(ferrocenylmethyl-L-
alanine)-3,4,5-trifluorobenzene carboxamide, N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide and N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene 
carboxamide all have strong anti-proliferative effects, with the IC50 values between 0.57-2.14 μM. 
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Chapter 1 
Cancer, cancer chemotherapy and bioorganometallic anti-cancer agents 
1.1. Cancer 
1.1.1. Introduction 
 
Cancer is the term used to describe a group of diseases characterized by the uncontrolled cell 
proliferation and spread of abnormal cells. It is one of the leading causes of death and disease. 
According to the World Health Organization, it causes one in seven deaths worldwide during the 
year 2012. Worldwide 14.1 million new cancer cases raised in 2012 and it is expected to grow to 
21.7 million with 13 million deaths by 2030. 1  
 
When normal cells are under uncontrolled growth, multiplication and loss of differentiation, cancer 
cells are formed. If the cancer is localized it is said to be benign. If the cancer cells invade other parts 
of the body, it is said to be malignant. Cancer is a complex dynamic human disease. There are more 
than 200 different cancers resulting from different cellular defects, therefore an effective treatment 
against one type may ineffective against another. 
 
The cause of cancer is not clearly defined whereas both external and internal factors can be involved. 
Environmental chemicals (chemical carcinogenesis), radiation (irradiation carcinogenesis, e.g. X-
rays and ultraviolet radiation), lifestyle (smoking, unhealthy diet) and aging (free radicals) can be 
referred as external factors, while immune system defects, genetic mutations, hormones and 
infections (e.g. human papillomavirus HPV) are treated as internal factors. Those factors may act 
together to cause cancer. 
 
5-year survival rate is a useful term used in monitoring progress in the early detection and treatment 
of cancer. The survival statistics vary greatly by the type of cancer and the stage of diagnosis. 
However, higher survival rates can be related with early detection or effective treatment of the cancer 
site. Especially if the cancers can be detected via screening. Female breast cancer and colorectal 
cancer are typical examples. 
2 
 
 
Figure 1. 1: Relative frequency of the most common invasive cancers (including non-melanoma skin 
cancer) diagnosed during 2011-2013 in Ireland. Reported from the National Cancer Registry. 2 
 
 
 
 
Figure 1. 2: Relative frequency for the cancer deaths between 2011 and 2012 in Ireland. Reported 
from the National Cancer Registry. 2 
 
According to the annual report form the national cancer registry, cancer was continuously as the 
second most common cause of death in Ireland after circulatory disease between 2011-2012. Lung, 
colorectal and breast cancers are the top three causes of cancer death whereas prostate, breast and 
colorectal are the most commonly diagnosed invasive cancers (Figure 1.1 and 1.2). 2 
 
The research within this project is focused on the synthesis of N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide esters, and N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides, and their biological evaluation as potential chemotherapeutic agents for the treatment 
of cervical and breast cancer. 
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1.1.2. Cervical cancer 
 
Cervical cancer was reported as the third most common type of cancer in women worldwide and the 
fourth most common cause of female mortality. 3 Cervical cancer begins when healthy cells on the 
cervix surface change and grow out of control, and a mass of tumor is formed. This tumor can be 
benign or cancerous. A benign tumor will not spread into other tissue while cancerous tumor will. 
There are mainly two types of cervical cancer: squamous cell carcinoma and adenocarcinoma. 
Around 80% to 90% of cervical cancers are squamous cell carcinoma, these cancers arise from the 
outer surface cells that cover the cervix. The cancer cells arise in the glandular cells that line the 
lower birth canal, and are named as adenocarcinoma, which contributed to 10%-20% of all cervical 
cancers. 4 
 
A few factors have influence with the development of cervical cancer. Human papillomavirus (HPV) 
infection is the most important risk. 5 There are over 180 types with HPV, HPV16 and HPV18 that 
are most frequently associated with cervical cancer. 6 Women with lowered immune systems have a 
higher risk of cervical cancer development, since the patient is less able to fight cancer. Woman who 
have genital herpes will have a higher risk of developing cervical cancer. Smoking is another factor 
linked to cervical cancer. Women who smoke are more likely to develop cervical cancer. Surgery, 
radiation therapy and chemotherapy are the most common treatments against cervical cancer. 4, 7 
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1.1.3. Breast cancer 
 
Breast cancer is a malignant tumor arising from the cells of the breast, it is the most frequently 
diagnosed cancer in women. Every one woman in eight suffers with breast cancer in the western 
world, and reported as the third most common causes of cancer death with 7.9% death rate between 
2011-2012 in Ireland. 2 Genetic factors, diet and life style are the main causes of breast cancer. 
 
There are many types of breast cancer, the most common types are ductal carcinoma in situ, invasive 
ductal carcinoma and invasive lobular carcinoma. Ductal carcinoma in situ can be diagnosed within 
the breast ducts, it is the type not spread therefore has a higher cure rate. About 80% of invasive 
breast cancers are caused by invasive ductal carcinoma. This cancer starts in a duct of the breast and 
grows into the surrounding tissue. Approximately 10% of invasive breast cancers belongs to invasive 
lobular carcinoma, the cancer starts to spread from the glands of the breast that produce milk. 8 
 
Breast cancer is often referred to as a hormonal cancer, knowing the hormone receptor status is 
important for treatment. Breast cancer cells that have estrogen receptors are called ER-positive 
cancers, the cancer cells have progesterone receptors are referred as PR-positive cancers, and the 
breast cancer cells that have none of the receptors as above are called triple-negative cancer cells. 9 
The hormone receptor-positive patients can use hormone therapy drugs that lower estrogen levels or 
block estrogen receptors, while patients diagnosed as triple-negative can be treated with 
chemotherapy and surgery. 8  
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1.2. Cancer chemotherapy 
 
Cancer can be treated by different approaches. Surgery, radiotherapy and chemotherapy are the 
traditional methods, which can be used alone or in combination. The treatment depends on the 
different stages of cancer and its locations. Surgery and radiotherapy are used to remove, kill or 
damage cancer cells in a specific area whereas chemotherapy can work throughout the whole body. 
In some cases, one or more anti-cancer drugs are used to achieve higher effect. The advantages 
include decreased toxicity, increased efficiency of action and evasion of drug resistance. 10  
 
The drugs used in chemotherapy are cytotoxic, powerful chemicals that are designed to interrupt cell 
replication process and stop cells from growing. There are a few subtypes of anti-cancer agents, 
based on its unique mode of actions. Alkylating agents, anti-metabolites, anti-microtubule agents and 
metallating agents are the typical examples. 
 
 
1.2.1. Alkylating agents 
 
Alkylating agents are highly electrophilic compounds that can react with nucleophilic sites of one or 
both strands in DNA. The main nucleophilic regions of DNA are the N-1 and N-3 of adenine 1, N-3 
of cytosine 2 and in particular N-7 of guanine 3. The alkylation prevents DNA replication and 
transcription, which results in cell death of affected cells.   
 
 
1                        2                      3 
 
Figure 1. 3: Nucleophilic groups on adenine, guanine and cytosine. 
 
The nitrogen mustards were the first alkylating agent used medicinally in 1942. In chlormethine 4, 
the nitrogen atom is able to displace a chloride ion intramolecularly to form the highly electrophilic 
aziridinium ion, the alkylation can take place. 10 
6 
 
 
4 
Dacarbazine 5 is a prodrug which generate a methyldiazonium ion 7 to act as the alkylating agent for 
metastatic melanoma cancer treatment. 11 Dacarbazine undergoes an activation by cytochrome P450 
enzymes in liver. Methyltriazenoimidazole carboxamide forms and spontaneously degrades to AIC 
(5-aminoimidazole-4-carboxamide) 6 and the methyldiazonium ion 7. This active ion reacts with 
RNA or DNA mainly at 7-position of guanine. 
 
 
5                      6                    7 
 
Figure 1. 4: Formation of AIC and methyldiazonium ion from dacarbazine. 
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1.2.2. Anti-metabolites  
 
Anti-metabolites are a type of anti-cancer agent that can disrupt DNA function via inhibition of the 
enzymes involved in the synthesis of DNA or its nucleotide building blocks. 10 
 
 
8 
 
5-Fluorouracil 8 inhibits thymidylate synthase. It forms a suicide substrate by irreversibly binding to 
the active site of the enzyme and disrupting the thymidine synthesis. Therefore, replication and cell 
division are blocked. 
 
 
9                             10 
 
Gemcitabine 9 is a widely used chemotherapy medication for several types of cancer treatment, 
including breast cancer, pancreatic cancer, ovarian cancer and non-small cell lung cancer. 12 It was 
patented in 1983 and released to market in 1995. This synthetic pyrimidine nucleoside prodrug is a 
fluorinated analogue of 2-deoxycytidine 10. After transported into the cell, this prodrug will be 
phosphorylated by deoxycytidine kinase to form two active metabolites: gemcitabine diphosphate 
(dFdCDP) and gemcitabine triphosphate (dFdCTP). Gemcitabine diphosphate inhibits the enzyme 
responsible for catalyzing the synthesis of deoxynucleotide triphosphates that is required for DNA 
synthesis, and gemcitabine triphosphate competes with endogenous deoxynucleotide triphosphates 
required in the DNA synthesis. 12 
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1.2.3. Anti-microtubule agents 
 
An anti-microtubule agent is a type of drug that blocks cell growth by stopping mitosis, by interfering 
with the formation of the mitotic spindle required for cell division. Agents acting on microtubules 
may either bind to tubulin and stop polymerisation or bind to the microtubules themselves and 
prevent depolymerisation. Hence inhibits cell dividing and induces cell death. 10 
 
Vincristine 11 and vinblastine 12 are naturally occurring vinca alkaloids. They act as anti-
microtubule agents to treat a number of types of cancers, e.g. small cell lung cancer, acute 
lymphocytic leukaemia and neuroblastoma. 13 
 
     
11                         12 
 
Vindesine 13 is a synthetic vinca alkaloid. It binds to the microtubular proteins of the mitotic spindle, 
leading to crystallization of the microtubule, and mitotic arrest or cell death. 13 
 
 
13 
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1.2.4. Metallating agents (platinum anti-cancer agents)  
 
Since Rosenberg and colleagues found the products of hydrolysis of the platinum electrode can 
inhibit bacterial growth in the 1960s, cisplatin (cis-diamminedichloroplatinum(II)) 14 has been 
extensively studied. 14 Cisplatin and other related platinum-based anti-cancer drugs belong to a class 
of agents called metallating agents. Cisplatin and other platinate derivatives are now commonly used 
as anti-cancer drugs for ovary, testes, head and neck and other cancers’ treatments. 15 
 
 
14 
 
Cisplatin is a square planar complex composed of two ammonia ligands and two chloro substituents 
coordinated to the platinum in cis configuration. The mode of action has been studied. Following 
administration, cisplatin enters the cell, where the environment has a low chloride ion concentration, 
aquated cisplatin acts as a positively charged complex. The highly active electrophilic complexes 
function as metalating agents to target nitrogen atoms of DNA. Indeed, the covalent Pt-DNA links 
within the same strand to form intra-strand bridges. The formation of these DNA-cisplatin adducts 
causes a change in the structure of the double helix therefore disrupts the replication and transcription 
of DNA, halting cancer cell proliferation.  
 
 
Figure 1. 5: Loss of chloro substituents in water and binding with DNA. 10 
 
Despite its huge success, the dose limiting toxicities associated with cisplatin has presented a serious 
concern in clinic. Therefore, different generations of derivatives of cisplatin have been developed. 
 
 
15                                  16 
10 
 
Carboplatin (cis-diammine(1,1-cyclobutanedicarboxylate) platinum(II)) 15, was created by 
substituting the readily exchangeable chloride ligands with a bidentate dicarboxylate ligand. This 
well-known second-generation platinum drug reduces the dose limiting toxicity of cisplatin by 
slowing down the rate of aquation reactions. This anti-cancer drug was released to the market in 1989, 
and used to treat ovarian cancer and non-small cell lung cancer in combination with paclitaxel. 
 
The third-generation platinum complexes were designed to overcome cellular resistance to cisplatin 
and carboplatin. Oxaliplatin (1, 2-diaminocyclohexane platinum(II) oxalate) 16 is a successful one 
approved in 1999. It also has great potential as a treatment option after failure of cisplatin or 
carboplatin therapy with less toxicity. Oxaliplatin is used for colorectal cancer treatment, typically 
along with folinic acid and 5-fluorouracil 8.  
 
A group of octahedral Pt(IV) complexes were called as fourth-generation platinum complexes. 
These complexes are prodrugs are eventually transformed into Pt (II) complexes, due to the reduction 
of Pt (IV) and loss of axial ligands. Satraplatin 17 is an orally bioavailable platinum chemotherapeutic 
agent belonging to this group. 
 
 
17 
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1.3. Bioorganometallic chemistry and organometallic anti-cancer agents 
 
Compounds contain metals (e.g. Fe, Rh, Ru and Ti) have appeared as chemotherapeutic agents with 
anti-proliferative and anti-neoplastic properties in recent years. 16 Those metal-containing substances 
can be divided into two types: organometallic and metal-organic compounds. Metal atom covalently 
bound to carbon atoms of organic ligands, such as, ferrocene 18 and its derivatives, are defined as 
organometallic compounds; metal-organic compounds refer to heteroatoms donates coordinate bond 
to the metal accepters, like cisplatin 14 and its derivatives in clinical use.  
 
 
1.3.1. Ferrocene 
 
The orange compound ferrocene which is also called di (ŋ5-cyclopentadienyl) iron (II) was first 
isolated in 1951 by two independent research groups, Kealy and Pauson and Miller et al. 17  Both 
groups noted that it was an air-stable, water insoluble and nontoxic compound with good redox 
properties. The d orbitals of the central iron atom overlap with π-electrons of p orbitals of the two 
parallel cyclopentadienyl rings, by forming π-complexation, resulting in the famous “sandwich” 
structure. This “sandwich” structure was confirmed by Ernst Fischer and Geoffrey Wilkinson 
through chemical, physical, spectroscopic and X-ray crystallography methods 17. Based on this, 
Wilkinson and Fischer shared the Nobel Prize for Chemistry in 1973 for their work in organometallic 
chemistry. 
 
Ferrocene can be viewed as consisting of an Fe2+ ion (six valence d-electrons) bonded with two 
electron rich, aromatic cyclopentadienyl anions (six π-electron species each), all valence shell 
electrons are paired and obey the 18-electron rule, and leaves the anti-bonding orbitals unpopulated, 
resulting in a stable diamagnetic compound. The bonding within ferrocene is illustrated as Figure 1.6 
(the semi-quantitative molecular orbital diagram), 12 paired electrons (a1g, a2u, e1g and e1u) are in 
strong bonding orbitals, which leaves 6 electrons (e2g and a1g*) in the non-bonding orbitals. The 
HOMO of ferrocene is a1g* while LUMO is e1g*. These electrons in the high energy level, non-
bonding orbitals are crucial for redox behaviour of ferrocene. 
12 
 
 
Figure 1. 6: The semi-quantitative molecular orbital diagram of ferrocene (D5d symmetry 
assignments). 
 
 
The aromatic character of the ferrocene rings facilitates electrophilic substitution due to six π-
electrons delocalized over five carbon atoms. The two main mechanistic routes for electronic 
substitution of ferrocene are shown in scheme 1.1. In the first mechanism, the electrophile interacts 
with the iron atom and transferred to the aromatic ring, and undergoes deprotonation. While in the 
second mechanism, the electrophile directly adds the ring and deprotonated by losing H+ without 
direct metal participation. 
 
 
 
 
 
 
Scheme 1. 1: Two main electrophilic substitution mechanisms for ferrocene. 
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There are six electrons in the high energy non-bonding orbitals, one electron can be easily removed 
to yield the ferricenium cation, which is a typical free-radical possessing an unpaired electron. 
 
 
   Ferrocene       Ferricenium cation 
18 
 
Scheme 1. 2: One-electron transfer in the ferrocene/ferricenium system. 
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1.3.2. Ferricenium salts 
 
Nowadays, ferrocene and its derivatives attract special attention for cancer treatment 18-20. Reports 
have shown that ferrocene derivatives are highly active in vitro against several types of cancer cell 
lines 21. Because of its unique properties, like aromaticity, low toxicity, kinetic stability, relatively 
lipophilic and redox activity. It has been wildly incorporated in drug design.  
Preparation of water-soluble ferrocenyl derivatives that have anti-cancer activity has attracted much 
attention. 22 Koepf-Maier is one of the pioneers in this field. 23. His group compared ferrocene and 
some ferricenium salts with different counter anions against mice bearing Ehrlich ascites tumor 
(EAT). It was observed that the neutral ferrocene complex lacked anti-tumor efficacy against EAT, 
whereas the ferricenium tetrachloroferrate, [Cp2Fe]+[FeCl4]- 19 with survival rate up to 83% against 
CH 1 human ovarian carcinoma cells. 23  
X- = [FeCl4]-                        
19                                      
                                                    
Soon after, a series of ferrocenylalkylazoles were synthesized by Popova et al. and analyzed in vivo. 
For compound 20, it presented up to 100% of tumor growth inhibition and 45% regression. The 
success of this compound was attributed to several reasons: the hydrophilic benzotriazolyl group 
facilitates transportation in aqueous media and the lipophilic ferrocenyl moiety provides permeability 
into the cell membrane; the swinging alkyl bridge allows the ligand-receptor complex formation; and 
the planar heterocyclic ring can intercalate between the planes of DNA nucleic bases. 24 
 
 
20 
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1.3.3. Ferrocifen type anti-cancer agents 
 
Tamoxifen (Tam) 21 is an estrogen receptor antagonist present in breast tissue. It can metabolize to 
form its metabolite hydroxytamoxifen (OH-Tam) 22. This hydroxylated form produced in vivo binds 
competitively to the estrogen receptor binding site to produce an anti-estrogenic effect, therefore 
tamoxifen has anti-proliferative effect. 25 The selective estrogen receptor modulators (SERMs) is 
commonly used in the endocrine therapy to treat with hormone-dependent breast cancers. The breast 
cancer cells have estrogen receptor (ER) are classified as ER positive cells [ER (+)], and the cancer 
cells do not express ER are referred as ER negative cells [ER(-)]. 25 
 
21                      22 
 
Ferrocifen is a ferrocenyl derivative of tamoxifen. Over the past decade, ferrocifen anti-cancer agents 
have been extensively studied by Jaouen’s group. 26 The ferrocifens 23 (Fc-OH-Tam) and 24 (Fc-
diOH) derived from hydroxytamoxifen (OH-Tam) 22 are among the earliest organometallic SERMs 
(selective estrogen receptor modulators). 26, 27 Compound 23 exhibits a strong anti-proliferation effect 
on both hormone-dependent and hormone-independent breast cancer cells. With IC50 as 0.8 μM and 
0.5 μM on MCF-7 and MDA-MB-231 cells respectively. Since the corresponding purely organic 
form shows antiestrogenic activity only on hormone-dependent cancer cells (MCF-7), a dual mode 
of ferrocifens action was suggested by Jaouen and co-workers: the anti-cancer pathway in the body 
depends both on the unique properties of ferrocene moiety, and mimic structure like tamoxifen. 28 
 
23 , R = O(CH2)2N(CH3)2                24,  R = OH  
16 
 
With the aim to seek related molecules that may have higher anti-cancer efficacy than 23, and to 
understand their mechanism of action, several series of ferrocifens have been designed and studied. 
27 28 29 30 31 
 
         
25                     26 
 
Compounds possess the [3]-ferrocenophane motif stand out with their excellent anti-cancer activity. 
Molecules 25 possesses a direct linkage between the cyclopentadienyl ring and the double bond, 
while in 26, the ferrocenyl is symmetrically linked to the double bond by a methylene bridge. 
Compound 25 showed an exceptional anti-proliferative effect on the hormone-independent MDA-
MB-231 and PC-3 cells, both with an IC50 value of 0.09 μM. This compound is eight times more 
active than compound 23. 32 Compound 26 had a weaker toxicity than 25, with an IC50 as 0.96 and 
1.08 μM on MDA-MB-231 and PC-3 cell lines. Cyclic voltammetry experiments were performed by 
Plazuk et al. for both compounds 25 and 26 to understand the possible mechanism. The cytotoxic 
effect of those ferrocenyl phenols is based on the in situ transformation to a quinone methide (QM). 
The intramolecular proton coupled electron transfer from the phenol to the ferricenium in 25 was due 
to the π-delocalized mechanism. For unconjugated 26, the electron transfer proceeds via the 
formation of an intermediate α-methylene radical, which can delocalize over the π system and 
undergo oxidation step to yield the QM. 32 
 
Jaouen’s group proposed that the ferrous cation undergoes a Fenton-type reaction to generate free 
hydroxyl radicals, the active metabolite hydroxyferrocifen is readily oxidized to yield a quinone 
methide (QM) intermediate. 29 These reactive intermediates undergo nucleophilic attack by 
nucleophiles and react with glutathione or nucleobases to generate toxicity. Scheme 1.3 is the 
mechanism of the redox activation of ferrocifens proposed by Jaouen and co-workers. The arrows 
indicate the position readily attacked by nucleophiles. 21 33 
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Scheme 1. 3: Redox activation of ferrocifens proposed by Jaouen and co-workers.  
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1.3.4. ROS-mediated mechanisms of ferrocenyl derivatives as anti-cancer agents 
 
Reactive oxygen species (ROS) are defined as reactive chemical species containing oxygen which is 
mainly divided into a type of free radicals and another type has unpaired electrons in outer molecular 
orbitals. Due to its highly reactive property, free radicals can react with biological molecules. A slight 
rise of ROS level in cells may lead to short-lived cellular alteration, while a severe increase could 
result in irreversible oxidative damage leading to cell death. Consequently, it is crucial for normal 
cells to maintain ROS homeostasis. 34 
Recent studies suggest that cancer tissue is known to be in an oxidative stress state. Most cancer cells 
exhibit high aerobic glycolysis, and are more vulnerable to damage by exogenous agents through 
increased ROS level. 34 Therefore, increasing the concentration of ROS may vanquish cancer cells 
by leaving the normal cells unaffected. Combining with the character of cancer cells, modulation of 
ROS production in cell is a way to selectively destroy cancer cells with no significant toxicity to 
normal cells.  
The redox properties of ferrocene in biological systems have been considered as one of the main 
reasons for ferrocenyl derivatives as an anti-cancer candidate. Many studies showed that the Fe (II) 
ferrocenyl compounds have higher activity than Fe (III) ones. 21 The ferrocifens bind with ERβ 
protein to form ferrocifen-ERβ complexes will attach to a specific region of DNA, and the generation 
of highly reactive hydroxyl radicals from H2O2 through oxidizing Fe2+ into Fe3+. This could damage 
the binding site of DNA strand, resulting in anti-proliferative effect. 33, 35 Overall, the high activity 
of ferrocene compounds relies on its good redox properties and the formation of ∙OH radicals to 
damage the cancer cell, represent anti-proliferative effects. 
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1.3.5. Ferrocenyl amino acid and peptide bioconjugates as anti-cancer agents 
 
 
 
A series of N-(ferrocenylmethyl)fluorobenzene-carboxamide derivatives were prepared by Kelly et 
al. using standard peptide coupling procedures. 36 By replacing hydrogen with fluorine, the 4-fluoro 
derivative 27 shows strongest anti-proliferative effect on MDA-MB-435-S-F breast cancer cell with 
an IC50 value between 11-14 µM. A dose-dependent relationship observed when tested 27 against a 
wider range of concentrations (1-40 μM). 36 
 
27 
Butler et al. prepared a series of N-(ferrocenylmethyl amino acid) fluorinated benzene carboxamide 
derivatives using glycine and alanine as linkers, found compound N-(ferrocenylmethyl-L-alanine)-3, 
4, 5-trifluorobenzene carboxamide 28 is the most active one against MCF-7 cancer cells, with an IC50 
value of 2.84 µM. 37 The position and the number of fluorine atoms on the aromatic ring were also 
investigated. 3,4,5-Trifluoro and 2,3,4,5,6-pentafluoro analogues were identified as having a higher 
inhibitory effect on the MCF-7 cell line. 37 
20 
 
 
28 
A series of N-(ferrocenyl) benzoyl dipeptide esters have been extensively studied and have shown to 
be highly active in vitro. N-{ortho-(ferrocenyl)-benzoyl}-glycine ethyl ester and its starting material 
ortho-ferrocenyl ethyl benzoate were both tested against H1299 non-small cell lung cancer (NSCLC) 
cell line. Results showed that the derivative has anti-cancer activity (IC50 = 48 µM) whereas its 
starting material was completely inactive. Therefore, more derivatives were designed to have higher 
anti-cancer activity. Savage et al. prepared a series of N-{meta-(ferrocenyl)-benzoyl} dipeptides, 
containing L-alanine as the first amino acid in the peptide chain. The derivative with L-alanine-
glycine ether ester had an IC50 value as 21 µM. 38 
 
29 
Corry et al. prepared N-ortho, meta and para ferrocenyl benzoyl amino acid and dipeptide derivatives, 
N-{meta-(ferrocenyl)-benzoyl}-glycine-L-alanine ethyl ester 29 found to be the most active one with 
IC50 of 4.0 μM in H1299 cells, whilst the ortho and para derivatives had a higher IC50 values of 5.3 
µM and 6.6 µM. These results indicate that the orientation around the benzoyl linker is not a crucial 
factor for bioactivity. Cell cycle analysis was performed on the cells treated with control sample and 
test compound N-{ortho-(ferrocenyl)-benzoyl}-glycine-L-alanine ethyl ester at different 
concentrations (5, 10, 20, 40 µM). As the concentration of test compound  increase, the percentage 
of cells in G1 phase decreases, suggesting a block in the G2/M phase. 39   
The peptide region of the compounds has been extensively studied by Corry et al., 40 N-(ferrocenyl) 
benzoyl tripeptide and tetrapeptide ethyl ester derivatives were designed to have higher cytotoxicity, 
21 
 
however they showed a negative effect on cytotoxicity by extending the peptide chain. The N-{ortho-
(ferrocenyl) benzoyl}-glycine-glycine-glycine ethyl ester had an IC50 value of 63 µM against H1299 
cancer cells whereas the tetra-glycine analogue did not show IC50 value within 1-100 µM 
concentration range. Thus, a dipeptide chain is required for optimum activity. 40 
Higher activities were reported by Mooney et al. via replacing the benzoyl conjugate with a 
naphthoyl linker. A series of N-(ferrocenyl) naphthoyl amino acid and dipeptide ethyl esters were 
prepared. 41 N-(6-ferrocenyl-2-naphthoyl) derivatives were found to be significantly more active: N-
(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester having an IC50 of 1.3 μM against H1299 
lung cancer lines, which was three times more active than the N-{ortho-(ferrocenyl) benzoyl}-
glycine-L-alanine ethyl ester. The N-(6-ferrocenyl-2-naphthoyl) derivatives were tested in H1299 
cells, with amino acid and peptide and IC50 as: γ-aminobutyric acid ethyl ester (IC50 = 0.62 µM), 
glycine-glycine methyl ester (IC50 = 0.3 µM), glycine-D-alanine ethyl ester (IC50 = 0.33 µM) and 
glycine-glycine ethyl ester 30 (IC50 = 0.13 µM). 42  
 
30 
It is worth investigating the mechanisms of action for those highly active N-(6-ferrocenyl-2-
naphthoyl) derivatives. Cell cycle analysis was performed on control samples and H1299 cells treated 
with the most active compound 30, at concentrations of 0.5 µM and 1.0 µM. A significant increase 
in the sub-G0/G1 population and decrease in the cells number in the S phase were detected after 48 
hours at 0.5 µM, the similar observations were made following incubation for 72 hours. At higher 
concentration of 1.0 µM, similar trends recorded, and due to the higher concentration, the increase 
in the sub-G0/G1 and S phase cell population were reported. Thus, the exposure of H1299 cells with 
30 leads to an accumulation of hypodiploid. This finding suggests that compound 30 most likely 
induces apoptosis in H1299 cells since apoptotic cells are characterized by DNA fragmentation and 
consequently a decrease in nuclear DNA content. 43 Oxidation studies were carried out to investigate 
if compound 30 is capable of causing oxidative damage to guanine. 8-Oxo-Gua concentrations were 
consistently higher than control levels confirming that oxidation is Fenton-mediated. 43 
22 
 
 
31                      32                  33  
As an extension of structure-activity relationship study, disubstituted derivatives of N-
(ferrocenyl)benzoyl amino acid and dipeptide esters were prepared. The alkyl group is thought to be 
important in further decreasing the redox potential of these compounds. Results show they have a 
greater cytotoxicity than the monosubstituted ones. The most active analogues are 1-methyl-1’-N-
{para-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester 31, 1-ethyl-1’-N-{para-(ferrocenyl)-
benzoyl}-glycine-glycine ethyl ester 32 and 1-propyl-1’-N-{para-(ferrocenyl)-benzoyl}-glycine-
glycine ethyl ester 33 with IC50 values as 2.8 ± 1.23, 3.5 ± 0.82 and 5.4 ± 1.21 μM in H1299 cell line, 
respectively. Therefore, the bioactivity decreases with the longer alkyl chains. 44 
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1.3.6. Other ferrocenyl derivatives in cancer research 
 
Topoisomerase II is an important enzyme that unwinds DNA to facilitate in nuclear replication, 
transcription and repair process, this behaviour was highly regulated in normal cells. In cancer cells, 
high levels of topoisomerase II exist, therefore inhibiting topoisomerase II actions will lead to 
chromosomal aberrations, followed by cell death. Thus, developing isoform-specific topoisomerase 
II inhibitors has become interest for researchers. Kondopi and co-workers reported a series of 
ferrocenyl derivatives act as topoisomerase II inhibitors, 1, 1’-dicarboxaldoxime of ferrocene was a 
powerful topoisomerase II inhibitor 45. This complex has a strong anti-proliferative activity against 
Colon 205 adenocarcinoma 45. It was proposed that the interaction between nitrogen and oxygen with 
the topoisomerase II enzyme is the key for anti-cancer activities. Meanwhile, azalactone ferrocene 
34 and thiomorpholide amido methyl ferrocene 35 are potential inhibitors. These two compounds 
interacted with topoisomerase II and inhibited its activity causing genetic implications. 46 
            
                     34                               35 
Retinoids are a class of chemicals that are vitamers of vitamin A. Retinoids have many important 
functions throughout the body including roles in vertebrate bone growth, supporting cell 
differentiation and immune response 47. Retinoids can incorporate ferrocenyl derivatives to form anti-
tumor agents. The actions are mediated through binding and activation of the retinoic acid receptors 
or retinoid X receptors. Compound 36 was tested against three types of human cancer cell line: lung 
cancer cell (A549), liver cancer cell line (BEL7404) and tongue cancer cell line (Tca) and it was 
found that the ferrocenyl analogues have modest IC50 values in the range of 19 to 40 µM against all 
those cell lines. 48 
 
36 
24 
 
Illudin M 37 is a fungal cytotoxin that belongs to a family of sesquiterpenes, produced by some 
mushrooms. Although the illudins are highly active against various tumors, their extreme toxicity 
has prevented clinical applications. Schobert and co-workers have prepared a series of compounds 
attached to illudins. Bis(illudinyl M) 1,1’-ferrocenedioate 38 was much less toxic and displayed 
better anti-cancer selectivity than its parent Illudin M.49 These improvements may be due to the 
shielding function of ferrocene and avoiding attack at the enone group by glutathione. 
       
            37                                    38 
 
Metallocenes with Fe and Ru metal centers have also shown anti-cancer activity. There are two 
reasons for the promising anti-tumor activity: firstly, ruthenium has accessible range of oxidation 
states (II, III and IV) under physiological conditions; secondly, ruthenium complexes spontaneously 
accumulate in rapidly dividing cells. 
 
39 
Ott et al. prepared compound 39, which has an ethylene linker between ferrocene and ruthenium 
complexes. When evaluated against colon and breast cancer cells, similar anti-tumor activity to 
cisplatin was reported. The high bioactivity may relate to the enhanced electron delocalization than 
corresponding monometallic ruthenium compounds. 50 
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1.4. Conclusions 
 
Cancer is a major cause of death worldwide; breast and cervical cancer are two main cancers causing 
of female mortality. The use of chemotherapeutic agents was restricted by severe toxicity and 
spontaneous or acquired resistance. Therefore, new therapeutic agents for cancer chemotherapy are 
constantly required. 
Organometallic agents have recently been found to be promising anti-cancer drug candidates, due to 
organometallics having a great structural variety and far more diverse stereochemistry than organic 
compounds. Furthermore, they are kinetically stable, relatively lipophilic and their metal atom is in 
a low oxidations state. The medicinal application of ferrocene derivatives has become a thriving area 
of anti-cancer research 51. Ferrocenyl compounds contain a [3]-ferrocenophane motif express anti-
proliferative effect in breast and prostate cancer cell lines, 32 and the ferrocenyl tamoxifen derivatives 
have promising anti-cancer activity, against both ER(+) and ER(-) breast cancer cell lines. 29 52 Kenny 
et al. synthesizing a series of novel ferrocene derivatives with anti-cancer activity. Therefore, a 
continued investigation is required.  
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Chapter 2 
Synthesis and structural characterisation of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-
(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 
2.1. Introduction 
 
Organometallic complexes have been successfully incorporated in a wide variety of materials that 
with diverse applications. Platinum coordination compounds, such as cisplatin, carboplatin and 
oxaliplatin are widely used in the cancer treatment. However, they exhibit many disadvantages such 
as poor selectivity, cross-resistance, acquired resistance and severe side effects. 1 Therefore, new 
metal-based therapeutic agents for cancer chemotherapy are constantly required.  
 
Recently, ferrocene is a particularly attractive candidate for incorporation into biomolecules and 
biologically active compounds for biological applications due to its aromatic nature, redox properties, 
stability and low toxicity.2 Ferrocene derivatives has been shown to have antiparasitic 3, antibacterial 
3, 4, antifungal 5 and indeed anti-cancer 6 activity. Ferrocene itself is not cytotoxic, however its 
derivatives, for example ferricenium salts, are known to inhibit tumor growth. The ability to form 
reactive oxygen species under physiological conditions that lead to the oxidative damage of DNA 
and other biomolecules is thought to be important to their mode of action. Jaouen et al. have prepared 
the earliest organometallic SERMs (selective estrogen receptor modulators), named ferrocifens. 
They have antiproliferative on both hormone-dependent (MCF-7) and hormone-independent (MDA-
MB-231) breast cancer cell lines. 7  
 
Kenny’s research group have shown the conjugation of amino acids and peptides with ferrocene 
complexes offers a desirable and alternative method to target cancer cells. 6 Mooney and Tiedt et al. 
have presented N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives that have excellent 
anti-proliferative activity in the lung cancer cell lines H1299 and A549 and the melanoma cell lines 
Sk-Mel-28, HT-144, MalMe-3M and Lox-IMVI.8 Compounds 30, 40-43 all showed activity greater 
than that of cisplatin against H1299 cell line (Table 2.1).  
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Table 2.1: IC50 values for the most active compounds in the N-(6-ferrocenyl-2-naphthoyl) series 
against H1299 cell line. 
 
Compound No. IC50 (μM) 
Cisplatin 14 1.50 ± 0.10 
N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 40 0.62 ± 0.07 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 41 0.30 ± 0.04 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 30 0.13 ± 0.02 
N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 42 1.30 ± 0.10 
N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 43 0.33 ± 0.02 
 
 
The aim of this research is synthesis, characterization and biological evaluation the disubstituent 
derivatives of N-(ferrocenyl) naphthoyl amino acid and dipeptide (Figure 2.1) for further structure-
activity relationship study. Four key moieties have been identified for the modification:  
 
(i) A redox active centre 
(ii) A conjugate linker (lowers the oxidation potential of the ferrocene moiety) 
(iii) An alkyl group (further lowers the oxidation potential of the ferrocene moiety) 
(iv) An amino acid or dipeptide ester chain (can interact with other biomolecules via 
hydrogen bonds). 
 
                                                                     
 
R1 = -CH3, -CH2CH3 
R2 = -CH3, -CH2CH3 
 
Figure 2.1: General structures of the N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 62-77. 
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The first region for modification is the ferrocene core of the molecule. The electroactive core has 
been shown to be required for activity. Mooney et al. prepared a N-(2-naphthoyl)-glycine-glycine 
ethyl ester 44 analogue of the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 30. When 
tested at 1 μM against either H1299 lung cancer or Sk-Mel-28 melanoma cell lines, the non-
organometallic analogue did not show any inhibitory effect compared with other dipeptide esters. 
The percentage cell growth was 87.6 ± 18.4 and 95.6 ± 10.9 for H1299 cells and Sk-Mel-28 cells 
respectively. 
 
        
30                     44  
 
Harry et al. synthesized disubstituted derivatives of N-(ferrocenyl)benzoyl amino acid and dipeptide 
esters, by having a methyl, ethyl and propyl group on the previously unsubstituted cyclopentadiene 
ring. The alkyl group is thought to be important in further decreasing the redox potential of these 
compounds. Those novel compounds have shown a greater cytotoxicity than the monosubstituted 
ones. The most active analogues are 1-methyl-1’-N-{para-(ferrocenyl)-benzoyl}-glycine-glycine 
ethyl ester 31, 1-ethyl-1’-N-{para-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester 32 and 1-
propyl-1’-N-{para-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester 33 with IC50 values as 2.8 ± 
1.23, 3.5 ± 0.82 and 5.4 ± 1.21 μM in H1299 cell line, respectively. Since the cytotoxicity of the 
derivatives decreased with the increased size of the alkyl chain, the methyl group and ethyl group 
were maintained for this study.  
 
 
31                    32                    33  
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The second region for consideration is the conjugated linker. Corry et al. prepared N-ortho, meta and 
para ferrocenyl benzoyl amino acid and dipeptide derivatives, N-{ortho-(ferrocenyl)benzoyl} 
glycine-L-alanine ethyl ester 29 found to be the most active one with IC50 of 4.0 μM in H1299 cells1. 
9 Mooney et al. replaced benzoyl linker with a naphthoyl. The naphthoyl spacer is thought to be 
important in decreasing the redox potential of these compounds. Based on commercial availability, 
both N-(3-ferrocenyl-2-naphthoyl) and N-(6-ferrocenyl-2-naphthoyl) derivatives were synthesized. 
It was found that the N-(6-ferrocenyl-2-naphthoyl) derivatives were significantly more active: N-(6-
ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 42 having an IC50 of 1.3 μM which is three 
times more active than the N-{ortho-(ferrocenyl) benzoyl}-glycine-L-alanine ethyl ester 45 (IC50 = 
5.3 μM). Since the introduction of a naphthoyl linker between the redox active ferrocene unit and the 
peptide chain has been shown to dramatically enhance the anti-proliferative effect of the ferrocenyl-
peptide bioconjugates, this unit was retained for further studies.  
 
                
42                                      45  
 
The peptide region of the compounds has been extensively studied 10. An amino acid or dipeptide 
chain have shown to be essential for the cytotoxic activity of the molecule. Methyl-6-
ferrocenylnaphthalene-2-carboxylate 46 was tested against H1299 and Sk-Mel-28 cell lines and 
displayed no activity. 8 Corry et al. have synthesized N-(ferrocenyl)benzoyl tripeptide and 
tetrapeptide derivatives, however increase chain leads to a decrease bioactivity. 10 As shown in table 
2.1, the most active derivatives of the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 
are with single α-amino acid or dipeptide. Therefore, the amino acid and dipeptide groups employed 
in this investigation were maintained as follows: glycine glycine (Gly-Gly), glycine-L-alanine (Gly-
L-Ala), glycine-D-alanine (Gly-D-Ala) and γ-aminobutyric acid (GABA). 
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The final moiety of the compounds which can be modified is the ester protecting group. In this study, 
a series of methyl and ethyl esters were prepared to investigate if ester chain length exerts an 
influence on the cytotoxicity of the molecule. 
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2.2. The synthesis of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl 2-
naphthoyl) amino acid and dipeptide ester derivatives 
 
The N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide esters were prepared via standard peptide coupling methods using the conventional N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS) coupling protocol. A solution of 1’-methyl-6-ferrocenyl-2-naphthoic acid or 1’-ethyl-6-
ferrocenyl-2-naphthoic acid in dichloromethane at 0 °C, was treated with EDC, NHS and 
triethylamine (Et3N) and allowed to stir for 45 minutes. An equimolar amount of the corresponding 
amino acid or dipeptide ester hydrochloride was added to the solution with stirring. The procedure 
is similar to that used for the synthesis of 1-alkyl-1’-N-(ferrocenyl) benzoyl dipeptide esters.11 
Scheme 2.1 outlines the synthetic route employed in the synthesis of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters. 
 
 
(i) NaNO2, HCl, 5 °C; (ii) NaOH, MeOH; (iii) EDC, NHS, Et3N, amino acid or dipeptide 
methyl/ethyl esters. 
Scheme 2.1: The general reaction scheme for the synthesis of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
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2.2.1. Synthesis of the methyl and ethyl ferrocene 
 
 
                        55 
(i) LiAlH4, AlCl3. 
Scheme 2.2: Synthesis of methyl ferrocene 55 through reductive deoxygenation of 
ferrocenecarboxaldehyde. 
 
 
                    56 
(i) LiAlH4, AlCl3. 
Scheme 2.3: Synthesis of ethyl ferrocene 56 through reductive deoxygenation of acetyl ferrocene. 
 
The reductive deoxygenation of acylferrocenes to the corresponding hydrocarbons via the combined 
action of lithium aluminium hydride and the use of the strong Lewis acid aluminium trichloride in 
diethyl ether, is shown in Scheme 2.2 and Scheme 2.3 yielded the desired alkylated ferrocene 
derivatives with percentage yields varying between 86-90 %. 
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2.2.2. Preparation of 1’-methyl and 1’-ethyl-6-ferrocenyl-methyl-2-naphthoates 
 
 
 
Scheme 2.4: Synthesis of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate and 1’-ethyl-6-ferrocenyl-
methyl-2-naphthoate via diazonium coupling reaction. 
 
Methyl 6-aminonaphthalene-2-carboxylate hydrochloride or ethyl 6-aminonaphthalene-2-
carboxylate hydrochloride was treated with sodium nitrite in the presence of hydrochloric acid at a 
temperature below 5 °C to yield the diazonium salt (Scheme 2.4). 
 
 
 
 
 
Scheme 2.5: Diazonium salt formation. 
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The mechanism for the diazonium coupling using 6-amino-2-naphthonic acid is shown in Scheme 
2.6. 6-Amino-2-naphthonic acid was treated with sodium nitrite and converted into the diazonium 
cation. Electrophile chlorine activates the reaction and alkylferrocene present in situ reacts with the 
aryl carbocation via electrophilic aromatic substitution to give the product as an orange solid or a red 
oil. 
 
 
 
Scheme 2.6: The mechanism of diazonium coupling reaction. 
 
At room temperature, by-product 6-hydroxy-2-naphthoic acid formed by reacting aryl carbocation 
with water (Scheme 2.7). Therefore, the reaction should be kept at around 0°C to stabilize the 
diazonium salts.  
 
 
 
 
Scheme 2.7: Stability of diazonium salts. 
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2.2.3. Base hydrolysis 
 
                                        
 
Scheme 2.8: Synthesis of 1’-methyl-6-ferrocenyl-2-naphthoic acid 60 and 1’-ethyl-6-ferrocenyl-2-
naphthoic acid 61. 
 
Base hydrolysis of ferrocenyl carboxylate ester in 10% sodium hydroxide solution effectively 
removes the ester group to produce ferrocenyl carboxylate. In the 1H NMR spectra a broad singlet 
between δ 12.7 to δ 13 indicates the presence of the carboxylic acid proton. Hydrolysis can also be 
monitored by the disappearance of the methyl ester peak from the 1H and 13C NMR spectra. 
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2.2.4. The synthesis of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6 ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters 
 
 
 
Scheme 2.9: Synthesis of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters 62-77. 
 
Table 2.2: Compounds 62-77 synthesized in this study. 
 
R1 R2 Compound No. 
 
 
 
-CH3 
Gly-Gly-OMe 62 
Gly-Gly-OEt 63 
Gly-L-Ala-OMe 64 
Gly-L-Ala-OEt 65 
Gly-D-Ala-OMe 66 
Gly-D-Ala-OEt 67 
GABA-OMe 68 
GABA-OEt 69 
 
 
 
-CH2CH3 
Gly-Gly-OMe 70 
Gly-Gly-OEt 71 
Gly-L-Ala-OMe 72 
Gly-L-Ala-OEt 73 
Gly-D-Ala-OMe 74 
Gly-D-Ala-OEt 75 
GABA-OMe 76 
GABA-OEt 77 
 
EDC/NHS coupling reactions allow introduction of the methyl-ferrocenyl naphthoyl and ethyl-
ferrocenyl naphthoyl group onto an amino acid or dipeptide esters under solution phase peptide 
40 
 
coupling conditions. A solution of 1’-methyl-6-ferrocenyl-2-naphthoic acid or 1’-ethyl-6-ferrocenyl-
2-naphthoic acid in dichloromethane at 0 oC, was treated with N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS) and triethylamine (Et3N) 
and allowed to stir for 45 min. An equimolar amount of the required amino acid or the dipeptide ester 
hydrochloride was added to this solution with stirring at room temperature for 48 hours. The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as an orange solid or an orange oil. 
As showed in Scheme 2.9, the EDC/NHS mediated coupling of the 1’-methyl-6-ferrocenyl-2-
naphthoic acid and 1’-ethyl-6-ferrocenyl-2-naphthoic acid with the dipeptide methyl or ethyl ester 
hydrochloride salts of Gly-Gly, Gly-L-Ala, Gly-D-Ala and GABA, progresses through a formation 
of an unstable intermediate, an O-acylisourea ester. This compound is formed by the reaction of the 
EDC with the 1’-methyl-6-ferrocenyl-2-naphthoic acid or 1’-ethyl-6-ferrocenyl-2-naphthoic acid. 
Attack of the nearby nucleophile on the activated carbon can result in an O to N shift intramolecular 
acyl transfer giving an N-acylurea as a by-product, which can limit product yield and interfere with 
product purification (Scheme 2.10). 
 
 
Scheme 2.10: Intramolecular acyl transfer from O-acylisourea to N-acylurea. 
 
The addition of NHS that act as a secondary nucleophile can stabilizes the O-acylisourea intermediate 
by converting it to an amine-reactive NHS ester, which is a much more stable compound and remains 
reactive with the amine moiety of the amino acid or dipeptide ester hydrochloride salts. Upon 
addition of the amino acid or dipeptide ester hydrochloride salts of Gly Gly, Gly L-Ala, Gly D-Ala 
and GABA, the NHS is displaced resulting in the formation of N-(1'-methyl-6-ferrocenyl-2-
naphthoyl) and N-(1'-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 62-77. 
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Scheme 2.11: Amide bond formation via EDC and NHS coupling.  
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2.3. Purification and yields of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide ester derivatives 
 
The N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide esters were synthesized by the condensation of 1’-methyl-6-ferrocenyl-2-naphthoic 
acid and 1’-ethyl-6-ferrocenyl-2-naphthoic acid with the amino acid or dipeptide esters of glycine-
glycine, glycine-L-alanine, glycine-D-alanine and γ-aminobutyric acid, under the standard 
EDC/NHS coupling conditions outlined in Section 2.2. Crude N-(1’-methyl-6-ferrocenyl-2-
naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters were purified 
by column chromatography, using a mixture of hexane and ethyl acetate as the eluent. The purified 
compounds were furnished as orange solids or an orange oil, with yields in the range of 13 % to 60 %, 
shown in Table 2.3. All compounds gave spectroscopic and analytical data in accordance with their 
proposed structures. 
General trend showed the larger the amino acid and dipeptide esters the lower the yield. And yield 
decreases with increasing the size of the alkyl chain in general. The side chains of the reacting amino 
acids or dipeptide and the alkyl chain incorporated can have an influence on the overall yield. γ-
aminobutyric acid ester derivatives gave highest yields due to its simple amino acid structure. Yields 
are lowest in Gly-L-Ala and Gly-D-Ala ester analogues where the side chain of these dipeptides are 
larger than Gly-Gly esters to exert greater steric hindrance.  
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Table 2.3: Percentage yields for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters. 
 
 Compound Name                                 Compound No.  % Yields                                                                                   
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OMe 62    18 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 63    37 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OMe  
 
64    17 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt   65    23 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OMe  
 
66    20 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt   67    15 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe   68    57 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OEt   69 32 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OMe 70    13 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 71    16 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OMe  
 
72    18 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt   73    23 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OMe  
 
74    17 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt   75    15 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe   76    36 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-GABA-OEt   77    60 
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2.4. Infra-red studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-
2-naphthoyl) amino acid and dipeptide derivatives 
 
Almost any compounds which has covalent bonds absorbs various frequencies of electromagnetic 
radiation in the infrared region of the electromagnetic spectrum. This wavelength region lies 
approximately 400 to 800 nm. Compounds can excite to a higher energy state when they absorb 
infrared radiation, and hence various molecular vibrations are induced, e.g. stretching, bending, 
rocking etc. However, only the molecules with bonds have a dipole moment that changes as a 
function of time are capable to absorb this radiation. Symmetric bonds do not absorb infrared 
radiation. Since different types of bond have a different natural frequency of vibrations, these 
localized vibrations can be used for the identification of key functional groups. 12  
 
 
Figure 2.2: IR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63. 
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Table 2.4: IR data for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters. Values are given in cm-1. 
 
Compound No. N-H  C=Oester  C=Oamide I(cm-1) C=Oamide II  
62 3307, 3064 1748 1629, 1603 1600 
63 3300 1740 1630 1608 
64 3290, 3090 1747 1640, 1620 1521 
65 3289, 3079 1733 1640, 1623 1521 
66 3285, 3078 1739 1642, 1625 1521 
67 3286, 3093 1735 1626, 1608 1517 
68 3280 1721 1600 * 
69 3283 1726 1605 * 
70 3303, 3081 1744 1643, 1625 1521 
71 3371, 3350 1723 1644, 1626 1532 
72 3387, 3090 1737 1642, 1627 1529 
73 3315, 3061 1750 1642, 1628 1534 
74 3379, 3090 1734 1642, 1627 1531 
75 3305, 3061 1734 1641, 1627 1532 
76 3274 1730 1622 * 
77 3318 1729 1636 * 
 
* GABA derivatives have only one C=Oamide present 
 
The IR spectra of the N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters were obtained as pure solids (Table 2.4). The spectra of 
these compounds generally showed two bands above 3000 cm-1 that correspond to the presence of 
the secondary amide groups. In the carbonyl region it is usual to observe at least two bands for 
primary and secondary amides. Amide I band that near 1650 cm-1 arises mainly from the C=O 
stretching vibration with minor contribution form the out-of-phase C-N stretching vibration, the C-
C-N deformation or the NH in-phase bend. The one at lower frequency is the out-of-phase 
combination of the NH in phase bend and CN stretching vibration; which is called the amide II band 
that typically lying between 1600 and 1500 cm-1. In the carbonyl region, the carbonyl attached to the 
ester moiety (C=Oester) usually appears between 1720-1750 cm-1 whilst carbonyl attached to the NH 
(C=Oamide) appears between 1600-1640 cm-1.  
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2.5. UV-Vis studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives 
 
Most organic molecules and functional groups absorb wavelengths in the range from 190 to 800 nm. 
The transitions result in the absorption of electromagnetic radiation in this region corresponding to 
transitions between electronic energy levels. An electron is promoted from an occupied orbital to an 
unoccupied orbital of greater potential since the molecule absorbs quantized energy. Generally, the 
most probable translation is form the highest occupied molecular orbital (HOMO) to the lowest 
unoccupied molecular orbital (LUMO). For most molecules, the lowest-energy occupied molecular 
orbitals are the σ orbitals, π orbitals lie at higher energy levels and orbitals hold unshared pairs n lie 
at even higher energies. The antibonding orbitals π* and σ* are the orbitals with highest energy. 
 
 
 
Figure 2.3: UV-Vis data for selected N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid 
methyl ester 68 and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 75. 
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Table 2.5: UV-Vis data for selected N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters. 
 
Compound No. λmax1 (nm) ε1  λmax2 (nm) ε2 
62 379 3132 454 1216 
63 371 3216 435 1308 
64 369 3081 450 1334 
65 367 3482 450 1497 
66 376 3211 452 1312 
67 373 3453 453 1483 
68 367 3283 452 1406 
69 378 3048 455 1388 
70 372 3040 449 1257 
71 367 3264 45 1326 
72 368 3086 454 1357 
73 367 3491 454 1499 
74 373 3217 452 1316 
75 372 3465 452 1497 
76 376 3306 450 1422 
77 380 3542 452 1483 
 
From the UV-Vis data of compound 62-77 in Table 2.5, the strongest absorptions in the UV spectrum 
are with local maxima at 375 nm and 450 nm, respectively. The absorptions are similar with those 
of the N-(6-ferrocenyl-2-naphthoyl) derivatives. 13 Low energy bands observed approximately at 450 
nm with a distinct λmax 2 values can be assigned as metal to ligand charge transfer (MLCT) band 
transition arising from the ferrocene moiety. The high energy band around 375 nm, with distinct λmax 
1 values are due to the π - π* transitions of the aromatic spacer group. It is well known from literature 
that the addition of a conjugate system to ferrocene causes the λmax value of ferrocene (400 nm) to 
shift toward the red region because of extended conjugation. In this UV-Vis study, the spectra of all 
compounds were obtained at a concentration of 1 x 10-4 M in acetonitrile. The molar extinction 
coefficient ε is calculated from the Beer-Lambert Law A=εcl, where A is the absorbance, c is the 
concentration and l is the path length of the sample cell. 
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2.6. 1H NMR and HPLC studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 
 
Nuclear magnetic resonance spectra (NMR) were obtained using a Bruker Avance 400 or 600 NMR 
spectrometer for 1H NMR. Chemical shifts are reported as ppm and all coupling constants (J) are in 
Hertz. All the 1H NMR experiments were performed in CDCl3. 
 
Table 2.6: 1H NMR spectral data for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters. 
 
Compound 
No. 
 
NH’s 
 
αH 
ortho on 
η5-C5H4-
naphthoyl  
meta on  
η5-C5H4-
naphthoyl 
meta on  
η5-C5H4-
alkyl 
ortho on  
η5-C5H4-
alkyl 
62 7.13, 6.73 - 4.59 4.26 3.91 3.87 
63 7.53, 7.18 - 4.64 4.29 3.91-3.87 3.91-3.87 
64 7.21, 6.84 4.54 4.62 4.29 4.00 3.87 
65 7.22, 6.83 4.54 4.63 4.29 4.00 3.85 
66 7.35, 7.09 4.59 4.67 4.32 3.94 3.90 
67 6.98, 6.51 4.58 4.74 4.39 4.07 3.97 
68 6.65 - 4.66 4.29 4.00 3.87 
69 6.68 - 4.65 4.29 4.00 3.86 
70 7.14, 6.79 - 4.67 4.31 3.94-3.71 3.94-3.71 
71 6.99, 6.51 - 4.68 4.33 3.95-3.91 3.95-3.91 
72 7.25, 6.91 4.44 4.56 4.29 3.92-3.86 3.92-3.86 
73 7.29, 6.96 4.53 4.71 4.35 4.05 3.93 
74 7.00, 6.56 4.58 4.68 4.26 3.93-3.88 3.93-3.88 
75 7.33, 6.99 4.56 4.66 4.29 4.11-3.93 4.11-3.93 
76 6.62 - 4.62 4.27 4.00-3.85 4.00-3.85 
77 6.67 - 4.76 4.38 4.02-3.96 4.02-3.96 
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The typical chemical shifts observed for the N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-
ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters in CDCl3 include the appearance of 
amide protons (Table 2.6). These signals can be found between δ 7.53 and δ 6.51. The naphthoyl 
spacer region confirms the presence of six protons, which appear as multiplets from δ 8.27-7.55. This 
complexity is due to six protons being magnetically inequivalent, following the second order splitting 
pattern. 
 
For the disubstituted ferrocene moiety, four splitting patterns are observed. For the cyclopentadiene 
ring attached to the naphthoyl spacer (η5-C5H4-naphthoyl), the ortho protons appear as an apparent 
triplet in the region of δ 4.76 to δ 4.56 with coupling constant J equal to 2 Hz; and the meta protons 
appear as a triplet signal in the region between δ 4.38 and δ 4.26 with the same coupling constants J 
equal to 2 Hz. Refer to the protons on the alkylated cyclopentadiene ring (η5-C5H4-alkyl), the meta 
and ortho protons of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters both 
appear as a triplet in the region of δ 4.07 to δ 3.91 and δ 3.97 to δ 3.85, respectively, with coupling 
constants J equal to 2 Hz. For the protons on the alkylated cyclopentadiene ring (η5-C5H4-alkyl) of 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, ortho and meta protons 
generated a multiplet between δ 4.11 to δ 3.92. 
 
The methylene protons (-OCH2CH3) of the ethyl ester derivatives appear between δ 4.10 and δ 4.21 
as a quartet while the methyl protons (-OCH2CH3) appear as a triplet between δ 1.17 and δ 1.24. The 
methyl protons (-OCH3) of the methyl derivatives appear as a singlet between δ 4.12 and δ 3.58. 
 
The methyl protons of the alkyl group (-CH3) attached to the cyclopentadiene ring appear as three 
singlets between δ 2.22-1.61 for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
esters. In the N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) derivatives, the methylene protons of the alkyl 
group (-CH2CH3) appear as two to three quartets, from δ 2.64-2.05, and the methyl protons of the 
alkyl group (-CH2CH3) typically appear as one to two triplet signals from δ 1.21 to δ 0.89. Those 
signals multiplicities are discussed in section 2.6.1. 
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2.6.1. 1H NMR spectroscopic studies of alkyl group of 1’-methyl-6-ferrocenyl-methyl-2-
naphthoate (58) and 1’-ethyl-6-ferrocenyl-methyl-2-naphthoate (59) 
 
Previous 1H NMR study shows the protons of the alkyl group attached to the cyclopentadiene ring 
of 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters generally follow 
(n+1) splitting pattern, and each proton generates one signal with corresponding integrations.11 
However this pattern was not observed in this NMR study. The presence of methyl and ethyl groups 
attached to the cyclopentadiene ring were found to have a strong influence on the appearance of these 
spectra. Signal multiplicities were observed in the 1H spectra for all resonating nuclei in starting 
material 51, 52 and all N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters (62-77). The methyl ferrocene and ethyl ferrocene were 
directly reacted with methyl-6-aminonaphthalene-2-carboxylate hydrochloride without protection, 
therefore there are two possibilities for methyl-6-aminonaphthalene-2-carboxylate hydrochloride to 
attack alkyl ferrocenyl groups. Methyl-6-aminonaphthalene-2-carboxylate hydrochloride can bound 
to the same or different cyclopentadienyl rings as the alkyl group. Figure 2.5 illustrates the proposed 
structure of those isomers. The proposed structures of atropisomers (I, II and III) is shown in Figure 
2.5. Atropisomers formed because of two planar are unsymmetrically substituted. Atropisomerism 
restricts the rotation about the two planar. The naphthoyl moiety can also bound to the same planar 
as the alkyl group (Figure 2.5). Atropisomers I, II and III thought to be the main products due to 
steric effects of the alkyl group. Since it is impossible to separate those isomers, structures like in 
Figure 2.5 are still possible. Variable temperature 1H NMR and HPLC-UV studies have been 
discussed in section 2.6.2 and 2.6.3.  
 
The 1H NMR spectrums of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate 58 and 1’-ethyl-6-
ferrocenyl-methyl-2-naphthoate 59 in DMSO-d6 are shown in Figure 2.6 and Figure 2.7. 
 
In the spectrum of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate 58, the methyl protons of the alkyl 
group (-CH3) attached to the cyclopentadiene ring appears as three separate singlets at δ 2.22, δ 2.02 
and δ 1.64, with total integration of three (Figure 2.6). This pattern maintains the same for all N-(1’-
methyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
 
For 1’-ethyl-6-ferrocenyl-methyl-2-naphthoate 59, the methylene protons of the alkyl group (-
CH2CH3) appear as three separate quartets, from δ 2.72-2.16, and the methyl protons of the alkyl 
group (-CH2CH3) appear as two separate triplet signals from δ 1.29 to δ 1.07 (Figure 2.7). This pattern 
maintains the same for all N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide. 
51 
 
 
 
 
R= -CH3 or -CH2CH3 
 
Figure 2.4: The proposed structure of atropisomers I, II and III of compound 58 and 59. 
 
 
 
 
 
Figure 2.5: The proposed structure of isomers of compound 58 and 59. 
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Figure 2.6: 1H NMR spectrum of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate 58 in CDCl3. 
 
 
 
 
Figure 2.7: 1H NMR spectrum of 1’-ethyl-6-ferrocenyl-methyl-2-naphthoate 59 in CDCl3. 
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2.6.2. Variable temperature 1H NMR studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester (69) 
 
Figure 2.8: N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 69. 
 
The 1H NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide 62-77 obtained at room temperature is highly complex due to 
the presence of atropisomers in solution for which the rate of interconversion is slow on the NMR 
time scale. A strong point of NMR spectroscopy is that information at various temperatures can be 
obtained without difficultly. When the temperature is lowered enough, different signals appear due 
to the exchange rate is slow enough for NMR to detect. Whereas a sole signal that corresponds to an 
average of those sites detected can be seen at higher temperature. This merging of the different 
signals is called coalescence. The line shapes of NMR spectra change dramatically at temperature 
slightly above or below coalescence temperature (Tc). Thus, a variable temperature study of the 1H 
NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 69 was 
performed at 20, 40, 60, 80, 100, and 120 °C in DMSO-d6 (Figure 2.9). 
The aromatic region of the 1H NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester 69, the amide proton of the γ-aminobutyric acid residue gives rise to 
two triplets at δ 8.39 and 8.61 at 20 °C (Figure 2.10). As the temperature is raised these signals 
shifting slightly upfield at 80 °C. Above 80 °C the signal sharpens. The ferrocenyl region (Figure 
2.11) does not alter significantly upon heating. In contrast, the methylene protons from the γ-
aminobutyric acid residue is more informative (Figure 2.12). At 20 °C, the signal belongs to the 
methylene protons attached to amide bond (-NHCH2CH2CH2-) is masked by the large signal due to 
H2O contained in the DMSO-d6 solvent. The methylene signal is shifted gradually downfield upon 
heating due to weakening of hydrogen bonds present in solution. No informative spectrum was 
recorded for the alkyl region (Figure 2.12). Therefore, the coalescence temperature of compound 69 
is not within the range between 20 and 120 °C. Compared with other deuterated solvent e.g. acetone-
d6, benzene-d6, chloroform-d6 and dimethylformamide-d6, DMSO-d6 is the deuterated solvent that 
have highest boiling point, hence no further investigation carried out for temperature 1H NMR study. 
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Figure 2.9: Variable temperature NMR study of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester 69 at 20, 40, 60, 80, 100 and 120 °C. 
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Figure 2.10: Variable temperature NMR study of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester 69: the aromatic region (7.5-10.0 ppm) of the 1H NMR spectrum. 
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Figure 2.11: Variable temperature NMR study of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester 69: the ferrocenyl region (3.7-5.3 ppm) of the 1H NMR spectrum. 
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Figure 2.12: Variable temperature NMR study of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid ethyl ester 69: the methylene and alkyl region (0.0-3.6 ppm) of the 1H NMR 
spectrum. 
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2.6.3. HPLC-UV studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 
(63) 
 
High-performance liquid chromatography (HPLC) is a useful technique used to separate, identify 
and quantify each component in a mixture. 14 The chromatography detector is a device used in HPLC 
to detect components of the mixture being eluted off the column. There are selective detectors and 
universal detectors used in HPLC. Selective detectors are based on physical or chemical property of 
the solute, mainly have following four subtypes: absorbance detectors, fluorescence detectors, 
electrochemical detectors and mass spectrometric detectors. Universal detectors used to measure the 
difference in some physical property of the solute in mobile phase compared to the mobile phase 
alone. It is highly dependent of the mobile phase. Refractive index detectors and evaporating light 
scattering detectors are the major two types of detectors used in universal detectors. Absorbance 
detector is a type of the most common spectroscopic detector used to measure the ability of solutes 
to absorb light at wavelengths in the UV-Vis wavelength range. The UV, VIS, and PDA detectors 
are categorized as absorbance detectors. A standard UV detector allows the user to choose 
wavelengths between 195 to 370 nm. Most commonly used wavelength is 254 nm. Compared to a 
UV detector, a VIS detector uses longer wavelength (400 to 700 nm). There are detectors that provide 
wider wavelength selection, covering both UV and VIS ranges (195 to 700 nm) called UV/VIS 
detector. UV and VIS detectors visualize the obtained result in light intensity and time dimensions. 
The photo diode array detector (PDA) operates by simultaneously monitoring absorbance of solute 
at an entire wavelength. Light from the broad emission source such as a deuterium lamp is collimated 
by an achromatic lens system so that the total light passes through the detector cell onto a holographic 
grating. Therefore, the sample is subjected to light of all wavelengths generated by the lamp. The 
dispersed light from the grating is allowed to fall on to a diode array. The output from diode is 
recorded on to a computer. PDA adds the third dimension - wavelength. This is convenient to 
determine the most suitable wavelength without repeating analyses. 14 ,15 
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Figure 2.13: The components of a diode array detector. 
 
In this study, UV-Vis photo diode array detector (PDA) is used with HPLC to measure the sample’s 
absorption. Different samples may have different retention times therefore the number of 
atropisomers exist in the mixture can be identified. 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63 was dissolved in ethanol and 
a C18 reversed column was used. The mixture was run at a flow rate of 4 mL min-1 with an injection 
volume of 20 μL. Two separate injections were carried out as shown in Figure 2.14. Similar signals 
were recorded for the sample at different concentrations. 
From Figure 2.15, two main peaks were detected with retention time at 31.068 and 34.267 minutes 
respectively. The peak generated at 31.068 minutes have a lower left shoulder which can divided this 
peak area into peak area number 1 and 2. The peak area from number 1, 2 and 3 have 18%, 50% and 
32% of the total peak area. Therefore, the ratio of those isomers detected from HPLC-PDA equal to 
1:3:2. This result shows there are three isomers in the compound with different retention time. From 
1H NMR study of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63. The 
integration raised from the alkyl group were 0.5H, 1H and 1.5H respectively, which also equal to 
1:2:3. Combined with the information from 13C NMR and MS, compounds gave spectroscopic and 
analytical data in accordance with their structures. 
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Figure 2.14: Two separate signals generated from PDA detector of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 63 at different concentrations by two injections. 
 
 
 
 
Figure 2.15: The HPLC-UV chromatogram of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-
glycine ethyl ester 63. 
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2.6.4. 1H NMR studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 
(63) 
 
 
 
The 1H NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63 
was measured in CDCl3 (Figure 2.16). The two amide protons (-CONH-) are positioned downfield 
at δ 7.53 and δ 7.18 with integration of one. The naphthoyl spacer region confirms the presence of 
six protons, which appears from δ 8.27 to δ 7.55. For the disubstituted ferrocene moiety, the peak 
due to the ortho of the cyclopentadiene ring attached to the naphthoyl spacer (η5C5H4-naphthoyl) 
appears as the furthest downfield. This signal appears as a triplet at δ 4.64 and with integration of 
two. Similarly, the meta (η5C5H4-naphthoyl) protons appear as a triplet at δ 4.29. The protons on the 
alkylated cyclopentadiene ring (η5-C5H4-alkyl) appear as two triplets with an overall integration of 
four at δ 3.91 and δ 3.87 for protons on meta and ortho, respectively.  
 
The methyl protons of the alkyl group (-CH3) attached to the cyclopentadiene ring appear as three 
singlets at δ 2.19, δ 2.00 and δ 1.61 with a total integration as three. The methylene group of the ethyl 
ester (-OCH2CH3) is presented as a quartet at downfield δ 4.14 with a coupling constant of 7.2 Hz. 
The methylene proton signal (-NHCH2CO-) of the glycine glycine ethyl ester moiety appears as a 
doublet at δ 4.21 with J = 6.1 Hz whilst another methylene proton signal (-CONHCH2CO-) appear 
as a doublet at δ 4.02 with J = 7.3 Hz, both with corresponding integration of 2. The methyl group 
of the ethyl ester (-OCH2CH3) is present as a triplet at δ 1.17 with J = 7.2 Hz.  
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Figure 2.16: 1H NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl 
ester 63 in CDCl3. 
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2.7. 13C NMR and DEPT-135 spectroscopic studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) 
and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 
 
13C and DEPT 135 NMR studies were carried out on all compounds. In a DEPT-135 spectrum, 
methine and methyl carbons appear as positive peaks, whereas methylene carbons appear as negative 
peaks i.e. below the resonance line. Carbonyl and quaternary carbons are absent in a DEPT 135 
spectrum. All the 13C and DEPT-135 NMR experiments were performed in CDCl3. The typical 13C 
NMR chemical shifts observed are presented in Table 2.7. 
 
In the 13C NMR spectra of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters, the typical peaks observed include the appearance of 
carbonyl signals between δ 173.9-166.6. In the amino acid derivatives only two carbonyl signals are 
observed whilst for the dipeptide derivatives found to have three carbonyl signals. In the aromatic 
region of the spectrum of these derivatives, ten unique carbon signals are observed which appear 
between δ 140.2- 120.8. The two quaternary carbon atoms present on the naphthoyl moiety can be 
easily identified by their absence in the DEPT-135 spectrum.  
 
For the 1-alkyl-1’ derivatives, six unique carbon signals are observed for the disubstituted ferrocene 
moiety with two ipso carbons being present. The ipso carbon (η5-C5H4- naphthoyl) appears between 
δ 86.8 - 84.0, whilst the ipso carbon (η5-C5H4-alkyl) appears between δ 92.0-88.8. The signals of 
ortho carbons on the substituted cyclopentadiene rings appear more downfield compared to the meta 
carbons due to deshielding by the naphthoyl linker and the alkyl chain attached. The carbon atom of 
the methyl group (-CH3), attached to the cyclopentadiene ring appears between δ 15.3-13.7. The 
methylene carbon of the ethyl ester (-OCH2CH3) derivatives appears between δ 62.3-61.4 whilst the 
methyl carbon (-OCH2CH3) appears between δ 15.1-14.0. The carbon atom of the methyl ester (-
OCH3) derivatives appear between δ 51.3-51.8.  
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Table 2.7: 13C and DEPT 135 NMR spectral data for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters. 
 
Compound 
No. 
 
C=O 
Ipso 
 (η5-C5H4-
alkyl)  
Ipso 
 (η5-C5H4-
naphthoyl) 
meta on  
(η5-C5H4- 
naphthoyl) 
meta on  
(η5-C5H4-
alkyl) 
ortho on  
(η5-C5H4-
alkyl) 
ortho on  
(η5-C5H4- 
naphthoyl) 
 
-CH3 
 
-CH2CH3 
 
-CH2CH3 
62 170.3-166.6 90.2 85.1 69.5 67.1 66.3 65.7 15.0 - - 
63 172.9-167.8 90.1 86.8 71.1 69.9 69.7 67.3 15.2 - - 
64 172.5-167.5 88.8 84.0 70.5 68.1 67.9 66.2 15.0 - - 
65 173.1-167.7 89.3 85.8 71.3 68.8 67.2 65.9 14.8 - - 
66 172.6-167.5 89.1 84.2 70.6 68.1 67.4 66.3 15.3 - - 
67 173.2-167.5 89.0 84.2 71.0 69.0 67.4 66.1 14.8 - - 
68 172.9-168.0 89.1 84.9 70.2 68.8 67.3 65.8 13.8 - - 
69 173.9-167.9 89.4 84.3 70.4 68.9 67.1 64.4 13.7 - - 
70 168.9-166.6 89.9 85.7 70.2 68.4 67.4 65.8 - 21.7 14.7 
71 169.7-166.9 92.0 84.2 68.9 67.1 66.4 65.6 - 21.6 14.7 
72 172.5-167.4 89.3 84.2 71.7 69.3 67.1 66.2 - 20.6 14.5 
73 172.-167.8 89.7 84.8 70.3 69.0 67.2 65.7 - 21.0 14.1 
74 172.6-167.5 88.9 84.5 71.0 69.1 67.2 66.3 - 21.3 14.5 
75 173.6-167.5 89.6 84.1 69.8 69.1 67.3 65.7 - 21.3 14.7 
76 174.3-167.6 88.9 84.3 71.3 69.1 67.2 66.5 - 21.5 14.7 
77 173.3-168.6 89.1 84.3 69.7 68.8 67.1 65.6 - 22.2 13.6 
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2.7.1. 13C NMR and DEPT-135 spectroscopic studies of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester (63) 
 
 
 
The 13C NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63 
displays three carbonyl carbon atoms at δ 172.9, δ 169.4 and δ 167.8. These are absent in the DEPT-
135 spectrum. The aromatic region shows ten unique carbon signals, representing the ten non-
equivalent carbon atoms of the 2, 6-disubstituted naphthalene group, between δ 134.8 and δ 120.8. 
The four quaternary carbon atoms from the naphthoyl spacer moiety at δ 134.8, δ 133.0, δ 130.7 and 
δ 130.2 can be easily identified by their absence in the DEPT-135 spectrum. The ipso carbon atom 
on (η5-C5H4-alkyl) ring appears at δ 90.1 whilst the ipso on (η5-C5H4- naphthoyl) ring appears at δ 
86.8. These are absent in the DEPT-135 spectrum. The remaining carbon atoms on the 
cyclopentadiene rings are present between δ 71.7-67.3. The methylene carbon atom of the ethyl ester 
(-OCH2CH3) is observed at δ 61.5, whilst the methyl carbon atom appears at δ 14.0. The two 
methylene carbon atoms (-NHCH2-) of the glycine glycine ethyl ester are observed at δ 43.8 and δ 
41.2. The carbon atom of the methyl group (-CH3) attached to the cyclopentadiene ring appears at δ 
15.0. (Figure 2.17 and Figure 2.18) 
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Figure 2.17: 13C NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl 
ester 63 in CDCl3. 
 
 
 
Figure 2.18: DEPT-135 NMR spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine 
ethyl ester 63 in CDCl3. 
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2.8. HMQC spectroscopic studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ- aminobutyric 
acid ethyl ester (69) 
 
HMQC (Heteronuclear Multiplet Quantum Coherence) is a 2D NMR technique that correlates each 
13C atom to the proton to which it is directly attached.12 Thus, HMQC allows assignment of proton 
and carbon spectra which aids in total structure elucidation. This technique correlates a carbon signal 
to any directly associated protons. Therefore, no signals are observed for those carbon atoms lacking 
protons i.e. carbonyl or quaternary carbon atoms. The structure and HMQC spectrum of N-(1’-
methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 69 is shown in Figure 2.19 and 
Figure 2.20, respectively. The positions of the C-H correlations are listed in Table 2.8. 
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Figure 2.19: N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 69. 
 
 
Figure 2.20: HMQC spectrum of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl 
ester 69. 
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Table 2.8: HMQC data for N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 
69. 
 
Site 1H NMR 13C NMR  HMQC 
1* 2.21, 2.01, 1.63 - 13.7 
2 - 89.4 - 
(3, 6)* 3.86 - 67.1 
(4, 5)* 4.00 - 68.9 
(8, 9)* 4.29 - 70.4 
(7, 10)* 4.65 - 64.4 
11 - 84.3 - 
12 - 135.1 - 
13* 7.81 - 127.2 
14* 7.61 - 123.1 
15 - 131.2a - 
16* 8.21 - 128.8 
17 - 139.5 - 
18* 7.84 - 127.9 
19* 7.74 - 123.9 
20 - 130.7b - 
21* 7.78 - 126.1 
22 - 173.9 - 
23* 3.53 - 39.8 
24* 1.94 - 24.5 
25* 2.40 - 32.1 
26 - 167.9 - 
27* 4.10 - 60.6 
28* 1.18 - 14.1 
* C-H correlation site. 
a,b Signals may be reversed. 
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2.9. Mass spectrometric studies of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 
 
Mass spectrometry enables the determination of the relative molecular mass of many different types 
of compounds. The mass spectrometer is composed of five distinct parts, namely the sample inlet, 
the ion source, the mass analyser, the detector and the data system. The sample is introduced into the 
ion source and this allows ionisation to occur. These ions are extracted into the analyser, where they 
are separated according to their mass (m) to charge (z) ratios (m/z). 12 The separated ions are detected 
and displayed as a mass spectrum. Electrospray ionization mass spectrometry (ESI-MS) was 
employed in the analysis of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters. Those compounds are non-volatile, and a soft ionization 
technique is employed in their analysis. The analysis confirmed the correct relative molecular mass 
for those compounds.  
 
 
Figure 2.21: Product ions observed in the ESI-MS/MS spectrum of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl)-glycine-glycine ethyl ester 63. 
 
The mass spectrum for of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 63 is 
shown in Figure 2.21. The sequence specific fragment ions are present at m/z 325, m/z 353, m/z 382 
and m/z 410. The signal at m/z 325 indicates the presence of a ferrocenyl naphthyl subunit while the 
signal at m/z 353 is due to cleavage at the naphthoyl carbonyl. And as expected, product ions at m/z 
382 and m/z 410 were observed. 
For compound 76, similar trends were detected as shown in Figure 2.22, the sequence specific 
fragment ions are present at m/z 339 and m/z 367. 
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Figure 2.22: Product ions observed in the ESI-MS/MS spectrum of N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid methyl ester 76. 
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2.10. Conclusion 
 
N-(ferrocenyl)naphthoyl amino acid and dipeptide derivatives have been identified as potential anti-
cancer agents against the H1299 NSCLC and Sk-Mel-28 cell lines. 6 The project sought to further 
explore the structure-activity relationship (SAR) of these compounds to enhance their anti-
proliferative effect. Both ferrocene and ester regions have been modified. Thus N-(1’-methyl-6-
ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 
have been prepared. Each novel compound contains an electroactive alkylated ferrocene core, a 
conjugated aromatic linker and an amino acid or dipeptide ester chain. These novel compounds were 
prepared by condensation of 1’-methyl-6-ferrocenyl-2-naphthoic acid and 1’-ethyl-6-ferrocenyl-2-
naphthoic acid with the amino acid or dipeptide esters under solution phase EDC/NHS coupling 
conditions. Purification by column chromatography furnished the required compounds as an orange 
solid or orange oil, in moderate yields 13% to 60%.  
 
The N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide derivatives were characterized by a range of spectroscopic techniques including 1H 
NMR, 13C NMR, DEPT-135, HMQC, IR, UV-Vis and MS. And all compounds gave spectroscopic 
and analytical data in accordance with their proposed structures. 
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Experimental Procedures 
Experimental Note 
 
 
All chemicals were purchased from Sigma-Aldrich or Fluorochem Limited; and used as received. 
Commercial grade reagents were used without further purification. When necessary, all solvents 
were purified and dried prior to use. Riedel-Haën silica gel was used for thin layer and column 
chromatography. Melting points were determined using a Griffin melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a PerkinElmer Spectrum 100 FT-IR with ATR. UV-
Vis spectra were recorded on a Hewlett Packard 8452A diode array UV-Vis spectrophotometer. 1H 
and 13C NMR spectra were recorded in deuterated solvents on either a Bruker Avance 400 or 600 
NMR. The 1H and 13C NMR chemical shifts are reported in ppm (parts per million). 
Tetramethylsilane (TMS) or the residual solvent peaks have been used as an internal reference. All 
coupling constants (J) are in Hertz. The abbreviations for the peak multiplicities are as follows: s 
(singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), qt (quintet), m (multiplet) and 
br (broad). Electrospray ionization mass spectra were performed on a Micromass LCT mass 
spectrometer. 
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General Procedures 
 
General procedure for the preparation of amino acid and dipeptide esters. 
Glycine-glycine methyl ester hydrochloride (47) 
 
Thionyl chloride (4 ml) was added slowly to methanol (25 ml) at -5 °C and glycine-glycine (2.00 g, 
15.2 mmol) was added to the solution. After 30 minutes, the reaction mixture was refluxed for 16 
hours. The solvent was removed in vacuo to yield the title compound as a white solid (2.01g, 72%), 
mp: 107-109 °C; 
1H NMR (600 MHz) δ (DMSO-d6): 9.07 (1H, t, J = 6.0 Hz, -CONH-), 8.38 (3H, br.s, -NH3CH2-), 
3.94 (2H, d, J = 6.1 Hz, -NHCH2-), 3.64 (3H, s, -OCH3), 3.43 (2H, s, -NH3CH2-);  
13C NMR (100 MHz) δ (DMSO-d6): 170.5 (C=O), 167.3 (C=O), 53.4 (-OCH3), 41.3 (NH3CH2-, -ve 
DEPT), 40.2 (-NHCH2-, -ve DEPT). 
 
Glycine-glycine ethyl ester hydrochloride (48) 
 
The synthesis followed that of glycine-glycine methyl ester hydrochloride using the following 
reagents: glycine-glycine (2.00 g, 15.2 mmol), ethanol (25 ml), thionyl chloride (4 ml). The solvent 
was removed in vacuo to yield the title compound as a white solid (1.96 g, 70%), mp: 178-179 °C; 
1H NMR (600 MHz) δ (DMSO-d6): 8.89 (1H, t, J = 6.0 Hz, -CONH-), 8.19 (3H, br.s, - NH3CH2-), 
4.14 (2H, q, J = 7.2 Hz, -OCH2CH3), 3.94 (2H, d, J = 6.1 Hz, -NHCH2-), 3.61 (2H, s, NH3CH2-), 
1.22 (3H, t, J = 7.2 Hz, -OCH2CH3);  
13C NMR (100 MHz) δ (DMSO-d6): 169.4 (C=O), 166.5 (C=O), 60.6 (-OCH2CH3, -ve DEPT), 40.7 
(NH3CH2-, -ve DEPT), 40.6 (-NHCH2-, -ve DEPT), 14.0 (-OCH2CH3). 
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γ-Aminobutyric acid methyl ester hydrochloride (49) 
 
The synthesis followed that of glycine-glycine methyl ester hydrochloride using the following 
reagents: γ-aminobutyric acid (2.00 g, 19.4 mmol), methanol (25 ml), thionyl chloride (4 ml). The 
solvent was removed in vacuo to yield the title compound as a white solid (1.75 g, 59%), mp: 115-
116 °C; 
1H NMR (600 MHz) δ (DMSO-d6): 8.19 (3H, br.s, -NH3), 3.60 (3H, s, -OCH3), 2.80 (2H, t, J = 7.2 
Hz, -COCH2-), 2.46 (2H, t, J = 7.2 Hz, NH3CH2-), 1.84 (2H, qt, J = 7.2 Hz,-CH2CH2CH2-);   
13C NMR (100 MHz) δ (DMSO-d6): 172.6 (C=O), 51.9 (-OCH3), 38.5 (NH3CH2-, -ve DEPT), 30.9 
(-COCH2-, -ve DEPT), 22.9 (-CH2CH2CH2-,-ve DEPT). 
 
γ-Aminobutyric acid ethyl ester hydrochloride (50) 
 
The synthesis followed that of glycine-glycine methyl ester hydrochloride using the following 
reagents: γ-aminobutyric acid (2.00 g, 19.4 mmol), ethanol (25 ml), thionyl chloride (4 ml). The 
solvent was removed in vacuo to yield the title compound as a white solid (2.15 g, 68%), mp: 46-
48 °C; 
1H NMR (600 MHz) δ (DMSO-d6): 8.04 (3H, br. s, -NH3CH2-), 4.09 (2H, q, J =7.3 Hz, -OCH2CH3), 
3.45 (2H, t, J =7.2 Hz, -COCH2-), 2.43 (2H, t, J =7.2 Hz, NH3CH2-), 1.84 (2H, qt, J =7.2 Hz, -
CH2CH2CH2-), 1.19 (3H, t, J =7.3 Hz, -OCH2CH3);  
13C NMR (100 MHz) δ (DMSO-d6): 172.1 (C=O), 59.9 (-OCH2CH3, -ve DEPT), 37.9 (NH3CH2-, -
ve DEPT), 30.4 (-COCH2-, -ve DEPT), 22.3 (-CH2CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3). 
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General procedure for the preparation of Boc protected dipeptide esters 
Boc-glycine-L-alanine-methyl ester (51) 
 
Boc-glycine (2.45 g, 14.0 mmol) was dissolved in DCM (60 ml) at 0 °C. L-alanine methyl ester 
hydrochloride (1.41 g, 14.0 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (2.68 g, 14.0 mmol), N-hydroxysuccinimide (1.61 g, 14.0 mmol) and triethylamine (5 
ml) were added and stirred at 0 °C for 1 hour. The reaction mixture was allowed to stir at room 
temperature for 48 hours. The solvent was removed in vacuo and the crude product was purified by 
column chromatography (eluent 1:1 ethyl acetate: hexane) to yield the product as a transparent oil 
(1.86 g, 48% ); 
1H NMR (600 MHz) δ (DMSO-d6): 8.20 {1H, d, J = 7.2 Hz, -CONHCH(CH3)-}, 6.90 (1H, t, J = 6.2 
Hz, -CONH-), 4.32 (1H, qt, J = 7.4 Hz, -NHCH-), 3.59 (3H, s, -OCH3), 3.58 (2H, dd, J = 6.2 and 
10.4 Hz, -NHCH2-), 1.38 {9H, s, -C(CH3)3}, 1.28 (3H, d, J = 7.4 Hz, -CHCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 173.5 (C=O), 170.1 (C=O), 156.5 (C=O), 78.6 (Cq), 52.2 (-
OCH3), 48.1 (-CHCH3-), 43.4 (-NHCH2-, -ve DEPT), 28.7 {-C(CH3)3}, 17.5 (-CHCH3). 
 
Boc-glycine-L-alanine-ethyl ester (52) 
 
The synthesis followed that of Boc-glycine-L-alanine-methyl ester using the following reagents: 
Boc-glycine (2.45 g, 14.0 mmol), L-alanine ethyl ester hydrochloride (1.58 g, 14.0 mmol), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.68 g, 14.0 mmol), N-
hydroxysuccinimide (1.61 g, 14.0 mmol) and triethylamine (5 ml). The product was purified by 
column chromatography (eluent 1:1 ethyl acetate: hexane) to give the title compound as a transparent 
oil (1.91 g, 48%);     
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1H NMR (600 MHz) δ (DMSO-d6): 8.18 {1H, d, J = 7.2 Hz, -CONHCH(CH3)-}, 6.91 (1H, t, J = 6.2 
Hz, -CONH-), 4.28 (1H, qt, J = 7.4 Hz, -NHCH-), 4.10 (2H, q, J = 7.3 Hz, -OCH2CH3), 3.61 (2H, 
dd, J = 6.2 and 10.4 Hz, -NHCH2-), 1.38 {9H, s, -(CH3)3}, 1.28 (3H, d, J = 7.4 Hz, -CHCH3), 1.20 
(3H, t, J = 7.3 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 173.1 (C=O), 169.9 (C=O), 156.3 (C=O), 78.8 (Cq), 61.3 (-
OCH2CH3, -ve DEPT), 48.1 (-CHCH3), 43.4 (-NHCH2-, -ve DEPT), 28.5{-C(CH3)3}, 17.7 (-CHCH3), 
14.5 (-CH2CH3). 
 
Boc-glycine-D-alanine-methyl ester (53) 
 
The synthesis followed that of Boc-glycine-L-alanine-methyl ester using the following reagents: 
Boc-glycine (2.45 g, 14.0 mmol), D-alanine methyl ester hydrochloride (1.41 g, 14.0 mmol), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.68 g, 14.0 mmol), N-
hydroxysuccinimide (1.61 g, 14.0 mmol) and triethylamine (5 ml). The product was purified by 
column chromatography (eluent 1:1 ethyl acetate:hexane) to give the title compound as a transparent 
oil (1.20 g, 31%); 
1H NMR (600 MHz) δ (DMSO-d6): 8.21 {1H, d, J = 7.2 Hz, -CONHCH(CH3)}, 6.92 (1H, t, J = 6.2 
Hz, -CONH-), 4.31 (1H, qt, J = 7.4 Hz, -NHCH-), 3.62 (3H, s, -OCH3), 3.58 (2H, dd, J = 6.2 and 
10.4 Hz, -NHCH2-), 1.38 {9H, s, -C(CH3)3}, 1.28 (3H, d, J = 7.4 Hz, -CHCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 172.9 (C=O), 169. 9 (C=O), 156.5 (C=O), 78.6 (Cq), 52.2 (-
OCH3), 48.1(-CHCH3-), 43.4 (-NHCH2-, -ve DEPT), 28.7 {-C(CH3)3}, 17.5 (-CH2CH3). 
Boc-glycine-D-alanine-ethyl ester (54) 
 
The synthesis followed that of Boc-glycine-L-alanine-methyl ester using the following reagents: 
Boc-glycine (2.45 g, 14.0 mmol), D-alanine ethyl ester hydrochloride (1.58 g, 14.0 mmol), N-(3-
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dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.68 g, 14.0 mmol), N-
hydroxysuccinimide (1.61 g, 14.0 mmol) and triethylamine (5 ml). The product was purified by 
column chromatography (eluent 1:1 ethyl acetate: hexane) to give the title compound as a transparent 
oil (1.81 g, 44%);      
1H NMR (600 MHz) δ (DMSO-d6): 8.18 {1H, d, J = 7.2 Hz, -CONHCH(CH3)-}, 6.92 (1H, t, J = 6.2 
Hz, -CONH-), 4.27 (1H, qt, J = 7.4 Hz, -NHCH-), 4.09 (2H, q, J = 7.3 Hz, -OCH2CH3), 3.61 (2H, 
dd, J = 6.2 and 10.4 Hz, -NHCH2-), 1.38 {9H, s, -(CH3)3}, 1.28 (3H, d, J = 7.4 Hz, -CHCH3), 1.20 
(3H, t, J = 7.3 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 172.8 (C=O), 169. 9 (C=O), 156.4 (C=O), 78. 6 (Cq), 61.1 (-
OCH2CH3, -ve DEPT), 48.1 (-CHCH3), 43.6 (-NHCH2-, -ve DEPT), 28.7{-C(CH3)3}, 17.7 (-CHCH3), 
14.6 ( -CH2CH3). 
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Synthesis of starting material 
Methyl ferrocene (55) 
 
Lithium aluminium hydride (1.42 g, 37.4 mmol) was dissolved in dry diethyl ether (50 ml) under 
nitrogen at 0 °C. Ferrocenecarboxaldehyde (4.00 g, 18.7 mmol) was slowly added and the reaction 
mixture was allowed to stir for 15 minutes. Anhydrous aluminum chloride (4.99 g, 37.4 mmol) was 
added slowly to the reaction mixture over 30 minutes. The reaction mixture was refluxed at room 
temperature for 8 hours and quenched on ice after. The diethyl ether layer was washed with water 
and dried over MgSO4. The solvent was removed in vacuo to yield the crude product. The crude 
product was purified by column chromatography {eluent 5:1 hexane: diethyl ether} yielding the title 
compound as dark orange solid (3.60 g, 90%), mp: 35.5-37.5 °C; 
1H NMR (600 MHz) δ (CDCl3): 4.04 (5H, s,η5-C5H5), 4.01 (2H, s, meta on η5-C5H4-alkyl ), 3.97 (2H, 
s, ortho on η5-C5H4-alkyl), 1.90 (3H, s, -CH3); 
13C NMR (100 MHz) δ (CDCl3): 89.5 (Cipso η5-C5H4-alkyl), 69.2 (Cmeta η5-C5H4-CH3), 68.6 (Cortho η5-
C5H4-CH3), 67.2 (η5-C5H5), 14.8 (-CH3). 
 
Ethyl ferrocene (56) 
 
The synthesis followed that of methyl ferrocene using the following reagents: lithium aluminium 
hydride (1.42 g, 37.4 mmol), acetylferrocene (4.00 g, 17.5 mmol), anhydrous aluminum chloride 
(4.99 g, 37.4 mmol). The crude product was purified by column chromatography {eluent 5:1 hexane: 
diethyl ether} yielding the title compound as a dark orange oil (3.23 g, 86%); 
1H NMR (600 MHz) δ (CDCl3): 4.08 (5H, s,η5-C5H5), 4.03 (2H, t, J = 1.6 Hz, meta on η5-C5H4-alkyl), 
3.99 (2H, t, J = 1.6 Hz, ortho on η5-C5H4-alkyl), 2.28 (2H , q, J = 7.4 Hz, -CH2CH3), 1.11 (3H, t, J = 
7.4 Hz , -CH2CH3); 
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13C NMR (100 MHz) δ (CDCl3): 91.1 (Cipso η5-C5H4-alkyl), 68.4 (Cmeta η5-C5H4-alkyl), 67.9 (Cortho 
η5-C5H4-alkyl), 66.9 (η5-C5H5), 22.3 (-CH2CH3, -ve DEPT), 14.9 (-CH2CH3). 
 
Methyl-6-aminonaphthalene-2-carboxylate hydrochloride (57) 
 
6-Amino-2-naphthoic acid (5.00 g, 26.7 mmol) was added slowly to a solution of methanol (30 ml) 
and thionyl chloride (8 ml) at 0 °C and refluxed for 48 hours. The solution was cooled to room 
temperature and the precipitate was isolated via vacuum filtration and washed with hexane to yield 
the title compound as a brown solid (4.77 g, 89%), mp: 221-223 °C (lit13: 250-251 °C); 
1H NMR (600 MHz) δ (DMSO-d6): 8.58 (1H, s, ArH), 8.13 (1H, d, J = 8.8 Hz, ArH), 7.96-7.90 
(2H, dd, J = 2.0 and 8.8 Hz, ArH), 7.62 (1H, s, ArH), 7.42 (1H, dd, J = 2.0 and 8.8 Hz, ArH), 3.90 
(3H, s, -OCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 166.9 (C=O), 136.6 (Cq ),135.4 (Cq ), 131.7, 130.5, 129.2 (Cq ), 
127.7, 126.2 (Cq ), 125.0, 121.7, 117.4, 52.5 (-OCH3). 
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1’-Methyl-6-ferrocenyl-methyl-2-naphthoate (58) 
 
Concentrated hydrochloric acid (5 ml) was added with intermittent cooling to a solution of methyl-
6-aminonaphthalene-2-carboxylate hydrochloride (2.39 g, 12.0 mmol) in 30 ml of water. A solution 
of sodium nitrite (0.83 g, 12.0 mmol) in 30 ml of deionised water was added slowly to this mixture 
with stirring, keeping the temperature below 5 oC furnishing a pale brown/yellow solution. The 
resulting diazo salt was added to a solution of methyl ferrocene (3.00 g, 15.0 mmol) in diethyl ether 
(100 ml) with polyethylene glycol (2 ml) and allowed to react for 48 hours. The reaction mixture was 
washed with water and brine and the ether layer was dried over MgSO4. The solvent was removed in 
vacuo to yield the crude product. The crude product was purified by column chromatography {eluent 
5:1 hexane: diethyl ether} yielding the title compound as an orange solid (0.92 g, 20%), mp: 170-
172 °C; 
1H NMR (600 MHz) δ (CDCl3):  8.52 (1H, t, J = 8.4 Hz, ArH), 7.95 (1H, dd, J = 1.6 and 8.8 Hz, 
ArH), 7.81-7.79 (3H, m, ArH), 7.58 (1H, dd, J = 1.6 and 8.8 Hz, ArH), 4.64 (2H, t, J = 2.0 Hz, ortho 
on η5-C5H4-naphthoyl ), 4.31 (2H, t, J = 2.0 Hz, , meta on η5-C5H4-naphthoyl ), 4.0 (3H, s, -OCH3), 
3.92 (2H, t, J = 2.0 Hz, meta on η5-C5H4-alkyl), 3.88 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-alkyl), 2.22 
(0.5H, s, -CH3), 2.02 (0.9H, s, -CH3), 1.64 (1.6H, s, -CH3); 
13C NMR (100 MHz) δ (CDCl3): 167.4 (C=O), 140.5 (Cq), 139.85 (Cq), 136.0 (Cq), 131.0, 129.2, 
127.8, 127.5, 126.6 (Cq), 125.6, 123.1, 88.9 (Cipso η5-C5H4-alkyl), 85.4 (Cipso η5-C5H4- naphthoyl), 
70.9 (Cmeta η5-C5H4-naphthoyl), 68.2 (Cmeta η5-C5H4-alkyl), 67.3 (Cortho η5-C5H4-alkyl), 65.8 (Cortho 
η5-C5H4-naphthoyl), 52.1 (-OCH3), 13.9 (-CH3). 
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1’-Ethyl-6-ferrocenyl-methyl-2-naphthoate (59) 
 
The synthesis followed that of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate using the following 
reagents: methyl-6-aminonaphthalene-2-carboxylate hydrochloride (2.39 g, 12.0 mmol), HCl (5 ml), 
sodium nitrite (0.83 g, 12.0 mmol), ethyl ferrocene (3.10 g, 15.0 mmol) and polyethylene glycol (2 
ml). The crude product was purified by column chromatography {eluent 5:1 hexane: diethyl ether} 
yielding the title compound as an orange solid (0.86 g, 17%), mp: 163-164 °C; 
1H NMR (400 MHz) δ (CDCl3): 8.61 (1H, t, J = 8.4 Hz, ArH), 8.06 (1H, dd, J = 1.6 and 8.8 Hz, 
ArH), 7.75-7.82 (3H, m, ArH), 7.71 (1H, dd, J = 1.6 and 8.8 Hz, ArH), 4.76 (2H, t, J = 2.0 Hz, ortho 
on η5-C5H4-naphthoyl ), 4.40 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.12 (2H, t, J = 2.0 
Hz, meta on η5-C5H4-alkyl), 4.03 (3H, s, -OCH3), 3.98 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-alkyl), 
2.72 (0.3H, q, J = 7.2Hz, -CH2CH3), 2.48 (0.4H, q, J = 7.2Hz, -CH2CH3), 2.20 (1.3H, q, J = 7.2Hz, 
-CH2CH3), 1.29 (1.5H, t, J = 7.2Hz, -CH2CH3), 1.08 (1.5H, t, J = 7.2Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 167.4 (C=O), 140.41 (Cq), 139.9 (Cq), 135.9 (Cq), 131.1, 130.9, 
129.1, 127.6, 126.0 (Cq), 125.7, 123.1, 122.8, 89.6 (Cipso η5-C5H4-alkyl), 84.2 (Cipso η5-C5H4- 
naphthoyl), 70.2 (Cmeta η5-C5H4-naphthoyl), 69.1 (Cmeta η5-C5H4-alkyl), 67.2 (Cortho η5-C5H4-alkyl), 
65.6 (Cortho η5-C5H4-naphthoyl), 52.2 (-OCH3), 21.5 (-CH2CH3, -ve DEPT), 14.5 (-CH2CH3). 
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1’-Methyl-6-ferrocenyl-2-naphthoic acid (60) 
 
10% NaOH solution (80 ml) was added to 1’-methyl-6-ferrocenyl-methyl-2-naphthoate (5.00 g, 
13.0 mmol) in 80 ml methanol and was refluxed for 12 hours. The solution was cooled on ice and 
acidified to pH 2 with concentrated HCl. Vacuum filtrated the precipitate and wash with deionised 
water yielding product as an orange solid (3.58 g, 74%), mp: 210 °C (decomp); 
1H NMR (600 MHz) δ (DMSO-d6): 12.85 (1H, br. s, -COOH), 8.53 (1H, s, ArH), 8.07-7.79 (5H, m, 
ArH), 4.91 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.41 (2H, t, J = 2.0 Hz, , meta on η5-
C5H4-naphthoyl ), 4.01 (2H, t, J = 2.0 Hz, meta on η5-C5H4-alkyl), 3.92 (2H, t, J = 2.0 Hz, ortho on 
η5-C5H4-alkyl), 2.27 (0.5H, s, -CH3), 2.05 (1H, s, -CH3), 1.57 (1.5H, s, -CH3);  
13C NMR (100 MHz) δ (CDCl3): 168.3 (C=O), 133.9 (Cq), 132.6 (Cq), 131.0 (Cq), 130.2, 129.6, 129.3, 
128.9, 126.6 (Cq), 127.8, 125.8, 88.1 (Cipso η5-C5H4-alkyl), 84.4 (Cipso η5-C5H4- naphthoyl), 84.6 (Cipso 
η5-C5H4-naphthoyl), 71.0 (Cmeta η5-C5H4-naphthoyl), 69.6 (Cmeta η5-C5H4-alkyl), 68.8 (Cortho η5-C5H4-
alkyl), 66.2 (Cortho η5-C5H4-naphthoyl), 14.3 (-CH3). 
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1’-Ethyl-6-ferrocenyl-2-naphthoic acid (61) 
 
The synthesis followed that of 1’-methyl-6-ferrocenyl-methyl-2-naphthoate using the following 
reagents: 1’-ethyl-6-ferrocenyl-methyl-2-naphthoate (5.00 g, 12.6 mmol), methanol (80ml), 10% 
NaOH solution (80 ml). Vacuum filtrated the precipitate and wash with deionised water yielding 
product as an orange oil (3.32 g, 70%); 
1H NMR (400 MHz) δ (DMSO): 12.73 (1H, br. s, -COOH), 8.58 (1H, t, J = 8.4 Hz, ArH), 8.03 (1H, 
dd, J = 1.6 and 8.8 Hz, ArH), 7.85-7.76 (3H, m, ArH), 7.64 (1H, dd, J = 1.6 and 8.8 Hz, ArH), 4.65 
(2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.23 (2H, t, J = 2.0 Hz, , meta on η5-C5H4-
naphthoyl ), 3.94 (2H, t, J = 2.0 Hz, meta on η5-C5H4-alkyl), 3.98 (2H, t, J = 2.0 Hz, ortho on η5-
C5H4-alkyl), 2.41 (1H, q, J = 7.2Hz, -CH2CH3), 2.12 (1H, q, J = 7.2Hz, -CH2CH3), 1.25 (1H, t, J = 
7.2Hz, -CH2CH3), 1.00 (2H, t, J = 7.2Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 168.5 (C=O), 134.8 (Cq), 132.9 (Cq), 131.8 (Cq), 131.4, 128.3, 128.6, 
127.7, 126.7 (Cq), 124.1, 123.0, 89.4 (Cipso η5-C5H4-alkyl), 84.0 (Cipso η5-C5H4- naphthoyl), 71.4 (Cmeta 
η5-C5H4-naphthoyl), 69.4 (Cmeta η5-C5H4-alkyl), 68.5 (Cortho η5-C5H4-alkyl), 65.9 (Cortho η5-C5H4-
naphthoyl), 21.5 (-CH2CH3, -ve DEPT), 14.7 (-CH2CH3). 
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General procedure for the synthesis of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester (62) 
 
1’-Methyl-6-ferrocenyl-2-naphthoic acid (1.00 g, 0.27 mmol) was dissolved in dichloromethane (100 
ml) at 0 °C. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.05 g, 0.27 mmol), 
N-hydroxysuccinimide (0.03 g, 0.27 mmol), glycine-glycine methyl ester (0.39 g, 0.27 mmol) and 
triethylamine (3 ml) were added and the reaction mixture was stirred at 0 oC. After 45 minutes, the 
solution was raised to room temperature and stirred for 48 hours. The reaction mixture was washed 
with water. The organic layer was dried over MgSO4 and the solvent was removed in vacuo. The 
crude product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding 
the title compound as an orange solid (0.24 g, 18%), mp: 162 - 164 oC; 
I.R. υmax (neat): 3307 (NH), 3264 (NH), 1748 (C=Oester), 1629 (C=Oamide I),1623 (C=Oamide I), 1600 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 369, 450 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.28-8.24 (1H, m, ArH),  7.82-7.75 (4H, m, ArH), 7.57 (1H, dd, J 
= 1.6 and 8.8 Hz, ArH), 7.13 (1H, t, J = 5.6 Hz, -CONH-), 6.73 (1H, t, J = 5.6 Hz, -CONH-), 4.59 
(2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.26 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 
4.21 (2H, d, J = 6.1 Hz, -NHCH2CO-), 4.12 (3H, s, -OCH3), 4.02 (2H, d, J = 6.1 Hz, -NHCH2CO-), 
3.91 (2H, t, J = 2.0 Hz, meta on η5-C5H4-alkyl), 3.87 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-alkyl), 2.22 
(0.5H, s, -CH3), 2.03 (1H, s, -CH3), 1.64 (1.5H, s, -CH3);  
13C NMR (100 MHz) δ (CDCl3): 170.3 (C=O), 169.9 (C=O), 166.6 (C=O), 139.4 (Cq), 135.0 (Cq), 
131.0 (Cq), 130.4 (Cq), 129.3, 128.0, 127.5, 125.9, 124.1, 122.8, 90.2 (Cipso η5-C5H4-alkyl), 85.1 (Cipso 
η5-C5H4-naphthoyl), 69.5 (Cmeta η5-C5H4-naphthoyl), 67.1 (Cmeta η5-C5H4-alkyl), 66.3 (Cortho η5-C5H4-
alkyl), 65.7 (Cortho η5-C5H4-naphthoyl), 51.7 (-OCH3), 44.7 (-NHCH2-, -ve DEPT), 40.5 (-NHCH2-, 
-ve DEPT), 15.0 (-CH3). 
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (63)   
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-glycine ethyl ester (0.42 g, 0.27 mmol). The crude product was 
purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title compound 
as an orange solid (0.50 g, 37%), mp: 125 - 127 oC; 
HRMS (ESI+) m/z: 512.1171 [M]+•, C28H28N2O4Fe requires 512.1398; 
I.R. υmax (neat): 3300 (NH), 3276 (NH), 1740 (C=Oester), 1630 (C=Oamide I), 1626 (C=Oamide I), 1608 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 367, 450 nm; 
1H NMR (600 MHz) δ (CDCl3): 8.27-8.20 (1H, m, ArH), 7.80-7.73 (4H, m, ArH), 7.55 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 7.53 (1H, t, J = 5.6 Hz, -CONH-), 7.18 (1H, t, J = 5.6 Hz, -CONH-), 4.64 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl), 4.29 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl), 4.21 
(2H, d, J = 6.1 Hz, -NHCH2CO-), 4.14 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.02 (2H, d, J = 7.3 Hz, -
CONHCH2CO-), 3.91 (2H, t, J = 2.0 Hz , meta on η5-C5H4-alkyl), 3.87（2H, t, J = 2.0 Hz , ortho on 
η5-C5H4-alkyl), 2.19 (0.5H, s, -CH3), 2.00 (1H, s, -CH3), 1.61 (1.5H, s, -CH3), 1.17 (3H, t, J = 7.2 Hz, 
-OCH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 172.9 (C=O), 169.4 (C=O), 167.8 (C=O), 134.8 (Cq), 133.0 (Cq), 
130.7 (Cq), 130.2 (Cq), 128.8, 127.8, 127.4, 124.8, 124.0, 120.8, 90.1 (Cipso η5-C5H4-alkyl), 86.5 (Cipso 
η5-C5H4-naphthoyl), 71.7 (Cmeta η5-C5H4-naphthoyl), 69.9 (Cmeta η5-C5H4-alkyl), 69.7 (Cortho η5-C5H4-
alkyl), 67.3 (Cortho η5-C5H4-naphthoyl), 61.5 (-OCH2CH3, -ve DEPT), 43.8 (-NHCH2-, -ve DEPT), 
41.2 (-NHCH2-, -ve DEPT), 15.2 (-CH3), 14.1 (-OCH2CH3). 
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl ester (64) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-L-alanine methyl ester (0.43 g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a light orange solid (0.24 g, 17%), mp: 142 - 144 oC; 
I.R. υmax (neat): 3290 (NH), 3090 (NH), 1747 (C=Oester), 1640 (C=Oamide I), 1620 (C=Oamide I), 1521 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 376, 452 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.13-8.04 (1H, m, ArH), 7.79-7.73 (4H, m, ArH), 7.48 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 7.21 (1H, t, J = 5.6 Hz, -CONH-), 6.84 (1H, t, J = 5.6 Hz, -CONH-), 4.62 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.54 (1H, q, J = 7.3 Hz, -CHCH3), 4.29 (2H, t, J = 2.0 
Hz, meta on η5-C5H4-naphthoyl ), 4.26 (2H, d, J = 7.3 Hz, -NHCH2-), 4.00 (2H, t, J = 2.0 Hz , meta 
on η5-C5H4-alkyl), 3.87 (2H, t, J = 2.0 Hz , ortho on η5-C5H4-alkyl), 3.63 (3H, s, -OCH3), 2.21 (0.5H, 
s, -CH3), 2.04 (1H, s, -CH3), 1.62 (1.5H, s, -CH3), 1.32 (3H, d, J = 7.3 Hz, -CHCH3); 
13C NMR (100 MHz) δ (CDCl3): 172.5 (C=O), 169.0 (C=O), 167.5 (C=O), 139.4 (Cq), 136.0 (Cq), 
131.3 (Cq), 130.4 (Cq), 128.7, 128.0, 126.9, 126.0, 124.4, 122.8, 88.8 (Cipso η5-C5H4-alkyl), 84.0 (Cipso 
η5-C5H4-naphthoyl), 70.5 (Cmeta η5-C5H4-naphthoyl), 68.1 (Cmeta η5-C5H4-alkyl), 67.9 (Cortho η5-C5H4-
alkyl), 66.2 (Cortho η5-C5H4-naphthoyl), 51.7 (-OCH3), 49.6 (-CHCH3), 43.0 (-NHCH2-, -ve DEPT), 
18.1 (-CHCH3), 15.0 (-CH3).  
88 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester (65) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-L-alanine ethyl ester (0.47g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange solid (0.34 g, 23%), mp: 154 - 156 oC; 
I.R. υmax (neat): 3289 (NH), 3079 (NH), 1734 (C=Oester), 1640 (C=Oamide I), 1624 (C=Oamide I), 1522 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 373, 453 nm; 
1H NMR (600 MHz) δ (CDCl3): 8.30-8.24 (1H, m, ArH), 7.84-7.73 (4H, m, ArH), 7.61 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 7.22 (1H, t, J = 5.6 Hz, -CONH-), 6.83 (1H, t, J = 5.6 Hz, -CONH-), 4.63 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.54 (1H, q, J = 7.3 Hz, -CHCH3), 4.29 (2H, t, J = 2.0 
Hz, meta on η5-C5H4-naphthoyl ), 4.26 (2H, d, J = 7.3 Hz, -NHCH2-), 4.21 (2H, q, J = 7.2 Hz, -
OCH2CH3), 4.00 (2H, t, J = 2.0 Hz, meta on η5-C5H4-alkyl), 3.85 (2H, t, J = 2.0 Hz , ortho on η5-
C5H4-alkyl), 2.21 (0.5H, s, -CH3), 2.02 (1H, s, -CH3), 1.63 (1.5H, s, -CH3), 1.40 (3H, d, J =7.3 Hz, -
CHCH3), 1.22 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 173.1 (C=O), 169.0 (C=O), 167.7 (C=O), 139.2 (Cq), 135.6 (Cq), 
131.6 (Cq), 130.3 (Cq), 128.9, 128.4, 127.9, 126.1, 124.0, 122.9, 89.3 (Cipso η5-C5H4-alkyl), 85.8 (Cipso 
η5-C5H4-naphthoyl), 71.3 (Cmeta η5-C5H4-naphthoyl), 68.8 (Cmeta η5-C5H4-alkyl), 67.2 (Cortho η5-C5H4-
alkyl), 65.9 (Cortho η5-C5H4-naphthoyl), 61.7 (-OCH2CH3, -ve DEPT), 48.4 (-CHCH3), 43.6 (-
NHCH2-, -ve DEPT), 18.3 (-CHCH3), 14.9 (-OCH2CH3), 14.8 (-CH3).  
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine methyl ester (66) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-D-alanine methyl ester (0.43 g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a light orange solid (0.28 g, 20%), mp: 139 - 140 oC; 
I.R. υmax (neat): 3286 (NH), 3078 (NH), 1739 (C=Oester), 1643 (C=Oamide I), 1625 (C=Oamide I), 1521 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 376, 455 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.25 (1H, t, J = 8.4 Hz, ArH), 7.79-7.73 (4H, m, ArH), 7.60 (1H, 
dd, J = 1.6 and 8.8 Hz, ArH), 7.35 (1H, t, J = 5.6 Hz, -CONH-), 7.09 (1H, t, J = 5.6 Hz, -CONH-), 
4.67 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.59 (1H, q, J = 7.3 Hz, -CHCH3), 4.32 (2H, 
t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.22 (2H, d, J = 7.3 Hz, -NHCH2-), 3.94 (2H, t, J = 2.0 
Hz , meta on η5-C5H4-alkyl), 3.90 (2H, t, J = 2.0 Hz , ortho on η5-C5H4-alkyl), 3.69 (3H, s, -OCH3), 
2.21 (0.5H, s, -CH3), 2.02 (1H, s, -CH3), 1.63 (1.5H, s, -CH3), 1.41 (3H, d, J = 7.3 Hz, -CHCH3); 
13C NMR (100 MHz) δ (CDCl3): 172.6 (C=O), 169.3 (C=O), 167.5 (C=O), 139.2 (Cq), 135.2 (Cq), 
131.1 (Cq), 130.6 (Cq), 129.0, 128.4, 127.9, 126.0, 124.2, 122.8, 89.1 (Cipso η5-C5H4-alkyl), 84.2 (Cipso 
η5-C5H4-naphthoyl), 70.6 (Cmeta η5-C5H4-naphthoyl), 68.1 (Cmeta η5-C5H4-alkyl), 67.4 (Cortho η5-C5H4-
alkyl), 66.3 (Cortho η5-C5H4-naphthoyl), 51.6 (-OCH3), 49.6 (-CHCH3), 43.1 (-NHCH2-, -ve DEPT), 
18.2 (-CHCH3), 15.3 (-CH3).
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester (67) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-D-alanine ethyl ester (0.47g, 0.27 mmol) The crude product was 
purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title compound 
as a dark orange solid (0.22 g, 15%), mp: 142 - 143 oC; 
I.R. υmax (neat): 3286 (NH), 3093 (NH), 1736 (C=Oester), 1626 (C=Oamide I), 1608 (C=Oamide I), 1518 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 379, 455 nm; 
1H NMR (600 MHz) δ (CDCl3): 8.23(1H, t, J = 8.4 Hz, ArH), 7.80-7.73 (4H, m, ArH), 7.74 (1H, dd, 
J = 1.6 and 8.8 Hz, ArH), 6.98 (1H, t, J = 5.6 Hz, -CONH-), 6.51 (1H, t, J = 5.6 Hz, -CONH-), 4.74 
(2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.58 ( 1H, t, J = 7.3 Hz, -CHCH3), 4.39 (2H, t, J = 
2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.18 (2H, d, J = 7.3 Hz, -NHCH2-), 4.13 (2H, q, J = 7.2 Hz, -
OCH2CH3), 4.07 (2H, t, J = 2.0 Hz , meta on η5-C5H4-alkyl), 3.97 (2H, t, J = 2.0 Hz , ortho on η5-
C5H4-alkyl), 2.17 (0.5H, s, -CH3), 2.02 (1H, s, -CH3), 1.61 (1.5H, s, -CH3), 1.39 (3H, d, J =7.3 Hz, -
CHCH3), 1.24 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 173.2 (C=O), 169.3 (C=O), 167.5 (C=O), 139.1 (Cq), 135.8 (Cq), 
131.3 (Cq), 130.7 (Cq), 128.6, 128.4, 127.0, 126.8, 124.8, 122.2, 89.0 (Cipso η5-C5H4-alkyl), 84.2 (Cipso 
η5-C5H4- naphthoyl), 71.0 (Cmeta η5-C5H4-naphthoyl), 69.0 (Cmeta η5-C5H4-alkyl), 67.4 (Cortho η5-C5H4-
alkyl), 66.1 (Cortho η5-C5H4-naphthoyl), 61.6 (-OCH2CH3, -ve DEPT), 47.9 (-CHCH3), 43.6 (-
NHCH2-, -ve DEPT), 17.9 (-CHCH3), 15.0 (-OCH2CH3), 14.8 (-CH3). 
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid methyl ester (68) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: gamma-aminobutyric acid methyl ester (0.31 g, 0.27 mmol). The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange solid (0.72 g, 57%), mp: 175 - 178 oC; 
HRMS (ESI+) m/z: 469.1082 [M]+•, C27H27NO3Fe requires 469.1340; 
I.R. υmax (neat): 3280 (NH), 1721 (C=Oester), 1600 (C=Oamide) cm-1; 
UV-Vis λmax (CH3CN): 379, 454 nm; 
1H NMR (600 MHz) δ (CDCl3): 8.23-8.17 (1H, m, ArH), 7.86-7.58 (4H, m, ArH), 7.50-7.45 (1H, m, 
ArH), 6.65 (1H, t, J = 5.6 Hz, -CONH-), 4.66 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.29 
(2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.00 (2H, t, J = 2.0 Hz , meta on η5-C5H4-alkyl), 
3.87 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-alkyl), 3.61 (3H, s, -OCH3), 3.52 ( 2H, q, J = 6.5 Hz, -
NHCH2CH2CH2-), 2.44 (2H, t, J = 6.5 Hz, -NHCH2CH2CH2CO-), 1.92 (2H, qt, J = 6.5 Hz, -
NHCH2CH2CH2-), 2.21 (0.5H, s, -CH3), 2.01 (1H, s, -CH3), 1.63 (1.5H, s, -CH3),;  
13C NMR (100 MHz) δ (CDCl3): 172.9 (C=O), 168.0 (C=O), 139.5 (Cq), 138.9 (Cq), 134.6 (Cq), 
131.7 (Cq), 129.0, 128.4, 127.7, 126.6, 123.9, 123.0, 89.1 (Cipso η5-C5H4-alkyl), 84.9 (Cipso η5-C5H4-
naphthoyl), 70.2 (Cmeta η5-C5H4-naphthoyl), 68.8 (Cmeta η5-C5H4-alkyl), 67.3 (Cortho η5-C5H4-alkyl), 
65.8 (Cortho η5-C5H4-naphthoyl), 51.7 (-OCH3), 39.8 (-NHCH2CH2CH2-, -ve DEPT), 31.8 (-
NHCH2CH2CH2-, -ve DEPT), 24.6 (-NHCH2CH2CH2-, -ve DEPT), 13.8 (-CH3).  
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N-(1’-methyl-6-ferrocenyl-2-naphthoyl) -γ-aminobutyric acid ethyl ester (69) 
 
The synthesis followed that of N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: gamma-aminobutyric acid ethyl ester (0.34 g, 0.27 mmol). The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange solid (0.34 g, 32%), mp: 196 - 198 oC; 
HRMS (ESI+) m/z: 483.1474 [M]+•, C28H29NO3Fe requires 483.1497; 
I.R. υmax (neat): 3283 (NH), 1726 (C=Oester), 1605 (C=Oamide) cm-1; 
UV-Vis λmax (CH3CN): 371, 447 nm; 
1H NMR (600 MHz) δ (CDCl3): 8.21-8.17 (1H, m, ArH), 7.84-7.74 (4H, m, ArH), 7.61 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 6.68 (1H, t, J = 5.6 Hz, -CONH-), 4.65 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.29 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.10 (2H, q, J = 7.3 Hz, -OCH2CH3), 
4.00 (2H, t, J = 2.0 Hz , meta on η5-C5H4-alkyl), 3.86 (2H, t,  J= 2.0 Hz ,ortho on η5-C5H4-alkyl), 
3.53 (2H, q, J = 6.5 Hz, -NHCH2CH2CH2-), 2.40 (2H, t, J = 6.5 Hz, -NHCH2CH2CH2-), 2.21 (0.5H, 
s, -CH3), 2.01 (1H, s, -CH3), 1.94 (2H, qt, J = 6.5 Hz, -NHCH2CH2CH2-), 1.63 (1.5H, s, -CH3), 1.18 
(3H, t, J = 7.3 Hz ,- OCH2CH3);  
13C NMR (100 MHz) δ (CDCl3): 173.9 (C=O), 167.9 (C=O), 139.5 (Cq), 135.1 (Cq), 131.2 (Cq), 
130.7 (Cq), 128.8, 127.9, 127.2, 126.1, 123.9, 123.1, 89.4 (Cipso η5-C5H4-alkyl), 84.3 (Cipso η5-C5H4-
naphthoyl), 70.4 (Cmeta η5-C5H4-naphthoyl), 68.9 (Cmeta η5-C5H4-alkyl), 67.1 (Cortho η5-C5H4-alkyl), 
64.4 (Cortho η5-C5H4-naphthoyl), 60.6 (-OCH2CH3, -ve DEPT), 39.8 (-NHCH2CH2CH2-, -ve DEPT), 
32.1 (-NHCH2CH2CH2-, -ve DEPT), 24.5 (-NHCH2CH2CH2-, -ve DEPT), 14.1 (-OCH2CH3), 13.7 (-
CH3).
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General procedure for the synthesis of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester (70) 
 
1’-Ethyl-6-ferrocenyl-2-naphthoic acid (1.12 g, 0.27 mmol) was dissolved in dichloromethane (100 
ml) at 0 oC. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.05 g, 0.27 mmol), 
N-hydroxysuccinimide (0.03 g, 0.27 mmol), glycine-glycine methyl ester (0.42 g, 0.27 mmol) and 
triethylamine (3 ml) were added and the reaction mixture was stirred at 0 oC. After 45 minutes, the 
solution was raised to room temperature and stir for 48 hours. The reaction mixture was washed with 
water. The organic layer was dried over MgSO4 and the solvent was removed in vacuo. The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as an orange oil (0.17 g, 13%); 
HRMS (ESI+) m/z: 512.1429 [M]+•, C28H28N2O4Fe requires 512.1398; 
I.R. υmax (neat): 3303 (NH), 3081 (NH), 1744 (C=Oester), 1643 (C=Oamide I), 1626 (C=Oamide I), 1522 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 368, 454 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.28-8.24 (1H, m, ArH), 7.90-7.76 (4H, m, ArH), 7.63 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 7.14 (1H, t, J = 5.4 Hz, -CONH-), 6.79 (1H, t, J = 5.4 Hz, -CONH-), 4.67 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.31 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl), 
4.23 (2H, d, J = 6.0 Hz, -NHCH2COOCH3), 4.06 ( 2H, d, J = 6.0 Hz, -CONHCH2CO-), 4.04 (3H, s, 
-OCH3), 3.94-3.71 (4H, m, η5-C5H4-alkyl), 2.62 (0.5H, q, J = 8.0 Hz, -CH2CH3), 2.39 (0.5H, q, J = 
8.0 Hz, -CH2CH3), 2.14 (1H, q, J = 8.0 Hz, -CH2CH3), 1.21 (1.5H, t, J = 8.0 Hz, -CH2CH3), 0.99 
(1.5H, t, J = 8.0 Hz, -CH2CH3);  
13C NMR (100 MHz) δ (CDCl3): 169.8 (C=O), 169.6 (C=O), 166.6 (C=O), 139.3 (Cq), 134.4 (Cq), 
132.3 (Cq), 131.2 (Cq), 128.7, 127.9, 126.7, 123.3, 123.0, 122.5, 89.9 (Cipso η5-C5H4-alkyl), 85.7 (Cipso 
η5-C5H4-naphthoyl), 70.2 (Cmeta η5-C5H4-naphthoyl), 68.4 (Cmeta η5-C5H4-alkyl), 67.4 (Cortho η5-C5H4-
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alkyl), 65.8 (Cortho η5-C5H4-naphthoyl), 51.8 (-OCH3), 43.4 (-NHCH2-, -ve DEPT), 40.7 (-NHCH2-, 
-ve DEPT), 21.7 (-CH2CH3, -ve DEPT), 14.7 (-CH2CH3).  
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N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (71)   
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-glycine ethyl ester (0.39 g, 0.27 mmol). The crude product was 
purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title compound 
as an orange oil (0.21 g, 16%); 
I.R. υmax (neat): 3371 (NH), 3350 (NH), 1733 (C=Oester), 1645 (C=Oamide I), 1626 (C=Oamide I), 1523 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 367, 454 nm; 
1H NMR (600 MHz) δ (CDCl3): 7.93-7.90 (1H, m, ArH), 7.76-7.74 (4H, m, ArH), 7.06 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 6.99 (1H, t, J = 5.6 Hz, -CONH-), 6.51 (1H, t, J = 5.6 Hz, -CONH-), 4.68 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl), 4.33 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl), 4.21 
(2H, d, J = 6.0 Hz, -NHCH2CO-), 4.18 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.05 (2H, d, J = 6.0 Hz, -
CONHCH2CO-), 3. 95-3.91 (4H, m , η5-C5H4-alkyl), 2.54 (1H, q, J = 8.0 Hz, -CH2CH3), 2.08 (1H, 
q, J = 8.0 Hz, -CH2CH3), 1.08 (3H, t, J = 8.0 Hz, -CH2CH3), 0.97 (3H, t, J = 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 169.7 (C=O), 168.2 (C=O), 166.9 (C=O), 139.4 (Cq), 135.4 (Cq), 
131.2 (Cq), 130.0 (Cq), 128.9, 128.1, 127.8, 126.1, 124.2, 122.9, 92.0 (Cipso η5-C5H4-alkyl), 84.2 (Cipso 
η5-C5H4-naphthoyl), 68.9 (Cmeta η5-C5H4-naphthoyl), 67.1 (Cmeta η5-C5H4-alkyl), 66.4 (Cortho η5-C5H4-
alkyl), 65.6 (Cortho η5-C5H4-naphthoyl), 62.3 (-OCH2CH3, -ve DEPT), 44.4 (-NHCH2-, -ve DEPT), 
40.8 (-NHCH2-, -ve DEPT), 21.6 (-CH2CH3, -ve DEPT), 14.9 (-OCH2CH3), 14.7 (-CH2CH3).  
96 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl ester (72) 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-L-alanine methyl ester (0.43 g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a light orange oil (0.25 g, 18%); 
I.R. υmax (neat): 3387 (NH), 3090 (NH), 1737 (C=Oester), 1642 (C=Oamide I), 1627(C=Oamide I), 1529 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 373, 452 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.29 (1H, t, J = 8.4 Hz, ArH), 7.90-7.73 (4H, m, ArH), 7.54 (1H, 
dd, J = 1.6 and 8.8 Hz, ArH), 7.25 (1H, t, J = 5.6 Hz, -CONH-), 6.91 (1H, t, J = 5.6 Hz, -CONH-), 
4.56 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.44 (1H, q, J = 7.3 Hz, -CHCH3), 4.29 (2H, 
t, J = 2.0 Hz, ortho on η5-C5H4-naphthoyl ), 4.27 (2H, d, J = 7.3 Hz, -NHCH2-), 3.92-3.86 (4H, m, 
η5-C5H4-alkyl), 3.68 (3H, s, -OCH3), 2.60 (0.8H, q, J = 7.2 Hz, - CH2CH3), 2.16 (1.2H, q, J = 7.2 
Hz, -CH2CH3), 1.40 (3H, d, J =7.3 Hz, -CHCH3), 1.18 (3H, t, J = 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 172.5 (C=O), 169.1 (C=O), 167.4 (C=O), 139.4 (Cq), 135.1 (Cq), 
131.3 (Cq), 130.4 (Cq), 129.6, 128.3, 127.9, 125.4, 123.3, 123.0, 89.3 (Cipso η5-C5H4-alkyl), 84.2 (Cipso 
η5-C5H4-naphthoyl), 71.7 (Cmeta η5-C5H4-naphthoyl), 69.3 (Cmeta η5-C5H4-alkyl), 67.1(Cortho η5-C5H4-
alkyl), 66.2 (Cortho η5-C5H4-naphthoyl), 51.7 (-OCH3), 49.6 (-CHCH3), 43.0 (-NHCH2-, -ve DEPT), 
20.6 (-CH2CH3, -ve DEPT), 17.5 (-CHCH3), 14.5 (-CH2CH3). 
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N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester (73) 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-L-alanine ethyl ester (0.47g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange oil (0.35 g, 23%); 
I.R. υmax (neat): 3315 (NH), 3061 (NH), 1750 (C=Oester), 1643 (C=Oamide I), 1629 (C=Oamide I), 1535 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 372, 452 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.28-8.24 (1H, m, ArH), 7.82-7.69 (5H, m, ArH), 7.29 (1H, t, J = 
5.6 Hz, -CONH-), 6.96 (1H, t, J = 5.6 Hz, -CONH-), 4.71 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.53 (1H, q, J = 7.3 Hz, -CHCH3), 4.35 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 
4.21 (2H, d, J = 7.3 Hz, -NHCH2-), 4.16 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.05 (2H, t, J= 2.0 Hz , 
meta on η5-C5H4-alkyl), 3.93 (2H, t, J = 2.0 Hz , ortho on η5-C5H4-alkyl), 2.45 (1.3H, q, J = 7.2 Hz, 
-CH2CH3), 2.34 (0.5H, q, J = 7.2 Hz, -CH2CH3), 2.04 (0.2H, q, J = 7.2 Hz, -CH2CH3), 1.41 (3H, d, 
J =7.3 Hz, -CHCH3), 1.19 (3H, t, J = 7.2 Hz, -OCH2CH3), 1.17 (3H, t, J = 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 172.1 (C=O), 169.6 (C=O), 167.8 (C=O), 140.2 (Cq), 136.2 (Cq), 
131.3 (Cq), 130.9 (Cq), 129.7, 128.3, 127.7, 125.4, 123.3, 123.2, 89.7 (Cipso η5-C5H4-alkyl), 84.8 (Cipso 
η5-C5H4-naphthoyl), 70.3 (Cmeta η5-C5H4-naphthoyl), 69.0 (Cmeta η5-C5H4-alkyl), 67.2 (Cortho η5-C5H4-
alkyl), 65.7 (Cortho η5-C5H4-naphthoyl), 61.6 (-OCH2CH3, -ve DEPT), 49.4 (-CHCH3), 42.6 (-
NHCH2-, -ve DEPT), 21.0 (-CH2CH3, -ve DEPT), 18.8 (-CHCH3), 14.9 (-OCH2CH3), 14.1 (-
CH2CH3). 
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N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine methyl ester (74) 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-D-alanine methyl ester (0.43 g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a light orange oil (0.26 g, 17%); 
I.R. υmax (neat): 3379 (NH), 3090 (NH), 1734 (C=Oester), 1642 (C=Oamide I), 1627 (C=Oamide I), 1531 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 376, 450 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.23(1H, t, J = 8.4 Hz, ArH), 7.79-7.61 (5H, m, ArH), 7.00 (1H, t, 
J = 5.6 Hz, -CONH-), 6.56 (1H, t, J = 5.6 Hz, -CONH-), 4.68 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.58 (1H, qt, J = 7.3 Hz, -CHCH3), 4.26 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 
4.17 (2H, d, J = 7.2 Hz, -NHCH2-), 3.93-3.88 (4H, m, η5-C5H4-alkyl), 3.71 (3H, s, -OCH3), 2.40 (1H, 
q, J = 7.2 Hz, -CH2CH3), 2.05 (1H, q, J = 7.2 Hz, -CH2CH3), 1.40 (3H, d, J =7.3Hz, -CHCH3), 1.12 
(3H, t, J = 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 172.6 (C=O), 169.0 (C=O), 167.5 (C=O), 139.2 (Cq), 135.1 (Cq), 
133.1 (Cq), 130.4(Cq), 129.3, 128.0, 127.2, 125.3, 123.2, 122.8, 88.9 (Cipso η5-C5H4-alkyl), 84.5 (Cipso 
η5-C5H4- naphthoyl), 71.0 (Cmeta η5-C5H4-naphthoyl), 69.1 (Cmeta η5-C5H4-alkyl), 67.2 (Cortho η5-C5H4-
alkyl), 66.3 (Cortho η5-C5H4-naphthoyl), 51.3 (-OCH3), 49.6 (-CHCH3), 43.1 (-NHCH2-, -ve DEPT), 
21.3 (-CH2CH3, -ve DEPT), 17.8 (-CHCH3), 14.5 (-CH2CH3). 
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N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester (75) 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: glycine-D-alanine ethyl ester (0.47g, 0.27 mmol). The crude product 
was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange oil (0.22 g, 15%); 
I.R. υmax (neat): 3305 (NH), 3061 (NH), 1734 (C=Oester), 1642 (C=Oamide I), 1628 (C=Oamide I), 1523 
(C=Oamide II) cm-1; 
UV-Vis λmax (CH3CN): 380, 452 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.28 (1H, t, J = 8.4 Hz, ArH), 7.82-7.60 (5H, m, ArH), 7.33 (1H, t, 
J = 5.6 Hz, -CONH-), 6.99 (1H, t, J = 5.6 Hz, -CONH-), 4.66 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.56 (1H, qt, J = 7.3 Hz, -CHCH3), 4.29 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 
4.21(2H, d, J = 7.3 Hz, -NHCH2-), 4.16 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.11-3.93 (4H, m, η5-C5H4-
alkyl), 2.63 (1.2H, q, J = 7.2 Hz, -CH2CH3), 2.10 (0.8H, q, J = 7.2 Hz, -CH2CH3), 1.41 (3H, d, J 
=7.3 Hz, -CHCH3), 1.22 (3H, t, J = 7.2 Hz, -OCH2CH3), 1.18 (3H, t, J = 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 173.6 (C=O), 169.8 (C=O), 167.5 (C=O), 139.2 (Cq), 136.2 (Cq), 
131.3 (Cq), 130.7 (Cq), 129.0, 128.4, 127.7, 125.8, 123.8, 123.2, 89.6 (Cipso η5-C5H4-alkyl), 84.1 (Cipso 
η5-C5H4-naphthoyl), 69.8 (Cmeta η5-C5H4-naphthoyl), 69.1 (Cmeta η5-C5H4-alkyl), 67.3 (Cortho η5-C5H4-
alkyl), 65.7 (Cortho η5-C5H4-naphthoyl), 61.8 (-OCH2CH3, -ve DEPT), 49.7 (-CHCH3), 42.6 (-
NHCH2-, -ve DEPT), 21.3 (-CH2CH3, -ve DEPT), 17.9 (-CHCH3), 14.8 (-OCH2CH3), 14.7 (-
CH2CH3). 
100 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid methyl ester (76) 
 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: gamma-aminobutyric acid methyl ester (0.31 g, 0.27 mmol). The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange oil (0.47 g, 36%); 
HRMS (ESI+) m/z: 483.1294 [M]+•, C28H29NO3Fe requires 483.1497; 
I. R. υmax (neat): 3274 (NH), 1730 (C=Oester), 1622 (C=Oamide) cm-1; 
UV-Vis λmax (CH3CN): 372, 449 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.21-8.15 (1H, m, ArH), 7.84-7.73 (4H, m, ArH), 7.61 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 6.62 (1H, t, J = 5.4Hz, -CONH-), 4.62 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.27 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.00-3.85 (4H, m, η5-C5H4-alkyl), 
3.58 (3H, s, -OCH3), 3.49 ( 2H, q, J = 6.5 Hz, -NHCH2CH2CH2-), 2.40 (2H, t, J = 6.5 Hz, -
NHCH2CH2CH2CO-), 2.62 (0.3H, q, J = 7.2, -CH2CH3), 2.39 (0.4H, q, J = 7.2, -CH2CH3), 2.14 (1.3H, 
q, J = 7.2 Hz, -CH2CH3), 1.93 (2H, qt, J = 6.5 Hz, -NHCH2CH2CH2-), 1.21 (1.5H, t, J = 7.2, -
CH2CH3), 0.99 (1.5H, t, J = 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (CDCl3): 174.3 (C=O), 167.6 (C=O), 134.7 (Cq), 132.6 (Cq), 131.6 (Cq), 
131.1 (Cq), 128.9, 128.4, 127.8, 126.7, 123.7, 123.5, 88.9 (Cipso η5-C5H4-alkyl), 84.3 (Cipso η5-C5H4-
naphthoyl), 71.3 (Cmeta η5-C5H4-naphthoyl), 69.1 (Cmeta η5-C5H4-alkyl), 67.2 (Cortho η5-C5H4-alkyl), 
66.5 (Cortho η5-C5H4-naphthoyl), 51.8 (-OCH3), 39.8 (-NHCH2CH2CH2-, -ve DEPT), 31.8 (-
NHCH2CH2CH2-, -ve DEPT), 24.4 (-NHCH2CH2CH2-, -ve DEPT), 21.5 (-CH2CH3, -ve DEPT),14.7 
(-CH2CH3).  
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N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester (77) 
 
 
The synthesis followed that of N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
using the following reagent: gamma-aminobutyric acid ethyl ester (0.34 g, 0.27 mmol). The crude 
product was purified by column chromatography {eluent 1:1 hexane: ethyl acetate} yielding the title 
compound as a dark orange oil (0.54 g, 60%); 
HRMS (ESI+) m/z: 497.1524 [M]+•, C29H31NO3Fe requires 497.1653; 
I.R. υmax (neat): 3318 (NH), 1729 (C=Oester), 1636 (C=Oamide) cm-1;  
UV-Vis λmax (CH3CN): 370, 447 nm; 
1H NMR (400 MHz) δ (CDCl3): 8.23-8.19 (1H, m, ArH), 7.85-7.75 (4H, m, ArH), 7.62 (1H, dd, J = 
1.6 and 8.8 Hz, ArH), 6.67 (1H, t, J = 5.4 Hz, -CONH-), 4.76 (2H, t, J = 2.0 Hz, ortho on η5-C5H4-
naphthoyl ), 4.38 (2H, t, J = 2.0 Hz, meta on η5-C5H4-naphthoyl ), 4.13 (2H, q, J = 8.0 Hz, -OCH2CH3), 
4.02-3.96 (4H, m, η5-C5H4-alkyl), 3.62 (2H, q, J = 6.5 Hz, -NHCH2CH2CH2-), 2.64 (0.6H, q, J = 7.2 
Hz, -CH2CH3), 2.56 (2H, t, J = 6.5 Hz, -NHCH2CH2CH2-), 2.45 (0.4H, q, J = 7.2 Hz, -CH2CH3), 2.18 
(1H, q, J = 7.2 Hz, -CH2CH3), 2.15 (2H, qt, J = 6.5 Hz, -NHCH2CH2CH2-), 1.29 (3H, t, J = 8.0 Hz, 
-OCH2CH3), 0.99 (1.5H, t, J = 7.2 Hz, -CH2CH3), 0.89 (1.5H, t, J = 7.2 Hz, -CH2CH3);  
13C NMR (100 MHz) δ (CDCl3): 173.3 (C=O), 168.6 (C=O), 134.7 (Cq), 133.3 (Cq), 131.6 (Cq), 
132.5 (Cq), 128.7, 128.3, 127.6, 126.4, 123.9, 123.2, 89.1 (Cipso η5-C5H4-alkyl), 84.3 (Cipso η5-C5H4-
naphthoyl), 69.7 (Cmeta η5-C5H4-naphthoyl), 68.8 (Cmeta η5-C5H4-alkyl), 67.1 (Cortho η5-C5H4-alkyl), 
65.6 (Cortho η5-C5H4-naphthoyl), 61.4 (-OCH2CH3, -ve DEPT), 40.1 (-NHCH2CH2CH2-, -ve DEPT), 
31.7 (-NHCH2CH2CH2-, -ve DEPT), 23.9 (-NHCH2CH2CH2-, -ve DEPT), 22.2 (-CH2CH3, -ve 
DEPT), 15.1 (-OCH2CH3), 13.6 (-CH3).  
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Chapter 3 
Biological Evaluation of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters 
3.1. Introduction 
 
Recent studies have shown N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 30 is the most 
active compound of the N-ferrocenyl amino acid and dipeptide esters to date in Kenny’s research 
group, with an IC50 value of 0.13 ± 0.02 μM in H1299 NSCLC cells. 1 Harry et al. synthesized 
disubstituted derivatives of N-(ferrocenyl)benzoyl amino acid and dipeptide esters, and have shown 
a greater cytotoxicity than the monosubstituted ones. 1-methyl-1’-N-{para-(ferrocenyl)-benzoyl}-
glycine-glycine ethyl ester 31 have IC50 value of 2.8 ± 1.23 μM in H1299 cell line. 2 
 
In a further structure-activity relationship (SAR) study of the ferrocenyl peptide conjugates, a series 
of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide esters have been prepared maintaining the most active amino acid and dipeptide esters 
whilst altering the ferrocenyl moiety and the ester functionality. In total, 14 compounds were tested 
for their anti-proliferative effect on human cervical carcinoma cells (ATCC HTB-35, SiHa) and 
human liver cells (ATCC CCL-13, Chang liver, HeLa markers). 
3.2. Miniaturised in vitro methods 
Miniaturised in vitro colorimetric assay is a simple and sensitive technique which has been widely 
used in the determination of a substance’s ability to enhance cell growth or promote cell death. 3 The 
most commonly used measure of toxicity is impairment of cell growth by reduced cell numbers when 
comparing between treated samples and untreated controls.  
 
Colorimetric end-point assays are not possible to distinguish the cell death due to cytotoxic or 
cytostatic effect. Cytotoxic effect leads to cell death by either apoptosis, necrosis or autophagy, while 
cytostatic effect is only a temporary manner. Apoptosis is programmed cell death that occurs in 
multicellular organisms, necrosis is an unprogrammed cell death caused by disease, cellular injury, 
or failure of the blood supply, and autophagy is a self-degrative process that delivers cytoplasmic 
constituents to the lysosome. 5 A substance will lose its anti-proliferative activity once the cytostatic 
agent is removed. 3 4 5  
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Several miniaturised in vitro colorimetric assays have been developed for the quantification of cell 
growth. The most common assays used are MTT assay 6 , acid phosphatase assay 7 and WST-1 assay 
8.  
 
3.2.1. MTT dye assay 
 
The MTT test is a colorimetric assay based on the formation of a coloured insoluble formazan salt. 
The amount of formazan produced, and the viable cell numbers have a direct proportional 
relationship thus this method can be used to measure cell viability and proliferation. The yellow 
water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) 
can be reduced into a purple insoluble formazan product by the mitochondrial succinate 
dehydrogenase. The resulting intracellular purple insoluble crystals can be solubilized in DMSO and 
quantified by spectrophotometric means at 570 nm. Nonetheless, the MTT assay have a number of 
problems: the intensity of the reduction varies in different cell lines; the reaction rate varies with a 
few factors (e.g. cellular and medium glucose levels, and pH). 6 
 
 
 
 
Figure 3.1: The dehydrogenase enzyme conversion of the MTT dye to the formazan product. 
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3.2.2. Acid phosphatase assay 
 
Acid Phosphatases are a group of enzymes that non-specifically catalyse the production of inorganic 
phosphate from p-nitrophenolate phosphate (pNPP) at an acidic pH. The ability of phosphatases to 
catalyse the hydrolysis of pNPP to p-nitrophenol is measured by spectrometric means. The addition 
of strong base not only ceases the reaction but also yields alkaline conditions in which p-
nitrophenolate is yellow. Colorimetric analysis of the p-nitrophenolate anion indirectly measures of 
the inhibition of cell growth. A direct correlation of the yellow intensity and viable cell number can 
be measured by spectrophotometric means at 405nm. The acid phosphatase assay is a simple and 
sensitive method with excellent reproducibility. It involves fewer steps hence uses fewer reagents. 7 
 
 
 
 
Figure 3.2: Acid phosphatase end-point assay: (i) phosphatase catalysed reaction (H2O); (ii) 
colorimetric reaction in strong alkaline conditions (NaOH). 
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3.2.3. WST-1 assay 
 
More recently, modified tetrazolium salts like WST-1 have become available. The assay principle is 
based on the conversion of the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)- -2H-
5-tetrazolio]-1,3-benzene disulfonate) into a coloured dye by mitochondrial dehydrogenase enzymes. 
The soluble salt is released into the media. Within a given period, the reaction produces a colour 
change which directly correlates to the amount of mitochondrial dehydrogenase in a given culture.  
 
The major advantage of this substance is that it can only be converted by viable cells to a water-
soluble formazan, which leads to a wider linear range and a higher stability. 8 No solubilization of 
the products is necessary as required in the MTT dye assay. In addition, the WST-1 is a ready-to-use 
solution. This convenient colorimetric assay is performed in the same microtiter plate where the cells 
were cultivated. Therefore, the entire step can be done in only one 96-well plate and the absorbance 
of the coloured solution is measured at 450 nm. For these reasons, the WST-1 assay was the chosen 
colorimetric end-point assay for the in vitro biological evaluation of N-(1’-methyl-6-ferrocenyl-2-
naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives. 
 
 
 
 
Figure 3.3: Cleavage of the tetrazolium salt WST-1 to formazan. 
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3.3. Biological evaluation of N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives  
 
The in vitro cytotoxicity of the N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives were evaluated at a single dose (200 
μM) in the human cervical carcinoma cell line (SiHa) and liver cell line (Chang). The endpoint of 
the growth inhibition was evaluated by the WST-1 assay. The screening of the compounds was 
performed in collaboration with Dr. Patricia González-Barranco and Dr. Mónica A. Ramírez-Cabrera 
of the School of Chemical Sciences, Universidad Autónoma de Nuevo León, México, and Karen G. 
Ontiveros-Castillo of the School of Chemical Sciences, Dublin City University. 
 
The preliminary screenings were performed in triplicate by treating individual wells of a 96-well 
plate containing SiHa and Chang cells with a 200 μM solution of each test compound prepared in 
DMSO/H2O/EtOH. A positive reference vincristine, a negative control (untreated cells with media) 
and blank control (empty wells) were included in the assays. The cells were incubated for 24 hours, 
until cell confluency was reached. At this point, cell survival was established through WST-1 assay. 
The results of the comprehensive screens are expressed as the percentage cell viability ± standard 
deviation (relative to the negative control). Standard deviations have been calculated using data 
obtained from three independent experiments. The student’s t-test was performed to determine 
significant difference between results obtained from ferrocenyl bioconjugates and vincristine, all 
results showed a p-value < 0.05. Therefore, there is significant difference in toxicity between these 
novel compounds and vincristine. The results of the preliminary screen are presented in Figure 3.4 
to 3.7. 
 
 
  
108 
 
3.3.1. In vitro study of N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives in the human cervical carcinoma cell line (SiHa) 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-69 and 
reference compound vincristine were both tested against SiHa cervical carcinoma cell lines at 200 
μM. As can be seen in Figure 3.4 and Table 3.1, all compounds show excellent growth inhibition, 
with a general anti-proliferative effect above 60%. The results shown these novel compounds are 
more toxic than chemotherapeutic medication vincristine. Strong growth inhibition also found for N-
(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 70, 71, 73-77 (Figure 3.5 
and Table 3.2). Except compound 77, rest compounds are more active than vincristine. A general 
trend was observed in these compounds: the gamma-aminobutyric esters are less active than the Gly-
Gly, Gly-L-Ala and Gly-D-Ala derivatives.  
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Table 3.1: Percentage cell viability at 200 μM on SiHa cervical carcinoma cells for N-(1’-methyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-69 and reference compound 
vincristine. 
 
Alkyl Linker Amino acid and 
dipeptide esters 
Compound 
No. 
% cell viability at  
200 µM 
 
 
 
-CH3 
 
 
 
naphthoyl 
Gly-Gly-OMe 62 4.45 ± 1.01 
Gly-Gly-OEt 63 30.47 ± 2.04 
Gly-L-Ala-OEt 65 1.77 ± 1.24 
Gly-D-Ala-OMe 66 10.13 ± 3.98 
Gly-D-Ala-OEt 67 18.50 ± 2.19 
GABA-OMe 68 22.49 ± 2.40 
GABA-OEt 69 40.31 ± 1.28 
Vincristine 42.47 ± 2.79 
 
 
 
 
 
Figure 3.4: Percentage cell viability at 200 μM on SiHa cervical carcinoma cells for N-(1’-methyl-
6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-69 and reference 
compound vincristine. Error bars represent the standard deviation of triplicate experiments. 
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Table 3.2: Percentage cell viability at 200 μM on SiHa cervical carcinoma cells for N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 70, 71, 73-77 and reference compound 
vincristine. 
 
Alkyl Linker Amino acid and 
dipeptide esters 
Compound 
No. 
% cell viability at  
200 µM 
 
 
 
-CH2CH3 
 
 
 
naphthoyl 
Gly-Gly-OMe 70 11.59 ± 1.83 
Gly-Gly-OEt 71 2.54 ± 0.60 
Gly-L-Ala-OEt 73 20.75 ± 1.83 
Gly-D-Ala-OMe 74 20.47 ± 0.14 
Gly-D-Ala-OEt 75 5.33 ± 0.72 
GABA-OMe 76 21.34 ± 2.90 
GABA-OEt 77 55.60 ± 1.19 
Vincristine 42.47 ± 2.79 
 
 
 
 
 
Figure 3.5: Percentage cell viability at 200 μM on SiHa cervical carcinoma cells for N-(1’-ethyl-6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 70, 71, 73-77 and reference compound 
vincristine. Error bars represent the standard deviation of triplicate experiments. 
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3.3.2. In vitro study of N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide 
derivatives in the human liver cell line (Chang) 
 
N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-71 and 73-77 
were tested against Chang normal liver cells at 200 μM (Figure 3.6 and Figure 3.7). Compound 62, 
65, 66, 70, 71, 73 and 74 were shown to have strong growth inhibition above 80%. However, N-(1’-
methyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 67, N-(1’-methyl-6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid methyl ester 68 and N-(1’-methyl-6-ferrocenyl-2-naphthoyl) -γ-
aminobutyric acid ethyl ester 69 were have inhibition around 76%, 53% and 64%. Similar trend was 
obtained for N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives; compound 
75, 76 and 77 with glycine-D-alanine ethyl ester, γ-aminobutyric acid methyl ester and γ-
aminobutyric acid ethyl ester have lower toxicity against Chang liver cells. 
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Table 3.3: Percentage cell viability at 200 μM on Chang liver cells for N-(1’-methyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-69. 
 
Alkyl Linker Amino acid and 
dipeptide esters 
Compound 
No. 
% cell viability at  
200 µM 
 
 
 
-CH3 
 
 
 
naphthoyl 
Gly-Gly-OMe 62 3.57 ± 1.72 
Gly-Gly-OEt 63 26.92 ± 2.66 
Gly-L-Ala-OEt 65 0.80 ± 0.24 
Gly-D-Ala-OMe 66 9.61 ± 3.06 
Gly-D-Ala-OEt 67 23.95 ± 0.45 
GABA-OMe 68 46.78 ± 0.03 
GABA-OEt 69 45.12 ± 1.79 
 
 
 
 
 
Figure 3.6: Percentage cell viability at 200 μM on Chang liver cells for N-(1’-methyl-6-ferrocenyl-
2-naphthoyl) amino acid and dipeptide derivatives 62, 63, 65-69. Error bars represent the standard 
deviation of triplicate experiments. 
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Table 3.4: Percentage cell viability at 200 μM on Chang liver cells for N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives 70, 71, 73-77. 
 
Alkyl Linker Amino acid and 
dipeptide esters 
Compound 
No. 
% cell viability at  
200 µM 
 
 
 
-CH2CH3 
 
 
 
naphthoyl 
Gly-Gly-OMe 70 9.58 ± 0.61 
Gly-Gly-OEt 71 0.92 ± 0.25 
Gly-L-Ala-OEt 73 3.78 ± 2.30 
Gly-D-Ala-OMe 74 12.05 ± 1.76 
Gly-D-Ala-OEt 75 41.01 ± 3.37 
GABA-OMe 76 50.90 ± 0.88 
GABA-OEt 77 56.30 ± 0.50 
 
 
 
 
 
Figure 3.7: Percentage cell viability at 200 μM on Chang liver cells for N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives 70, 71, 73-77. Error bars represent the standard 
deviation of triplicate experiments. 
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3.3.3. In vitro comparison study of N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives against the human cervical carcinoma cell line (SiHa) and the human 
liver cell line (Chang) 
 
Toxicity is a common side effect of chemotherapeutic agents. 5 In recent years, the Chang cell line 
was widely used as a human hepatocyte model. 9 10 N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino 
acid and dipeptide derivatives 62, 63, 65-69 and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide derivatives 70, 71, 73-77 were both tested against cervical carcinoma cell SiHa and 
human liver cells Chang at 200 μM. To compare the inhibitory effects between SiHa and Chang cell 
lines, the observations can suggest there might be differences in susceptibilities to ferrocenyl amino 
acid and dipeptide bioconjugates toxicity by different cells.  Therefore, the compounds show 
stronger anti-proliferative effect on SiHa and with less toxicity against Chang cells will be selected 
for further IC50 determination. 
 
For N-(1’-methyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives, compound 68 and 
69 are less toxic than others in Chang cell lines, with more than 45% cell growth. And compound 75, 
76 and 77 are less toxic than the rest from N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters against Chang cells, have more than 40% cell viability. Despite compound 77, other 
compounds 68, 69, 75, 76 have more than 50% cell inhibition against SiHa cells. Therefore, 
compound 68, 69, 75, 76 were selected for IC50 determination.  
 
  
115 
 
Table 3.5: Comparison of percentage cell viability at 200 μM in SiHa and Chang cell lines for compound 62, 63, 65-71 and 73-77. 
 
 
 
Compound name Compound 
No. 
% cell viability 
in SiHa cells 
% cell viability 
in Chang cells 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OMe 62 4.45 ± 1.01 3.57 ± 1.72 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OEt 63 30.47 ± 2.04 26.92 ± 2.66 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 65 1.77 ± 1.24 0.80 ± 0.24 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OMe 66 10.13 ± 3.98 9.61 ± 3.06 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 67 18.50 ± 2.19 23.95 ± 0.45 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe 68 22.49 ± 2.40 46.78 ± 0.03 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OEt 69 40.31 ± 1.28 45.12 ± 1.79 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-Gly-OMe 70 11.59 ± 1.83 9.58 ± 0.61 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OMe 71 2.54 ± 0.60 0.92 ± 0.25 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OEt 73 20.75 ± 1.83 3.78 ± 2.30 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OMe 74 20.47 ± 0.14 12.05 ± 1.76 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt 75 5.33 ± 0.72 41.01 ± 3.37 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe 76 21.34 ± 2.90 50.90 ± 0.88 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-GABA-OEt 77 55.60 ± 1.19 56.30 ± 0.50 
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3.3.4. IC50 value determination for N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives  
 
The effect of selected compounds 68, 69, 75, 76 on SiHa cell growth was expressed as an IC50 value, 
which corresponds to the concentration of the drug required for 50% inhibition of cell growth. To 
determine the IC50 values of the four target compounds, individual 96-well plates containing SiHa 
cells were treated with the test compounds at concentrations ranging from 3.125 μg/mL to 100 μg/mL. 
The cells were incubated for 5-6 days, until cell confluency was reached. Cell survival was 
determined by performing the WST-1 assay. The IC50 value for each compound was calculated using 
Calcusyn software, and standard deviations have been calculated using data obtained from three 
independent experiments. The values obtained are listed in Table 3.6. 
 
Table 3.6: IC50 values in SiHa cell line. 
 
Compound Name                            Compound No.  IC50 values (μM)                                                                                   
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe   68 50.83 ± 1.29 
 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-GABA-OEt   69 61.81 ± 2.52 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OEt   75 8.76 ± 0.98 
 
N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-GABA-OMe   76 44.27 ± 2.89 
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Figure 3.8: IC50 plot for selected compounds in SiHa cell line.  
 
 
The four N-(1’-alkyl-6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives were shown to 
exert an anti-proliferative effect in the SiHa cell lines. The N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-
γ-aminobutyric acid methyl ester 68, N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid 
ethyl ester 69 and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid methyl ester 76 
display an IC50 value of 50.83 ± 1.29, 61.81 ± 2.52 and 44.27 ± 2.89 respectively. Compound N-(1’-
ethyl-6-ferrocenyl-2-naphthoyl)-glycine-D-alanine ethyl ester 75 is the most active one with the IC50 
value below 10 μM. Since those compounds show stronger anti-proliferative effect on human 
cervical carcinoma cells (SiHa) and with less toxicity against human liver cells (Chang), they have 
some selectivity for cancer treatment. 
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3.4. Conclusion 
 
A series of N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl) 
amino acid and dipeptide esters have been prepared and evaluated for their biological activities. 
These novel-ferrocenyl bioconjugates exhibited a moderate to strong anti-proliferative effect in the 
human cervical carcinoma cells (ATCC HTB-35, SiHa). Except N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid ethyl ester, all compounds have over 60% growth inhibition and 
found to be more active than anti-cancer drug vincristine. A general trend was observed: the gamma-
aminobutyric esters are less toxic than the Gly-Gly, Gly-L-Ala and Gly-D-Ala derivatives. Those 
compounds were also tested against human liver cells (ATCC CCL-13, Chang liver, HeLa markers). 
N-(1’-methyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid methyl ester 68, N-(1’-methyl-6-
ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 69, N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-
glycine-D-alanine ethyl ester 75, N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid methyl 
ester 76 and N-(1’-ethyl-6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester 77 did not exhibit 
strong inhibition effect. Due to the less toxicity against Chang cells than SiHa, compound 68, 69, 75, 
76 were selected for further investigation. Compound 68, 69, 75, 76 have IC50 value (μM) of 50.83 
± 1.29, 61.81 ± 2.52, 8.76 ± 0.98 and 44.27 ± 2.89 respectively in SiHa cell line. The observations 
can suggest that there are differences in susceptibilities to novel ferrocenyl amino acid and dipeptide 
bioconjugates toxicity between cancer and normal cells. Therefore compound 75 is a potential anti-
cancer agent with selectivity.  
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Materials and Methods 
Cells and cell culture 
 
The SiHa HTB-35 and Chang CCL-13 cell lines were obtained from the American Type Culture 
Collection (ATCC). All cell culture work was carried out in laminar airflow cabinet (Thermo Fischer 
Scientific). Before and after use the laminar airflow, cabinet was cleaned with 70% industrial 
methylated spirits (IMS). Any items brought to the airflow cabinet were swabbed using IMS. At any 
one time, only one cell line was used in the laminar airflow cabinet and after completion of work, 
the laminar airflow cabinet was allowed stand for 10 minutes before use. This was to eliminate any 
possibility of cross contamination between cell lines.  
 
The cells were thawed and placed in culture flasks by adding 4 mL of minimal essential medium 
EMEM (Caisson) supplemented with 10% fetal bovine serum (Corning) and 1% antibiotic penicillin-
streptomycin (Sigma-Aldrich). EMEM was changed every 3 days. Cells were fed with fresh media 
when confluency reached 80%, washed twice with 4 mL of a PBS solution, dead cells were removed 
along with other residues. 1 mL of 0.25% trypsin-EDTA was added to the cell and incubated at 37 ° 
C for less than 3 minutes. Trypsin (Corning) was neutralized with 2 mL of EMEM. Cells were 
centrifuged to remove the medium with trypsin. 3 mL of EMEM were added after. Cell pellet formed 
was re-suspended, 20 μL of the suspension was taken to determine the cell concentration by counting 
cells in a Neubauer chamber with an inverted microscope. Once the cell concentration is obtained, a 
dilution was performed to obtain a 10,000 cell/100 μL concentration, which were deposited in a 96-
well plate. After 24 hours, both lines were grown as a monolayer culture at 37 °C, under a humidified 
atmosphere of 95 % O2 and 5 % CO2.  
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In vitro proliferation assays 
 
Assessment of cell survival in the presence of test sample was determined by the WST-1 assay.  
After a monolayer formed in the 96-well plate, plates were exposed with test samples with different 
concentrations. Plates were incubated at 37 °C for 24 hours. For the full comprehensive screen, cell 
growth percentage in the presence of each sample was calculated relative to the vincristine (positive 
control), cells with medium (negative control), and wells (blank control). After incubation time, 
medium was removed, and two washes were performed with 100μL of PBS. 100μL of 5% 
EMEM(Caisson) with 5% WST-1(Roche) was added, and the initial optical density reading was 
recorded at 450 nm on the ELx800 microplate reader (BIOTEK). The plates were incubated further 
for 2 hours under the same conditions as above, and the absorbance of each well was read. 
 
 
Statistical analysis 
 
IC50 values were calculated using CalcuSyn Software (BioSoft). Student t-test (two tailed with 
unequal variances) was used to compare the activity of test compounds to their corresponding control 
group, and p-value < 0.05 was considered. 
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Chapter 4 
Synthesis and structural characterisation of N-(ferrocenylmethylamino acid)-fluorinated 
benzene carboxamides. 
4.1. Introduction 
 
The incorporation of amino acids in bioconjugations is a common strategy in medicinal chemistry 
research. 1,2 Antihypertensive agent Valsartan 78 and the DNA alkylating agent Mephalan 79 are 
drugs containing amino acid on the market. Valsartan 78 is an angiotensin II receptor agonist while 
Mephalan 79 is a nitrogen mustard alkylating agent with phenylalanine moiety. Similarly, Levodopa 
80 contains an amino acid group that can be recognized by the phenylalanine transporter. 
 
                       
78                              79 
 
           
80 
 
Fluorine substitution has been frequently used to increase the biological activity of a drug. 3 There 
were many fluorinated derivatives approved by the FDA for use as an anti-cancer, antidepressant 
and antibacterial agents. 4 There are over 150 fluorinated drugs on the market, including the anti-
cancer Tegafur 81, 5 the anti-depressant Lexapro 82 and anti-bacterial Levaquine 83 and 
ciprofloxacin 84. 4,6 Tegafur 81 is a prodrug of 5-fluorouracil that interferes with DNA synthesis by 
blocking the thymidylate synthetase conversion. Lexapro 82 acts in the brain by blocking the 
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reuptake of the neurotransmitter serotonin into presynaptic cells. Levaquine 83 and Ciprofloxacin 
84 are from the fluoroquinolone antibiotic family. They can bind to DNA gyrase (topoisomerase II) 
of bacterial hence prevents bacteria’s cell replication. 3, 4 It has emerged that to have fluorine atom 
on 9-position of the quinolone ring is essential.  
 
                 
81                              82 
 
         
83                               84 
 
Fluorine is highly electronegative, lipophilic with small atomic size, those properties aids its addition 
to other active molecules to improve biological activity. Replace the hydroxyl groups with fluorine 
atoms to the parent compound resveratrol, an increasing anti-proliferative effect was reported by 
Moran et al. The general structure of 85 is shown below. 7 
 
 
85 
124 
 
A preliminary structure-activity relationship (SAR) study of N-(ferrocenylmethyl) fluorinated 
benzene carboxamide derivatives was conducted by Kelly et al. and Butler et al. 8 , 9 The results 
demonstrated that the derivatives are effective at inhibiting the in vitro proliferation of breast cancer 
cell lines MDA-MB-435-SF and MCF-7. Their research gave IC50 data in the range of 11μM to 
50μM on the MDA-MB-435-SF cell line and 2.84 μM to 46.5 μM on the MCF-7 cell line (Table 
4.1). 8, 9 The position and the number of fluorine atoms on the aromatic ring were investigated, 3,4,5-
trifluoro and 2,3,4,5,6-pentafluoro analogues were identified as having an excellent inhibitory effect 
on MCF-7 cell line. 9  
 
Table 4.1: IC50 values for the most active compounds in the N-(ferrocenylmethyl) fluorinated 
benzene carboxamide derivatives against MCF-7 cell line. 
 
Compound No. IC50 (μM) 
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene  
carboxamide 
 
28 
 
2.84 ± 0.10 
N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-pentafluorobenzene 
carboxamide 
 
86 
 
10.3 ± 0.12 
N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene 
carboxamide 
 
87 
 
11.1 ± 0.12 
 
 
The primary objective of this research is to explore the SAR of these novel N- 
(ferrocenylmethylamino acid) fluorobenzene carboxamide derivatives in order to enhance their 
cytotoxic effect. Since the position and the number of fluorine atoms on the aromatic ring have been 
investigated, it is now focused on varying the amino acid or peptide chains to determine the 
contributions toward the biological effect. This was carried out by substituting various amino acids 
and dipeptides between the ferrocene and the aromatic ring containing 3,4,5-trifluoro or 2,3,4,5,6-
pentafluoro moiety. A series of compounds synthesized and discussed in this chapter have three key 
moieties (Figure 4.1): a redox active ferrocenyl centre; an amino acid or dipeptide moiety and a 
fluorinated aromatic ring. 
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Figure 4.1: General structure of the N-(ferrocenylmethyl) fluorinated benzene carboxamides 28, 86, 
87, 101-108. 
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4.2. The synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides 
 
The N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides were prepared via standard 
peptide coupling methods using conventional N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) coupling protocol. A solution of N-
(fluorobenzoyl) amino acids or dipeptides in dichloromethane at 0 °C, was treated with EDC, NHS 
and triethylamine (Et3N) and allowed to stir for 45 minutes. Ferrocenylmethylamine was added to 
the solution with stirring. Subsequent to coupling, the crude compounds were purified via column 
chromatography. The eluent used in all the column chromatography was hexane : ethyl acetate 
mixture (2:1). Scheme 4.1 and Scheme 4.2 outline the synthetic route employed. 
 
 
R = -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH2(CH2)2CH3, -CH2CH(CH3)2, -CH2CH2SCH3, -Ph. 
 (i) 2M NaOH (ii) EDC, NHS, Et3N. 
Scheme 4.1: The general reaction scheme for the synthesis of N-(ferrocenylmethylamino acid) 
fluorinated benzene carboxamide using N-(fluorobenzoyl) amino acids.  
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 (i) 2M NaOH (ii) EDC, NHS, Et3N. 
Scheme 4.2: The reaction scheme for the synthesis of N-(ferrocenylmethyl-glycine-glycine) 
fluorinated benzene carboxamide 108 using N-(fluorobenzoyl)-glycine-glycine. 
 
4.2.1. Synthesis of ferrocenecarbaldoxime 
 
The synthesis of ferrocenecarbaldoxime is outlined in Scheme 4.3. The amine of the hydroxylamine 
hydrochloride attacks the carbonyl group of the ferrocenecarboxaldehyde hence a dipolar tetrahedral 
intermediate formed. An amino alcohol formed due to intermolecular proton transfer form nitrogen 
to oxygen. Protonation of the oxygen produces a good leaving group, and loss of water yields an 
oxime ion. Transfer of a proton to water produces the oxime. 10 
 
Reaction yields of the ferrocenecarboaldoxime ranged between 80% and 89%. After complete 
drying, ferrocenecarboaldoxime was reduced to ferrocenylmethylamine by using lithium aluminum 
hydride (Scheme 4.4), with around 97% yield. 
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Scheme 4.3: Reaction mechanism for the synthesis of ferrocenecarbaldoxime. 
 
 
 
Scheme 4.4: Synthesis of ferrocenylmethylamine via reduction of ferrocenecarbaldoxime. 
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4.2.2. Synthesis of N-(fluorobenzoyl) amino acids and dipeptides 
 
 
                        
Scheme 4.5: Schotten Baumann reaction mechanism of fluorobenzoyl chlorides with the amino 
acids and dipeptides. 
 
N-(fluorobenzoyl) amino acids and dipeptides were synthesized via Schotten Baumann reaction 
(Scheme 4.5). This two-phase system of immiscible water and dichloromethane allowing the 
formation of the amino acid intermediates and the neutralisation of the excess acid formed during 
the reaction. 11 The desired products were with percentage yields varying between 19.6-49 %. 
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4.2.3. Preparation of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
EDC/NHS coupling reactions were used to facilitate the attachment of the ferrocenylmethylamine 
to the various N-(fluorobenzoyl) amino acids and dipeptides. N-(fluorobenzoyl) amino acids or 
dipeptides was treated with EDC, NHS and triethylamine (Et3N) in dichloromethane at 0 °C, 
ferrocenylmethylamine was added to mixture to stir for 48 hours. The crude product was purified by 
column chromatography {eluent 2:1 hexane: ethyl acetate} yielding the title compound as an orange 
solid. 
 
 
R = -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH2(CH2)2CH3, -CH2CH(CH3)2, -CH2CH2SCH3, -Ph. 
(i) EDC, NHS, Et3N 
Scheme 4.6: Synthesis of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 28, 
86, 87, 101-107. 
 
 
 
(i) EDC, NHS, Et3N 
Scheme 4.7: Synthesis of N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-pentafluorobenzene 
carboxamide 108. 
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4.3. Purification and yields of N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides 
 
The N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides were synthesized by the 
condensation of various N-(fluorobenzoyl) amino acids and dipeptides with ferrocenylmethylamine, 
under the standard EDC/NHS coupling conditions. Crude products were purified in the usual manner 
by column chromatography, using a mixture of hexane and ethyl acetate as the eluent. The purified 
compounds were furnished as orange solids, with yields in the range of 11 % to 52 %, shown in 
Table 4.2. All compounds gave spectroscopic and analytical data in accordance with their proposed 
structures. Yields were found to vary according to the amino acids and dipeptides. General trend 
showed the larger the side chain of the amino acid the lower the yield. For example, compound 103 
have the lowest yield as 11% whereas compound 28 have highest yield 52%. Such low yield may be 
due to the side chain to exert greater steric hindrance. 
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Table 4.2: Percentage yields for N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
Compound Name                                                                Compound No.        %Yields    
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 28 52 
 
N-(ferrocenylmethyl-L-2-aminobutyric acid)-3,4,5-trifluorobenzene carboxamide 101 34 
 
N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene carboxamide 102 17 
 
N-(ferrocenylmethyl-L-leucine)-3,4,5-trifluorobenzene carboxamide   103 11 
 
N-(ferrocenylmethyl-L-norleucine)-3,4,5-trifluorobenzene carboxamide  104 13 
 
N-(ferrocenylmethyl-L-methionine)-3,4,5-trifluorobenzene carboxamide  105 13 
 
N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-3,4,5-trifluorobenzene carboxamide  106 15 
 
N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide   87 28 
 
N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide 86 29 
 
N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide 107 12 
 
N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-pentafluorobenzene carboxamide   108 16 
 
133 
 
4.4. Infra-red studies of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
The IR spectra of the N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides were 
obtained as pure solids and shown in Table 4.3. The spectra of these compounds generally showed 
strong bands around 3200 cm-1 that correspond to the N-H stretching from amide groups. Bands 
observed in the region of 2960 to 2850 cm-1 correspond for the saturated C-H stretches in methylene 
and methyl groups. The two or three bands between 1600 and 1475 cm-1 are due to the C=C ring 
stretch of the aromatic ring system. 
 
 
  
 
Figure 4.2: IR spectrum of N-(ferrocenylmethyl-L-methionine)-3,4,5-trifluorobenzene 
carboxamide 105.   
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Table 4.3: IR data for N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides. Values 
are given in cm-1. 
 
Compound No. N-H  C-H C=O Aromatic  
28 3290 3075 1641 1621-1559 
101 3282 2926 1639 1518 
102 3307 3094 1638 1621-1519 
103 3289 3067 1637 1604-1516 
104 3242 3073 1634 1619-1520 
105 3281 3074 1637 1619-1517 
106 3282 2957 1664 1623-1518 
87 3309 3067 1653 1506 
86 3286 3051 1653 1621-1506 
107 3257 2926 1669 1631-1519 
108 3239 3057 1649 1523 
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4.5. UV-Vis studies of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
In this UV-Vis study, the spectra of all compounds were obtained at a concentration of 5 x 10-4 M 
in acetonitrile. The molar extinction coefficient ε is calculated from the Beer-Lambert Law A=εcl, 
where A is the absorbance, c is the concentration and l is the path length of the sample cell. 
 
 
 
 
Figure 4.3: UV-Vis data for selected N-{ferrocenylmethyl(L-alanine), (L-leucine), (L-
methionine)}-3, 4, 5-trifluorobenzene carboxamides 28, 103, and 105. N-{ferrocenylmethyl (L-
alanine)}-2, 3, 4, 5, 6-pentafluorobenzene carboxamide 86. 
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Table 4.4: UV-Vis data for selected N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides. 
 
Compound No. λmax1 (nm) ε1  λmax2 (nm) ε2 
28 432 2483 317 2940 
103 429 2312 313 2894 
105 430 2019 315 2687 
86 427 2895 314 3320 
 
From the UV-Vis data for N-(1’-methyl-6-ferrocenyl-2-naphthoyl) and N-(1’-ethyl-6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide esters shown in Figure 4.3 and Table 4.4, the strongest 
absorptions in the UV spectrum with local maxima at 375 nm and 450 nm respectively. The 
absorptions are similar with those of the N-(6-ferrocenyl-2-naphthoyl) derivatives. 12 Low energy 
bands observed approximately at 450 nm with a distinct λmax 2 value can be assigned as metal to 
ligand charge transfer (MLCT) band transitions arising from the ferrocene moiety. The high energy 
band around 375 nm, with distinct λmax1 values are due to the π - π* transitions of the aromatic spacer 
group.  
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4.6. 1H NMR studies of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
All the 1H NMR experiments were performed in DMSO-d6 as the N-(ferrocenylmethylamino acid) 
fluorinated benzene carboxamide derivatives showed limited solubility in other deuterated solvents. 
Table 4.5 summarises the main features of the 1H NMR spectra. 
 
In the 1H NMR spectra of the N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides, 
the amide protons peaks appear downfield from δ 9.82-8.16. The equivalent protons in the ortho-
position of the aromatic ring are split by fluorine coupling, appear as a doublet of doublets with 
integration of two for trifluorinated derivatives. This signal absences for pentafluorinated 
compounds. 
 
The 1H NMR spectra of the N-(ferrocenylmethylamino acid) fluorinated benzene carboxamides 
derivatives showed peaks in the range of δ 4.19-4.02 that are representative of a monosubstituted 
ferrocene derivative. The signal for the unsubstituted (η5-C5H5) cyclopentadienyl ring and the 
protons in the ortho position on the substituted ring (η5-C5H5) occur as a multiplet between δ 4.20 
and δ 4.02. This multiplet with an integration of seven protons is observed due to the overlap of 
signals. The meta protons of the substituted (η5-C5H5) cyclopentadienyl ring appears as a triplet 
between δ 4.14 and δ 4.02 for most derivatives, except for compound 101 and 107 that the signal 
overlaps with either ferrocenyl protons or methylene protons attached to ferrocene. The peaks belong 
to methylene group from Fc-CH2 appears between δ 4.15 - δ 3.92, integrating for two. 
  
138 
 
Table 4.5: 1H NMR spectral data for N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides. 
 
 
 
Compound 
No. 
 
CONH 
 
FcCH2NH 
 
ArH 
 
 
αH 
(η5-C5H5) & 
ortho on 
(η5-C5H4) 
 
meta on 
(η5-C5H4) 
 
FcCH2 
 
28 8.75 8.18 7.93 4.50 4.19-4.17 4.08 4.05-3.90 
101 8.62 8.16 7.91 4.40 4.17-4.16 4.08-4.04 4.08-4.04 
102 8.64 8.16 7.90 4.48 4.16-4.15 4.09 4.06-3.97 
103 8.72 8.28 7.92 4.58 4.18-4.15 4.08 4.06-3.92 
104 8.69 8.24 7.91 4.46 4.07-4.04 4.03 3.99-3.94 
105 8.75 8.25 7.90 4.55 4.16-4.13 4.04 3.99-3.94 
106 9.16 8.55 7.94 5.74 4.15-4.07 4.02 3.97-3.92 
87 9.20 8.20 - - 4.20-4.17 4.10 4.05 
86 9.24 8.32 - 4.57 4.19-4.16 4.12 4.15-4.05 
107 9.82 8.70 - 5.80 4.14-4.02 4.14-4.02 3.97-3.95 
108 9.16, 8.01 8.28 - - 4.19-4.17 4.09 4.03-4.00 
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4.6.1. 1H NMR spectroscopic studies of N-(ferrocenylmethyl-L-2-aminobutyric acid)-3,4,5-
trifluorobenzene carboxamide (101) 
 
 
 
In the 1H NMR spectrum of N-(ferrocenylmethyl-L-2-aminobutyric acid)-3,4,5-trifluorobenzene 
carboxamide 101, two amide protons occur at the relatively downfield positions of δ 8.62 and δ 8.16 
respectively. They appear as a doublet and a triplet due to the coupling of the nearby methine group 
of aminobutyric acid group and methylene group of the ferrocenylmethylamine moiety. The 
coupling constants observed for the amide protons at δ 8.62 and δ 8.16 were both 8.0 Hz.  
 
The aromatic protons appear as a doublet of doublets at δ 7.91 due to the fluorine-proton coupling. 
This was observed in all trifluorinated derivatives synthesized. The aromatic peak integrates as two 
hydrogens.  
 
The signal for the unsubstituted (η5-C5H5) cyclopentadienyl ring and the protons in the ortho position 
on the substituted ring (η5-C5H4) occur as a multiplet between δ 4.17 and δ 4.16. A multiplet with 
an integration of seven protons is observed due to the overlap of signals. The meta protons of the 
substituted (η5-C5H4) cyclopentadienyl ring and the protons attached to ferrocenyl group appear as 
a multiplet between δ 4.08-4.04 with integration of four. 
 
The methylene and methyl protons belong to aminobutyric acid were appear as a multiplet and a 
triplet at δ 1.83-1.72 and δ 0.94, with corresponding integration of two and three. 
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Figure 4.4: 1H NMR spectrum of N-(ferrocenylmethyl-L-2-aminobutyric acid)-3,4,5-
trifluorobenzene carboxamide 101. 
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4.6.2. 1H NMR spectroscopic studies of N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-
pentafluorobenzene carboxamide (108) 
 
 
 
In the 1H NMR spectrum of N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-pentafluorobenzene 
carboxamide 108, three amide protons occur at δ 9.16, δ 8.28 and δ 8.01 respectively. All amide 
groups appear as triplets due to the coupling of the nearby methylene groups of glycine and of the 
ferroceneylmethylamine moiety. The coupling constants observed for the amide protons at δ 9.16 
and δ 8.01 were 7.2 Hz while at δ 8.28 was 8.0 Hz. 
 
The signal for the unsubstituted (η5-C5H5) cyclopentadienyl ring and the protons in the ortho position 
on the substituted ring (η5-C5H4) occur as a multiplet between δ 4.19 and δ 4.17. This signal has an 
integration of seven protons because of the overlap of signals. The meta protons of the substituted 
(η5-C5H4) cyclopentadienyl ring occurs as a triplet at δ 4.09. 
 
The methylene protons belong to the ferrocenylmethylamine group and glycine group appear as a 
multiplet between δ 4.03-4.00. And another methylene group of the amino acid occur most upfield 
is split into a doublet at δ 3.78 with a coupling constant of 5.6 Hz. 
 
  
142 
 
 
 
Figure 4.5: 1H NMR spectrum of N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-
pentafluorobenzene carboxamide 108. 
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4.7. 13C NMR and DEPT-135 spectroscopic studies of N-(ferrocenylmethylamino acid)-
fluorinated benzene carboxamides 
 
13C and DEPT 135 NMR studies were carried out on all compounds. In a DEPT-135 spectrum, 
methine and methyl carbons appear as positive peaks, whereas methylene carbons appear as negative 
peaks. Carbonyl and quaternary carbons are absent in a DEPT-135 spectrum. All the 13C and DEPT-
135 NMR experiments were performed in CDCl3. The typical 13C NMR chemical shifts observed 
were recorded in Table 4.6. 
 
In the 13C NMR spectra of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides, the 
amide carbonyl peak appears between δ 168.5 and δ 171.5 as a triplet due to the effect of 19F-13C 
coupling, and the carbonyl carbon atoms of the benzene carbonyl carbon atoms appear in the region 
of δ 167.9 to δ 156.8 for all the derivatives synthesized. In the amino acid derivatives only two 
carbonyl signals are observed whilst for the dipeptide derivatives three carbonyl signals are observed. 
Carbon signals belong to trisubstituted derivatives appears four peaks, due to four unique carbons. 
Pentafluoro derivatives have six distinct peaks. This effect is due to 19F-13C coupling in the 13C NMR 
spectra. 
 
The ferrocenyl carbon atoms appear in the region between δ 86.7 and δ 67.2. The unsubstituted 
cyclopentadienyl ring (η5-C5H5) appears as an intense peak in the range of δ 69.0 to δ 68.3, while the 
other ferrocenyl peaks, the ortho and meta carbons of the substituted cyclopentadienyl ring (η5-C5H4) 
produce chemical shifts between δ 68.8 and δ 67.2. The ipso carbon on the substituted 
cyclopentadienyl ring appears in the range of δ 86.7 to δ 85.9. This peak does not appear in any of 
the DEPT 135 NMR spectra. 
 
The methylene carbon atom of ferrocenylmethylamine appears in the region of δ 38.1 to δ 37.4. And 
the α carbon belongs to amino acid groups has peak between δ 57.2 and δ 49.7. The methylene carbon 
belongs to amino acid or dipeptide have signal between δ 42.9 and δ 19.4 while the methyl groups 
from amino acid or dipeptide shows signal around δ 23.1 to δ 11.2. 
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Table 4.6: 13C and DEPT 135 NMR spectral data for N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
 
 
Compound 
No. 
 
C=O 
Ipso 
(η5-C5H4) 
 
(η5-C5H5) 
ortho on 
(η5-C5H4) 
meta on 
(η5-C5H4) 
 
α-C 
 
Fc-CH2 
28 170.5, 167.9 86.2 68.4 67.5 67.1 49.7 37.4 
101 171.3, 163.7 86.7 68.8 68.0 67.7 55.7 38.0 
102 171.5, 163.6 86.7 68.8 68.0 67.7 54.0 38.0 
103 171.3, 162.9 86.2 68.8 68.0 67.7 52.0 37.4 
104 171.1, 163.1 86.1 68.3 67.5 67.2 53.8 37.6 
105 171.0, 163.8 86.6 68.8 68.0 67.7 53.6 38.1 
106 168.9, 156.8 86.6 69.0 68.8 67.7 57.2 38.1 
87 168.3, 165.1 85.9 68.3 67.8 67.3 - 37.5 
86 170.6, 164.9 86.2 68.3 67.5 67.2 49.8 37.4 
107 168.9, 156.8 86.4 69.0 68.8 67.7 57.2 37.4 
108 168.5, 168.4, 147.5 86.4 68.8 68.4 67.7 - 38.1 
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4.7.1. 13C NMR and DEPT-135 spectroscopic studies of N-(ferrocenylmethyl-L-(+)-α-
phenylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide (107) 
 
 
 
The 13C NMR spectrum of N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-
pentafluorobenzene carboxamide 107 displays two carbonyl carbon atoms at δ 168.9 and δ 156.8. 
These are not present in the DEPT-135 spectrum. The fluorinated aromatic region shows six unique 
carbon signals, representing the six non-equivalent quaternary carbon atoms, between δ 143.0 and δ 
112.9. Each of the carbon atoms on the fluorinated aromatic ring appear as multiplets and triplet (J 
= 14.0 Hz) due to the effect of 19F-13C coupling. These six quaternary carbon atoms can be identified 
by their absence in the DEPT-135 spectrum. Four peaks from the aromatic protons belong to 
phenylglycine appear between δ 144.6 to δ 127.5. 
 
The carbon located at δ 86.4, is the ipso carbon. This peak is not present in the DEPT-135 spectrum. 
The 5 equivalent carbons of the unsubstituted (η5-C5H5) cyclopentadienyl ring occurs at δ 69.0. The 
carbons of the substituted cyclopentadienyl ring, in the positions of ortho and meta, occur at δ 68.8 
and δ 67.7 respectively. 
 
The α-C from phenylglycine appear at δ 57.2. The methylene group belongs to ferrocenylamine is 
easily assigned, as it shows negative resonance in the DEPT-135 at δ 38.1. 
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Figure 4.6: 13C NMR spectrum of N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide 107. 
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Figure 4.7: DEPT-135 NMR spectrum of N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-
pentafluorobenzene carboxamide 107.  
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4.8. 19F NMR spectroscopic studies of N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamide derivatives 
 
For the characterization of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives, fluorine was identified via 19F NMR spectroscopy. The position and the number of 
fluorine atoms on the aromatic moiety of the N-(ferrocenylmethylamino acid) fluorobenzene 
carboxamides played a vital role in the characterization of the compounds.  
 
For trisubstituted derivatives, the meta fluorines appear as a doublet of doublets with integration of 
two, this splitting is caused by the one adjacent para fluorine (3JFmFp = 22.6 Hz) and two ortho 
hydrogens (3JFmHo = 7.5 Hz) coupling. The para fluorine occurs as a triplet of triplets with integration 
of one. It is a triplet of triplets because of the two adjacent meta fluorine atoms (3JFpFm = 22.6 Hz) 
and two ortho hydrogens (4JFpHo = 7.5 Hz). 
 
The pentafluoro derivatives show a distinctive pattern in the 19F NMR. The fluorine atoms in the 
ortho positions appear as a doublet of doublets. The fluorine atoms couple with the meta fluorine 
atoms to give a coupling constant of 22.6 Hz and with each other giving a decreased coupling 
constant of 7.5 Hz. The para-fluoro substituent appears as a triplet with coupling constant equal to 
22.6 Hz. This signal is caused by coupling with two meta fluorine atoms. The integration of this 
peak gives a value of one. The meta fluorine atoms on the aromatic moiety is observed as a triplet 
of doublets with integration as two. The fluorine atoms in these positions couple with each other, 
the ortho fluorine atoms and the para fluorine atom. 
 
The chemical shifts appear in the negative region within the range of δ -134.3 to δ -161.7. Figure 4.8 
and Figure 4.9 present the 19F NMR spectrum for compound 104 and 107. 
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Figure 4.8: 19F NMR spectrum of N-(ferrocenylmethyl-L-norleucine)-3,4,5-trifluorobenzene 
carboxamide 104. 
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Figure 4.9: 19F NMR spectrum of N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-
pentafluorobenzene carboxamide 107. 
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4.9. COSY study of N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene carboxamide 
(102) 
 
COSY (Correlation Spectroscopy) is a two-dimensional experiment that indicates all the spin-spin 
coupled protons in one spectrum. In the COSY spectrum, two essentially identical chemical shift 
axes are plotted orthogonally. All peaks that are mutually spin-spin coupled are shown by cross-
peaks in the third dimension, which are placed symmetrically about the diagonal. 13  
 
The structure and COSY spectrum of N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene 
carboxamide 102 is shown in Figure 4.10 and Figure 4.11, respectively. The amide proton of the L-
norvaline amino acid a (δ 8.64) correlates with the methine group of the amino acid b (δ 4.48), while 
the amide proton of the ferrocenylmethylamine f (δ 8.16) correlates with the methylene group of 
adjacent to it g (δ 4.06-3.97). Correlation is also present between the meta and ortho protons of the 
substituted ring (η5-C5H4), i.e. i (δ 4.16) and j (δ 4.09). The central methylene group of the L-
norvaline chain c (δ 1.75-1.70) is easily identified due to its coupling with the methine proton b (δ 
4.48) and d (δ 1.33-1.22) positioned on either side. The proton d (δ 1.33-1.22) have correlation with 
proton e (δ 0.19). 
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Figure 4.10: N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene carboxamide 102. 
 
 
 
Figure 4.11: COSY spectrum of N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene 
carboxamide 102. 
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4.10. Conclusion 
 
N-(ferrocenylmethyl)-fluorobenzene carboxamide derivatives have been identified as potential anti-
cancer agents on the MDA-MB-435-SF and MCF-7 cancer cell lines. 8 ,9 This project sought to 
further explore the structure-activity relationship (SAR) of these compounds to enhance the anti-
proliferative effect. Thus, various amino acids and dipeptides were modified between the ferrocene 
moiety and fluorinated aromatic group. Those novel compounds were prepared by EDC/NHS 
condensation and purified by column chromatography furnished the required compounds as orange 
solids, in moderate yields (11 % to 52 %).  
 
The N-(ferrocenylmethyl)-fluorobenzene carboxamides were characterized by a range of 
spectroscopic techniques including 1H NMR, 13C NMR, DEPT-135, 19F, COSY, IR and UV-Vis. All 
compounds gave spectroscopic and analytical data in accordance with their proposed structures. 
  
154 
 
Experimental Procedures 
Experimental Note 
 
 
All chemicals were purchased from Sigma-Aldrich or Fluorochem Limited, and used as received. 
Commercial grade reagents were used without purification. When necessary, all solvents were 
purified and dried prior to use. Riedel-Haën silica gel was used for thin layer and column 
chromatography. Melting points were determined using a Griffin melting point apparatus and are 
uncorrected. Infrared spectra were recorded on a PerkinElmer Spectrum 100 FT-IR with ATR. UV-
Vis spectra were recorded on a Hewlett Packard 8452A diode array UV-Vis spectrophotometer. 
NMR spectra were obtained on a Bruker AC 400 NMR spectrometer operating at 400 MHz for 1H 
NMR, 376 MHz for 19F NMR and 100 MHz for 13C NMR. The 1H and 13C NMR chemical shifts (δ) 
are relative to tetramethylsilane and the 19F NMR chemical shifts (δ) are relative to trifluoroacetic 
acid. All coupling constants (J) are in Hertz. The abbreviations for the peak multiplicities are as 
follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), and m (multiplet). 
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General Procedures 
 
General procedure for the preparation of starting materials for N-(ferrocenylmethylamino acid)-
fluorinated benzene carboxamides. 
 
Ferrocenecarbaldoxime (88) 
 
  
 
Ferrocenecarboxaldehyde (2.02 g, 9.4 mmol) was dissolved in warm ethanol (10 ml). Sodium acetate 
(2.28 g, 27.8 mmol) and hydroxylamine hydrochloride (1.75 g, 25.2 mmol) were dissolved 
thoroughly in distilled water (15 ml). The solutions were combined and refluxed for 40 minutes. 
After cooling to room temperature, diethyl ether (50 ml) was added to mixture. The ether layer was 
washed with water and dried over MgSO4. The solvent was removed in vacuo to yield an orange 
solid. (1.90 g, 89 %), mp: 135-136 °C (Lit 9: 135-136 °C); 
 
1H NMR (400 MHz) δ (DMSO-d6): 10.97 (1H, s, -OH), 7.17 (1H, s, CHNOH), 4.78 (2H, t, J = 1.6 
Hz, ortho on η5-C5H4), 4.35, (2H, t, J = 1.6 Hz, meta on η5-C5H4), 4.19 (5H, s, η5-C5H5); 
 
13C NMR (100 MHz) δ (DMSO-d6): 144.9 (CHNOH), 73.5 (Cipso η5-C5H4), 70.9 (Cortho η5-C5H4), 
69.34 (Cmeta η5-C5H4), 68.6 (η5-C5H5). 
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Ferrocenylmethylamine (89) 
 
 
 
Lithium aluminium hydride (2.63 g, 69.4 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) 
under nitrogen. Ferrocenecarbaldoxime (3.00 g, 13.1 mmol) was dissolved in anhydrous 
tetrahydrofuran (20 ml) and added slowly to the LiAlH4 solution via syringe. The reaction was stirred 
for 48 hours. The reaction flask was cooled to 0 °C. Ethyl acetate (30 ml) and 3 M sodium hydroxide 
(10 ml) were added. The reaction mixture was filtered and diethyl ether (100 ml) was added. The 
ether layer was washed with water and dried over MgSO4. The solvent was removed in vacuo to 
yield the crude product as an orange oil (2.75 g, 97 %); 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.14-8.06 (2H, m, -NH2), 4.18-4.15 (7H, m, η5-C5H5 and ortho 
on η5-C5H4), 4.08 (2H, t, J = 5.6 Hz, meta on η5-C5H4), 3.95-3.91 (2H, m, -CH2NH2);  
 
13C NMR (100 MHz) δ (DMSO-d6): 86.1 (Cipso η5-C5H4), 68.4 (Cortho η5-C5H4), 67.7 (Cmeta η5-C5H4), 
67.1 (η5-C5H5), 37.3 (-CH2NH2). 
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General procedure for the synthesis of N-(fluorobenzoyl) amino acids: 
 
N-(3,4,5-trifluorobenzoyl)-L-alanine (90) 
 
 
 
L-alanine (1.00 g, 11.3 mmol) was dissolved in dichloromethane (20 ml). 3,4,5-Trifluorobenzoyl 
chloride (1.50 ml, 11.4 mmol) was added slowly via a syringe. 2 M sodium hydroxide (10 ml) was 
added, and the reaction mixture was stirred for 48 hours. Concentrated hydrochloric acid was added 
to the aqueous layer until a precipitate formed. Vacuum filtration yielded a white powder (0.75 g, 
23.3 %), mp: 199-200 °C (Lit 9: 199-201 °C); 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.27 (1H, bs, -COOH), 8.94 (1H, d, J = 7.2 Hz, CONH), 7.89-
7.79 (2H, m, ArH), 4.40 (1H, q, J = 7.2 Hz, -NHCH), 1.39 {3H, d, J = 7.2 Hz, -CH(CH3)}; 
 
13C NMR (100 MHz) δ (DMSO-d6): 173.9 (C=O), 162.8 (C=O), 151.2 (d, J = 166 Hz, -ArC3 & -
ArC5), 148.6 (t, J = 166 Hz , -ArC4), 130.2 (t, J = 4 Hz, -ArC1), 112.4 (d, J = 12 Hz, -ArC2 & -ArC6), 
48.6 {-CH(CH3)}, 16.5 (-CH3). 
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N-(3,4,5-trifluorobenzoyl)-L-2-aminobutyric acid (91) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
2-aminobutyric acid (1.17 g, 11.3 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M 
sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (0.98 
g, 33.3 %), mp: 206-207 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.10 (1H, bs, -COOH), 8.71 (1H, d, J = 7.2 Hz, CONH), 7.94-
7.85 (2H, m, ArH), 4.51-4.42 (1H, m, -NHCH), 1.84-1.70 (2H, m, -CH2CH3), 0.95 (3H, t, J = 7.3 
Hz, -CH2CH3);  
 
13C NMR (100 MHz) δ (DMSO-d6): 171.0 (C=O), 164.0 (C=O), 154.4 (d, J = 166 Hz, -ArC3 & -
ArC5), 146.4 (t, J = 166 Hz , -ArC4), 130.1 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
54.0 (-NHCH), 25.5 (-CH2CH3, -ve DEPT), 11.0 (-CH2CH3). 
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N-(3,4,5-trifluorobenzoyl)-L-norvaline (92) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
norvaline (1.34 g, 11.4 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M sodium 
hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (0.68 g, 
21.7 %), mp: 213-215 °C; 
 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.24 (1H, bs, -COOH), 8.71 (1H, d, J = 7.2 Hz, CONH), 7.96-
7.88 (2H, m, ArH), 4.54-4.48 (1H, m, -NHCH), 1.75-1.70 (2H, m, -CH2CH2CH3), 1.35-1.32 (2H, m, 
-CH2CH2CH3), 0.93 (3H, t, J = 7.3 Hz, -CH2CH2CH3); 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.4 (C=O), 163.5 (C=O), 155.2 (d, J = 166 Hz, -ArC3 & -
ArC5), 146.3 (t, J = 166 Hz, -ArC4), 131.2 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
54.0 (-NHCH), 34.0 (-CH2CH2CH3, -ve DEPT), 19.2 (-CH2CH2CH3, -ve DEPT), 14.9 (-
CH2CH2CH3). 
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N-(3,4,5-trifluorobenzoyl)-L-norleucine (93) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
norleucine (1.49 g, 11.3 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M sodium 
hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (0.64 g, 
19.6 %), mp: 219-220 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.31 (1H, bs, -COOH), 8.68 (1H, d, J = 7.2 Hz, CONH), 7.93-
7.85 (2H, m, ArH), 4.49-4.42 (1H, m, -NHCH), 1.83-1.64 (2H, m, -CH2CH2CH2CH3), 1.45-1.31 
(4H, m, -CH2CH2CH2CH3), 0.93 (3H, t, J = 7.3 Hz, -CH2CH2CH2CH3);  
 
13C NMR (100 MHz) δ (DMSO-d6): 171.0 (C=O), 163.3 (C=O), 151.4 (d, J = 166 Hz, -ArC3 & -
ArC5), 142.3 (t, J = 166 Hz , -ArC4), 130.1 (t, J = 4 Hz, -ArC1), 112.5 (d, J = 12 Hz, -ArC2 & -ArC6), 
54.0 (-NHCH), 31.3 (-CH2CH2CH2CH3, -ve DEPT), 27.9 (-CH2CH2CH2CH3, -ve DEPT), 22.0 (-
CH2CH2CH2CH3, -ve DEPT), 13.6 (-CH2CH2CH2CH3). 
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N-(3,4,5-trifluorobenzoyl)-L-leucine (94) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
leucine (1.51 g, 11.5 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M sodium 
hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (1.50 g, 45 %), 
mp: 203-205 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.36 (1H, bs, -COOH), 8.99 (1H, d, J = 8.0 Hz, CONH), 7.97-
7.86 (2H, m, ArH), 4.49-4.45 (1H, m, -NHCH), 1.86-1.75 {2H, m, -CHCH2CH(CH3)2}, 1.68-1.61 
{1H, m, -CHCH2CH(CH3)2}, 0.98 {6H, dd, J = 4.0 and 8.0 Hz, -CHCH2CH(CH3)2};  
 
13C NMR (100 MHz) δ (DMSO-d6): 171.4 (C=O), 164.6 (C=O), 151.0 (d, J = 166 Hz, -ArC3 & -
ArC5), 142.2 (t, J = 166 Hz , -ArC4), 130.1 (t, J = 4 Hz, -ArC1), 113.0 (d, J = 12 Hz, -ArC2 & -ArC6), 
52.1 (-NHCH), 30.6 {-CHCH2CH(CH3)2, -ve DEPT}, 24.8 {-CHCH2CH(CH3)2}, 22.9 {-
CHCH2CH(CH3)2}, 21.0 {-CHCH2CH(CH3)2}. 
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N-(3,4,5-trifluorobenzoyl)-L-methionine (95) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
methionine (1.72 g, 11.5 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M sodium 
hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (1.08 g, 31%), 
mp: 234-236 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.13 (1H, bs, -COOH), 9.01 (1H, d, J = 7.2 Hz, CONH), 7.92-
7.85 (2H, m, ArH), 4.52-4.47 (1H, m, -NHCH), 2.51 (2H, t, J = 2.0 Hz, -CH2CH2SCH3), 2.10-2.06 
(2H, m, -CH2CH2SCH3), 2.05 (3H, s, -CH2CH2SCH3);  
 
13C NMR (100 MHz) δ (DMSO-d6): 171.7 (C=O), 163.5 (C=O), 151.4 (d, J = 166 Hz, -ArC3 & -
ArC5), 148.1 (t, J = 166 Hz , -ArC4), 130.0 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
54.2 (-NHCH), 31.7 (-CH2CH2SCH3, -ve DEPT), 29.7 (-CH2CH2SCH3, -ve DEPT), 15.6 (-
CH2CH2SCH3). 
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N-(3,4,5-trifluorobenzoyl)-L-(+)-α-phenylglycine (96) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
(+)-α-phenylglycine (1.74 g, 11.5 mmol), 3,4,5-trifluorobenzoyl chloride (1.50 ml, 11.4 mmol), 2 M 
sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (1.34 
g, 38 %), mp: 251-252 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.27 (1H, bs, -COOH), 9.28 (1H, d, J = 7.2 Hz, CONH), 7.54-
7.32 { (5H, m, -CH(C6H5) }, 5.56 { (1H, d, J = 8.0 Hz, -CH(C6H5) }; 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.9 (C=O), 156.8 (C=O), 144.6 (d, J = 166 Hz, -ArC3 & -
ArC5), 138.7 (t, J = 166 Hz , -ArC4), 136.5 (t, J = 4 Hz, -ArC1), 128.9, 128.3, 127.5, 113.1 (d, J = 
12 Hz, -ArC2 & -ArC6), 109.5, 57.2 (-NHCH). 
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N-(2,3,4,5,6-pentafluorobenzoyl)-glycine (97) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: 
glycine (0.86 g, 11.5 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (1.74 ml, 11.4 mmol), 2 M 
sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (0.77 
g, 25.2 %), mp: 189-190 °C (Lit 9: 188-190 °C); 
 
1H NMR (400 MHz) δ (DMSO-d6): 11.82 (1H, bs, -COOH), 9.46 (1H, t, J = 5.6 Hz, -CONH), 3.98 
(2H, d, J = 5.6 Hz, -NHCH2); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.4 (C=O), 165.0 (C=O), 155.3-155.2 (m, -ArC2), 154.6-
154.4 (m, -ArC6), 133.8-133.6 (m, -ArC4), 130.2-130.0 (m, -ArC3), 130.0-129.9 (m, -ArC5), 115.1 (t, 
J = 12 Hz, -ArC1), 42.0 (-NHCH2, -ve DEPT). 
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N-(2,3,4,5,6-pentafluorobenzoyl)-L-alanine (98) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
alanine (1.02 g, 11.5 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (1.74 ml, 11.4 mmol), 2 M 
sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder (0.91 
g, 28.3 %), mp: 201-202 °C (Lit 9: 200-203 °C); 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.15 (1H, bs, -COOH), 9.30 (1H, t, J = 7.2 Hz, -CONH), 4.43 
(1H, q, J = 7.2 Hz, -NHCH),1.40 {3H, d, J = 5.6 Hz, -NHCH(CH3)}; 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.8 (C=O), 164.9 (C=O), 144.6-144.4 (m, -ArC2), 142.9-
142.8 (m, -ArC6), 136.6-136.5 (m, -ArC4), 130.2-130.0 (m, -ArC3), 129.8-129.6 (m, -ArC5), 115.3 (t, 
J = 12 Hz, -ArC1), 48.6 (-NHCH), 16.7 (-CHCH3). 
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N-(2,3,4,5,6-pentafluorobenzoyl)-L-(+)-α-phenylglycine (99) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: L-
(+)-α-phenylglycine (1.74 g, 11.5 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (1.74 ml, 11.4 
mmol), 2 M sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white 
powder (1.54 g, 39 %), mp: 263-265 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.37 (1H, bs, -COOH), 9.80 (1H, d, J = 8.0 Hz, CONH), 7.48-
7.34 { 5H, m, -CH(C6H5) }, 5.56 {1H, d, J = 8.0 Hz, -CH(C6H5)}; 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.9 (C=O), 156.8 (C=O), 144.4 (Cq), 144.0-143.9 (m, -ArC2), 
143.5-143.2 (m, -ArC6), 140.9-140.5 (m, -ArC4), 138.6-138.3 (m, -ArC3), 136.5-136.2 (m, -ArC5), 
128.9, 128.3, 127.5, 113.1 (t, J = 12 Hz, -ArC1), 57.2 (-NHCH). 
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N-(2,3,4,5,6-pentafluorobenzoyl)-glycine-glycine (100) 
 
 
 
The synthesis followed that of N-(3,4,5-trifluorobenzoyl)-L-alanine using the following reagents: 
glycine-glycine (1.52 g, 11.5 mmol), 2,3,4,5,6-pentafluorobenzoyl chloride (1.74 ml, 11.4 mmol), 2 
M sodium hydroxide (10 ml). Vacuum filtrated the precipitate yielded product as a white powder 
(1.82 g, 49 %), mp: 288-290 °C; 
 
1H NMR (400 MHz) δ (DMSO-d6): 12.46 (1H, bs, -COOH), 9.10 (1H, t, J = 8.0 Hz, CONH), 8.01 
(1H, t, J = 8.0 Hz, CONH), 4.02-4.00 (4H, m, -NHCH2- and -NHCH2COOH); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.5 (C=O), 168.2 (C=O), 147.5 (C=O), 145.3-145.0 (m, -
ArC2), 144.4-144.2 (m, -ArC6), 141.5-141.3 (m, -ArC4), 136.4-136.3 (m, -ArC3), 136.0-135.7 (m, -
ArC5), 112.8 (t, J = 12 Hz, -ArC1), 43.0 (-NHCH2-, -ve DEPT)), 42.5 (-NHCH2COOH, -ve DEPT). 
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General procedure for the synthesis of N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides. 
 
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (28) 
 
 
 
N-(3,4,5-trifluorobenzoyl)-L-alanine (0.92 g, 3.7 mmol) was dissolved in DCM (20 ml) at 0 °C. 
Ferrocenylmethylamine (0.80 g, 3.7 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.7 mmol), N-hydroxysuccinimide (0.43 g, 3.7 mmol) and triethylamine (3 
ml) were added and stirred at 0 °C for 1 hour. The reaction mixture was allowed to stir at room 
temperature for 48 hours. The solvent was removed in vacuo and the crude product was purified by 
column chromatography (eluent 2:1 ethyl acetate: hexane) to yield the product as a orange powder 
(0.85 g, 52 %), mp: 134 –135 °C (Lit 9: 134-136 °C); 
 
I.R. υmax (neat): 3290, 3075, 1647, 1620, 1557, 1231, 1043 cm-1; 
 
UV-Vis λmax (CH3CN): 317, 432 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.75 (1H, d, J = 8.0 Hz, -CONH), 8.18 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.93 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.50 (1H, q, J = 7.2 Hz, -NHCH), 4.19-4.17 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.08 (2H, t, J = 2 Hz, meta on η5-C5H4), 4.05-3.90 (2H, m, 
FcCH2), 1.39 {3H, d, J = 7.2 Hz, -CH(CH3)}; 
 
13C NMR (100 MHz) δ (DMSO-d6): 170.5 (C=O), 167.9 (C=O), 155.9 (d, J = 166 Hz, -ArC3 & -
ArC5), 147.5 (t, J = 166 Hz , -ArC4), 130.2 (t, J = 4 Hz, -ArC1), 112.7 (d, J = 12 Hz, -ArC2 & -ArC6), 
86.2 (Cipso η5-C5H4), 68.4 (η5-C5H5), 67.5 (Cortho η5-C5H4), 67.1 (Cmeta η5-C5H4), 49.7 {-CH(CH3)}, 
37.4 (FcCH2, -ve DEPT), 17.9 (-CH3); 
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.0 (1F, tt, J = 22.6 and 
7.5 Hz).  
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N-(ferrocenylmethyl-L-2-aminobutyric acid)-3,4,5-trifluorobenzene carboxamide (101) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-2-aminobutyric acid (0.80 g, 3.7 mmol), 
ferrocenylmethylamine (0.80 g, 3.7 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.7 mmol), N-hydroxysuccinimide (0.43 g, 3.7 mmol) and triethylamine (3 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.58 g, 34 %), mp: 138 –140 °C; 
 
I.R. υmax (neat): 3282, 3214, 2926, 1639, 1621, 1518, 1356, 1231, 1045 cm-1; 
 
UV-Vis λmax (CH3CN): 322, 416 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.62 (1H, d, J = 8.0 Hz, -CONH), 8.16 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.91 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.40 (1H, qt, J = 7.2 Hz, -NHCH), 4.17-4.16 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.08-4.04 (4H, m, meta on η5-C5H4 and FcCH2), 1.83-1.72 
(2H, m, -CH2CH3), 0.94 (3H, t, J = 7.3 Hz, -CH2CH3); 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.3 (C=O), 163.7 (C=O), 155.9 (d, J = 166 Hz, -ArC3 & -
ArC5), 146.8 (t, J = 166 Hz , -ArC4), 131.0 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
86.7 (Cipso η5-C5H4), 68.8 (η5-C5H5), 68.0 (Cortho η5-C5H4), 67.7 (Cmeta η5-C5H4), 55.7 (-NHCH), 38.0 
(FcCH2, -ve DEPT), 25.5 (-CH2CH3, -ve DEPT), 11.2 (-CH2CH3);  
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.1 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethyl-L-norvaline)-3,4,5-trifluorobenzene carboxamide (102) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-norvaline (1.02 g, 3.7 mmol), 
ferrocenylmethylamine (0.80 g, 3.7 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.7 mmol), N-hydroxysuccinimide (0.43 g, 3.7 mmol) and triethylamine (3 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.63 g, 36 %), mp: 163-165 °C; 
 
I.R. υmax (neat): 3307, 3248, 3094, 2960, 2926, 1666, 1621, 1519, 1232, 1046 cm-1; 
 
UV-Vis λmax (CH3CN): 320, 428 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.64 (1H, d, J = 8.0 Hz, -CONH), 8.16 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.90 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.48 (1H, qt, J = 7.2 Hz, -NHCH), 4.16-4.15 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.09 (2H, t, J = 2 Hz, meta on η5-C5H4), 4.06-3.97 (2H, m, 
FcCH2), 1.75-1.70 (2H, m, -CH2CH2CH3), 1.33-1.32 (2H, m, -CH2CH2CH3), 0.91 (3H, d, J = 7.3 
Hz, -CH2CH2CH3); 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.5 (C=O), 163.6 (C=O), 155.8 (d, J = 166 Hz, -ArC3 & -
ArC5), 146.8 (t, J = 166 Hz, -ArC4), 131.1 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
86.7 (Cipso η5-C5H4), 68.8 (η5-C5H5), 68.0 (Cortho η5-C5H4), 67.7 (Cmeta η5-C5H4), 54.0 (-NHCH), 38.0 
(FcCH2, -ve DEPT), 34.2 (-CH2CH2CH3, -ve DEPT), 19.4 (-CH2CH2CH3, -ve DEPT), 14.1 (-
CH2CH2CH3);  
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.1 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethyl-L-leucine)-3,4,5-trifluorobenzene carboxamide (103) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-leucine (1.07 g, 3.7 mmol), 
ferrocenylmethylamine (0.80 g, 3.7 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.7 mmol), N-hydroxysuccinimide (0.43 g, 3.7 mmol) and triethylamine (3 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.19 g, 11 %), mp: 144 –145 °C; 
 
I.R. υmax (neat): 3289, 3067, 2957, 1663, 1637, 1604, 1556, 1516, 1233, 1107, 1043 cm-1; 
 
UV-Vis λmax (CH3CN): 313, 429 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.72 (1H, d, J = 8.0 Hz, -CONH), 8.28 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.92 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.58 (1H, qt, J = 7.2 Hz, -NHCH), 4.18-4.15 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.08 (2H, t, J = 2 Hz, meta on η5-C5H4), 4.06-3.92 (2H, m, 
FcCH2), 1.76-1.62 {2H, m, -CHCH2CH(CH3)2}, 1.57-1.51 {1H, m, -CHCH2CH(CH3)2}, 0.96 {6H, 
dd, J = 4.0 and 8.0 Hz, -CHCH2CH(CH3)2}; 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.3(C=O), 162.9 (C=O), 151.2 (d, J = 166 Hz, -ArC3 & -
ArC5), 142.0 (t, J = 166 Hz, -ArC4), 130.3 (t, J = 4 Hz, -ArC1), 112.7(d, J = 12 Hz, -ArC2 & -ArC6), 
86.2 (Cipso η5-C5H4), 68.8 (η5-C5H5), 68.0 (Cortho η5-C5H4), 67.7 (Cmeta η5-C5H4), 52.0 (-NHCH), 37.4 
(FcCH2, -ve DEPT), 30.7 {-CHCH2CH(CH3)2, -ve DEPT}, 24.4 {-CHCH2CH(CH3)2 }, 23.1 {-
CHCH2CH(CH3)2}; 
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.0 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethyl-L-norleucine)-3,4,5-trifluorobenzene carboxamide (104) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-norleucine (1.07 g, 3.7 mmol), 
ferrocenylmethylamine (0.80 g, 3.7 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.58 g, 3.7 mmol), N-hydroxysuccinimide (0.43 g, 3.7 mmol) and triethylamine (3 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.24 g, 13 %), mp: 170-172 °C; 
 
I.R. υmax (neat): 3242, 3073, 2966, 1662, 1634, 1619, 1549, 1520, 1233, 1106, 1045 cm-1; 
 
UV-Vis λmax (CH3CN): 317, 430 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.69 (1H, d, J = 8.0 Hz, -CONH), 8.24 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.91 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.46 (1H, q, J = 7.2 Hz, -NHCH), 4.07-4.04 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.03 (2H, t, J = 2 Hz, meta on η5-C5H4), 3.99-3.94 (2H, m, 
FcCH2), 1.79-1.69 (2H, m, -CH2CH2CH2CH3), 1.36-1.24 (4H, m, -CH2CH2CH2CH3), 0.88 (3H, t, J 
= 7.3 Hz, -CH2CH2CH2CH3); 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.1(C=O), 163.1 (C=O), 151.4 (d, J = 166 Hz, -ArC3 & -
ArC5), 142.0 (t, J = 166 Hz , -ArC4), 130.3 (t, J = 4 Hz, -ArC1), 112.7 (d, J = 12 Hz, -ArC2 & -ArC6), 
86.1 (Cipso η5-C5H4), 68.3 (η5-C5H5), 67.5 (Cortho η5-C5H4), 67.2 (Cmeta η5-C5H4), 53.8 (-NHCH), 37.6 
(FcCH2, -ve DEPT), 31.3 (-CH2CH2CH2CH3, -ve DEPT), 27.9 (-CH2CH2CH2CH3, -ve DEPT), 21.8 
(-CH2CH2CH2CH3, -ve DEPT), 13.8 (-CH2CH2CH2CH3); 
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.0 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethyl-L-methionine)-3,4,5-trifluorobenzene carboxamide (105) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-methionine (0.28 g, 0.9 mmol), 
ferrocenylmethylamine (0.19 g, 0.9 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.14 g, 0.9 mmol), N-hydroxysuccinimide (0.10 g, 0.9 mmol) and triethylamine (1.5 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.06 g, 13 %), mp: 193 –194 °C; 
 
I.R. υmax (neat): 3281, 3074, 2919, 1669, 1637, 1619, 1559, 1517, 1232, 1106, 1043 cm-1; 
 
UV-Vis λmax (CH3CN): 318, 430 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 8.75 (1H, d, J = 8.0 Hz, -CONH), 8.25 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.90 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 4.55 (1H, qt, J = 7.2 Hz, -NHCH), 4.16-4.13 
(7H, m, η5-C5H5 and ortho on η5-C5H4), 4.04 (2H, t, J = 2 Hz, meta on η5-C5H4), 3.99-3.94 (2H, m, 
FcCH2), 2.51 (2H, t, J = 2.0 Hz, -CH2CH2SCH3), 2.12-1.93 (5H, m, -CH2CH2SCH3 and -
CH2CH2SCH3); 
 
13C NMR (100 MHz) δ (DMSO-d6): 171.0 (C=O), 163.8 (C=O), 151.3 (d, J = 166 Hz, -ArC3 & -
ArC5), 149.6 (t, J = 166 Hz , -ArC4), 130.9 (t, J = 4 Hz, -ArC1), 113.2 (d, J = 12 Hz, -ArC2 & -ArC6), 
86.6 (Cipso η5-C5H4), 68.8 (η5-C5H5), 68.0 (Cortho η5-C5H4), 67.7 (Cmeta η5-C5H4), 53.6 (-NHCH), 38.1 
(FcCH2, -ve DEPT), 31.9 (-CH2CH2SCH3, -ve DEPT), 30.5 (-CH2CH2SCH3, -ve DEPT), 15.1 (-
CH2CH2SCH3); 
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.0 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-3,4,5-trifluorobenzene carboxamide (106) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(3,4,5-trifluorobenzoyl)-L-(+)-α-phenylglycine (0.43 g, 1.4 mmol), 
ferrocenylmethylamine (0.30 g, 1.4 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.22 g, 1.4 mmol), N-hydroxysuccinimide (0.16 g, 1.4 mmol) and triethylamine (1.5 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.11 g, 15 %), mp: 201 –202 °C; 
 
I.R. υmax (neat): 3282, 2957, 1664, 1623, 1552, 1518, 1256, 1106 cm-1; 
 
UV-Vis λmax (CH3CN): 315, 416 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 9.16 (1H, d, J = 8.0 Hz, -CONH), 8.55 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.94 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 7.57 (2H, dt, J = 4.0 and 8.0 Hz, meta on -
CHC6H5), 7.40 (1H, tt, J = 4.0 and 8.0 Hz, ortho on -CHC6H5), 7.35 (1H, tt, J = 4.0 and 8.0 Hz, para 
on -CHC6H5), 5.74 (1H, d, J = 7.2 Hz, -NHCH), 4.15-4.07 (7H, m, η5-C5H5 and ortho on η5-C5H4), 
4.02 (2H, t, J = 2 Hz, meta on η5-C5H4), 3.97-3.92 (2H, m, FcCH2); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.9 (C=O), 156.8 (C=O), 144.6 (d, J = 166 Hz, -ArC3 & -
ArC5), 138.7 (t, J = 166 Hz , -ArC4), 136.5 (t, J = 4 Hz, -ArC1), 128.9, 128.3, 127.5, 113.1 (d, J = 
12 Hz, -ArC2 & -ArC6), 109.5, 86.6 (Cipso η5-C5H4), 69.0 (η5-C5H5), 68.8 (Cortho η5-C5H4), 67.7 (Cmeta 
η5-C5H4), 57.2 (-NHCH), 38.1 (FcCH2, -ve DEPT);  
 
19F NMR (376 MHz) δ (DMSO-d6): -134.3 (2F, dd, J = 22.6 and 7.5 Hz), -157.1 (1F, tt, J = 22.6 and 
7.5 Hz). 
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N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide (87) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(2,3,4,5,6-pentafluorobenzoyl)-glycine (0.37 g, 1.4 mmol), 
ferrocenylmethylamine (0.30 g, 1.4 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.22 g, 1.4 mmol), N-hydroxysuccinimide (0.16 g, 1.4 mmol) and triethylamine (1.5 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.19 g, 28.6 %), mp: 138 –139 °C (Lit 9: 138-140 °C); 
 
I.R. υmax (neat): 3309, 3067, 1693, 1653, 1559, 1506, 1223, 1107 cm-1; 
 
UV-Vis λmax (CH3CN): 327, 420 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 9.20 (1H, t, J = 7.6 Hz, -CONH), 8.20 (1H, t, J = 8.0 Hz, 
FcCH2NH), 4.20-4.17 (7H, m, η5-C5H5 and ortho on η5-C5H4), 4.10 (2H, t, J = 2.0 Hz, meta on η5-
C5H4), 4.05 (2H, d, J = 5.6 Hz, FcCH2), 3.96 (2H, d, J = 5.6 Hz, -NHCH2); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.3 (C=O), 165.1 (C=O), 156.9-156.8 (m, -ArC2), 156.6-
156.4 (m, -ArC6), 133.7-133.6 (m, -ArC4), 130.2-130.1 (m, -ArC3), 130.0-129.9 (m, -ArC5), 115.1 
(t, J = 12 Hz, -ArC1), 85.9 (Cipso η5-C5H4), 68.3 (η5-C5H5), 67.8 (Cortho η5-C5H4), 67.3 (Cmeta η5-C5H4), 
42.6 (-NHCH2-, -ve DEPT), 37.5 (FcCH2, -ve DEPT);  
 
19F NMR (376 MHz) δ (DMSO-d6): -141.5 (2F, dd, J = 22.6 and 7.5 Hz), -153.6 (1F, t, J = 22.6 Hz), 
-161.6 (2F, td, J = 22.6 and 7.5 Hz). 
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N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-pentafluorobenzene carboxamide (86) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(2,3,4,5,6-pentafluorobenzoyl)-L-alanine (0.40 g, 1.4 mmol), 
ferrocenylmethylamine (0.30 g, 1.4 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.22 g, 1.4 mmol), N-hydroxysuccinimide (0.16 g, 1.4 mmol) and triethylamine (1.5 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.20 g, 29.0 %), mp: 123 –125 °C (Lit 9: 123-125 °C); 
 
I.R. υmax (neat): 3286, 1653, 1621, 1559, 1506, 1373, 1260, 1105 cm-1; 
 
UV-Vis λmax (CH3CN): 314, 427 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 9.24 (1H, t, J = 7.2 Hz, -CONH), 8.32 (1H, t, J = 8.0 Hz, 
FcCH2NH), 4.57 (1H, q, J = 7.2 Hz, -NHCH), 4.19-4.16 (7H, m, η5-C5H5 and ortho on η5-C5H4), 
4.12 (2H, t, J = 2.0 Hz, meta on η5-C5H4), 4.15-4.05 (2H, m, FcCH2), 1.32 {3H, d, J =7.2 Hz, -
CH(CH3)};  
 
13C NMR (100 MHz) δ (DMSO-d6): 170.6 (C=O), 164.9 (C=O), 163.6-163.5 (m, -ArC2), 162.9-
162.6 (m, -ArC6), 136.6-136.5 (m, -ArC4), 130.2-130.1 (m, -ArC3), 129.8-129.7 (m, -ArC5), 115.3 
(t, J = 12 Hz, -ArC1), 86.2 (Cipso η5-C5H4), 68.3 (η5-C5H5), 67.5 (Cortho η5-C5H4), 67.2 (Cmeta η5-C5H4), 
49.8 (-NHCH), 37.4 (FcCH2, -ve DEPT), 18.4 (-CH3); 
 
19F NMR (376 MHz) δ (DMSO-d6): -141.4 (2F, dd, J = 22.6 and 7.5 Hz), -153.1 (1F, t, J = 22.6 Hz), 
-161.5 (2F, td, J = 22.6 and 7.5 Hz). 
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N-(ferrocenylmethyl-L-(+)-α-phenylglycine)-2,3,4,5,6-pentafluorobenzene carboxamide (107) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(2,3,4,5,6-pentafluorobenzoyl)-L-(+)-α-phenylglycine (1.45 g, 4.2 
mmol), ferrocenylmethylamine (0.90 g, 4.2 mmol), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (0.65 g, 4.2 mmol), N-hydroxysuccinimide (0.48 g, 4.2 mmol) and 
triethylamine (3 ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: 
hexane) to give the title compound as a yellow solid (0.27 g, 12 %), mp: 207 –209 °C; 
 
I.R. υmax (neat): 3257, 2926, 1669, 1631, 1549, 1519, 1045 cm-1; 
 
UV-Vis λmax (CH3CN): 316, 416 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 9.82 (1H, d, J = 8.0 Hz, -CONH), 8.70 (1H, t, J = 8.0 Hz, 
FcCH2NH), 7.55 (2H, dd, J = 4.0 and 8.0 Hz, ArH), 7.43 (2H, dd, J = 4.0 and 8.0 Hz, meta on -
CHC6H5), 7.35 (1H, dt, J = 4.0 and 8.0 Hz, ortho on -CHC6H5), 7.35 (1H, tt, J = 4.0 and 8.0 Hz, 
para on -CHC6H5), 5.80 (1H, d, J = 7.2 Hz, -NHCH), 4.14-4.02 (9H, m, η5-C5H5, ortho on η5-C5H4 
and meta on η5-C5H4 ), 3.97-3.95 (2H, m, FcCH2); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.9 (C=O), 156.8 (C=O), 144.6 (Cq), 143.0-142.9 (m, -ArC2), 
142.5-142.2 (m, -ArC6), 140.9-140.5 (m, -ArC4), 138.3-137.9 (m, -ArC3), 136.6-136.2 (m, -ArC5), 
128.9, 128.3, 127.5, 113.1 (t, J = 12 Hz, -ArC1), 86.4 (Cipso η5-C5H4), 69.0 (η5-C5H5), 68.8 (Cortho η5-
C5H4), 67.7 (Cmeta η5-C5H4), 57.2 (-NHCH), 38.1 (FcCH2, -ve DEPT);  
 
19F NMR (376 MHz) δ (DMSO-d6): -141.8 (2F, dd, J = 22.6 and 7.5 Hz), -153.6 (1F, t, J = 22.6 Hz), 
-162.0 (2F, td, J = 22.6 and 7.5 Hz). 
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N-(ferrocenylmethyl-glycine-glycine)-2,3,4,5,6-pentafluorobenzene carboxamide (108) 
 
 
 
The synthesis followed that of N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 
using the following reagents: N-(2,3,4,5,6-pentafluorobenzoyl)-glycine-glycine (1.37 g, 4.2 mmol), 
ferrocenylmethylamine (0.90 g, 4.2 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.65 g, 4.2 mmol), N-hydroxysuccinimide (0.48 g, 4.2 mmol) and triethylamine (3 
ml). The product was purified by column chromatography (eluent 2:1 ethyl acetate: hexane) to give 
the title compound as a yellow solid (0.35 g, 16 %), mp: 221 –223 °C; 
 
I.R. υmax (neat): 3352, 3239, 3057, 2924, 1693, 1649, 1537, 1500, 1223, 1106 cm-1; 
 
UV-Vis λmax (CH3CN): 329, 426 nm; 
 
1H NMR (400 MHz) δ (DMSO-d6): 9.16 (1H, t, J = 7.2 Hz, -CONH), 8.28 (1H, t, J = 8.0 Hz, 
FcCH2NH), 8.01 (1H, t, J = 7.2 Hz, -CONH), 4.19-4.17 (7H, m, η5-C5H5 and ortho on η5-C5H4), 
4.09 (2H, t, J = 2.0 Hz, meta on η5-C5H4), 4.03-4.00 (4H, m, FcCH2 and -NHCH2), 3.78 (2H, d, J = 
5.6 Hz, -NHCH2); 
 
13C NMR (100 MHz) δ (DMSO-d6): 168.5 (C=O), 168.4 (C=O), 147.5 (C=O), 145.3-145.0 (m, -
ArC2), 144.3-144.2 (m, -ArC6), 141.6-141.3 (m, -ArC4), 136.6-136.3 (m, -ArC3), 136.2-136.0 (m, -
ArC5), 112.7 (t, J = 12 Hz, -ArC1), 86.4 (Cipso η5-C5H4), 68.8 (η5-C5H5), 68.4 (Cortho η5-C5H4), 67.7 
(Cmeta η5-C5H4), 42.9 (-NHCH2, -ve DEPT), 42.5 (-NHCH2, -ve DEPT), 38.1 (FcCH2, -ve DEPT); 
 
19F NMR (376 MHz) δ (DMSO-d6): -141.4 (2F, dd, J = 22.6 and 7.5 Hz), -153.1 (1F, t, J = 22.6 Hz), 
-161.6 (2F, td, J = 22.6 and 7.5 Hz). 
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Chapter 5 
Biological evaluation of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides 
5.1. Introduction 
 
A preliminary structure-activity relationship (SAR) study of N-(ferrocenylmethyl) fluorinated 
benzene carboxamide derivatives was conducted by Kenny’s research group, N-(ferrocenylmethyl-
L-alanine)-3,4,5-trifluorobenzene carboxamide 28, N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-
pentafluorobenzene carboxamide 86 and N-(ferrocenylmethylglycine)-2,3,4,5,6-pentafluorobenzene 
carboxamide 87 were reported as the most active ones, with an IC50 value as 2.84 ± 0.10, 10.3 ± 0.12 
and 11.1 ± 0.12 μM in MCF-7 cells after 6 days treatment . 1 2  As a further SAR and biological 
evaluation study, a series of 3,4,5-trifluoro and 2,3,4,5,6-pentafluoro analogues were synthesized 
with various amino acids and dipeptides.  
 
As discussed in chapter 3, several miniaturised in vitro colorimetric assays have been developed for 
the quantification of cell growth. There are a number of factors should be considered when carrying 
out in vitro toxicity tests, including the cell line being used in the particular assay has a suitable level 
of sensitivity, cell number analysed is within a sufficient range, and choose the best system for the 
analysis of cell number under the certain experimental conditions.  
 
The aims of this research project were to optimize the conditions used in the acid phosphatase assay 
for N-(ferrocenylmethyl) fluorinated benzene carboxamide derivatives and extend the SAR study of 
this class of compounds. Compound 28, 86 and 87 were used for acid phosphatase assay’s 
development. Parameters (i.e. cell number, concentration of DMSO and incubation time against test 
compounds) were analyzed. It was thought that higher accuracy will be achieved by improving 
sensitivity. This screening was performed in collaboration with Dr. Rosaleen Devery, of the School 
of Biotechnology, Dublin City University. Now the preliminary screening and in vitro toxicity tests 
for the newly synthesised ferrocenyl carboxamide derivatives are carried out in collaboration with 
Dr. Patricia González-Barranco and Dr. Mónica A. Ramírez-Cabrera of the School of Chemical 
Sciences, Universidad Autónoma de Nuevo León, México, and Karen G. Ontiveros-Castillo of the 
School of Chemical Sciences, Dublin City University.  
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5.2. Acid phosphatase assay development and optimization 
 
The acid phosphatase assay was the chosen colorimetric end-point assay for the in vitro biological 
evaluation of this study. A distinct advantage the acid phosphatase assay has over other cytotoxicity 
assays is in its simplistic protocol. Once alkaline conditions are introduced, the plates are set to be 
read directly. Fewer steps in this semi-automated assay reduces the possibility of human error. The 
assay also requires less reagents, is less expensive and has better reproducibility. The sensitivity is 
high, but as a consequence, it has a low range of linearity between optical density and cell number. 
Therefore, a few parameters were considered in assay’s optimization. 3  
 
5.2.1. The relationship between cell number and optical density in acid phosphatase assay 
against MCF-7 cell line in different time range 
 
 
 
Figure 5.1: The acid phosphatase activity against MCF-7 cells after 24 hours. Error bars represent 
the standard deviation of triplicate experiments. 
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Figure 5.2: The acid phosphatase activity against MCF-7 cells after 72 hours. Error bars represent 
the standard deviation of triplicate experiments. 
 
 
Figure 5.1 and 5.2 show the linear relationship between assay duration and O.D. after 24 to 72 hours 
in MCF-7 cell line, over a complete range of cell densities (0-10,000 cells per 100 µL). To investigate 
the effect time had on the linear relationship between acid phosphatase activity and cell number. A 
10,000 cells per 100 µL stock solution was serially diluted to represent a 0-10,000 cell population in 
each respective well. Results show that the acid phosphatase activity, after 24 and 72 hours, is a 
function of MCF-7 cell number. Overall it appeared that while increased incubation time improved 
assay sensitivity, the linearity did not generally suffer, as the assay was still linear to high cell 
densities. Therefore, the sensitivity of the assay was upheld across differing time points. From these 
results, 1000 cells per well are used for further in vitro proliferation assays. 
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5.2.2. DMSO tolerance study in acid phosphatase assay against MCF-7 cell line 
 
 
 
Figure 5.3: Percentage cell viability between 0 and 1.5 μM DMSO on MCF-7 cell line after 48 hours. 
Error bars represent the standard deviation of triplicate experiments. 
 
 
DMSO tolerance is a common factor considered into toxicity assays. 4 5 Ferrocenyl derivatives have 
limited solubility other than DMSO. Therefore, it is important to ascertain whether or not DMSO, in 
concentrations likely to be encountered, causes any significant interference in the acid phosphatase 
assay (e.g., by affecting enzyme activity or product fluorescence). An increasing increment of 0.075% 
DMSO was applied in the range of 0-1.5%. The dose response curve was plotted after 72 hours 
incubation time in a 37ºC, 5% CO2 incubator. Plates were seeded for treatment at a cell density of 
1000 cells per well. Control cells were untreated in media with a cell density of 1000 cells per well.   
 
As can be seen in Figure 5.3, concentrations of DMSO is a function of percentage cell viability 
against MCF-7 cells. Clearly, the effect of DMSO on MCF-7 is too strong with 0.4% or higher, thus 
the DMSO level are maintained as 0.25% for further in vitro cytotoxicity investigation. 
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5.3. IC50 value determination of N-(ferrocenylmethylamino acid)-fluorinated benzene 
carboxamides in MCF-7 cell line after 24, 48 and 72 hours 
 
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 28, N-(ferrocenylmethyl-L-
alanine)-2,3,4,5,6-pentafluorobenzene carboxamide 86 and N-(ferrocenylmethylglycine)-2,3,4,5,6-
pentafluorobenzene carboxamide 87 were tested against MCF-7 breast cancer cells to find the 
relationship between incubation time and IC50 results. To determine the IC50 values of the target 
compounds, individual 96-well plates containing MCF-7 cells were treated with the N-
(ferrocenylmethylamino acid)-fluorinated benzene carboxamides at concentrations ranging from 
0.25 to 50 μM. The endpoint of the growth inhibition was evaluated by the acid phosphatase assay 
after 24, 48 and 72 hours. The IC50 value for each compound was calculated using Calcusyn software, 
and standard deviations have been calculated using data obtained from three independent 
experiments.  
 
 
Table 3.7: IC50 values for selected compounds in the MCF-7 cell line after 24, 48 and 72 hours. 
  
Assay time (hours) Compound No. IC50 values (μM) 
 
24 
28 0.86 ± 0.02 
86 2.41 ± 0.05 
87 3.71 ± 0.05 
 
48 
28 0.53 ± 0.01 
86 1.43 ± 0.03 
87 2.06 ± 0.34 
 
72 
28 0.57 ± 0.03 
86 0.76 ± 0.02 
87 2.19 ± 0.04 
 
 
  
185 
 
 
 
 
 
Figure 5.4: IC50 plot for compound 28, 86 and 87 in MCF-7 cell line after 24 hours growth. 
 
 
 
 
 
Figure 5.5: IC50 plot for compound 28, 86 and 87 in MCF-7 cell line after 48 hours growth. 
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Figure 5.6: IC50 plot for compound 28, 86 and 87 in MCF-7 cell line after 72 hours growth. 
 
 
All N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides were shown to exert an anti-
proliferative effect in the MCF-7 cell line. In general, the longer the breast cancer cells exposed to 
the test compounds, the lower the IC50 values are. For example, the IC50 dramatically decreased from 
2.41 to 1.43 and 0.76 μM after 24, 48 and 72 hours test point for N-(ferrocenylmethyl-L-alanine)-
2,3,4,5,6-pentafluorobenzene carboxamide 86. The IC50 results are 3.71 (24 hours), 2.06 (48 hours) 
and 2.19 (72 hours) μM for compound 87. The strongest cell growth inhibitions were found for 
compound N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide 28 at all test points. 
Initially, the IC50 value dropped from 0.86 to 0.53 μM, and increased slightly to 0.57 μM. Butler et 
al reported the IC50 values belong to compound 28, 86 and 87, as 2.84 ± 0.10, 10.3 ± 0.12 and 11.1 
± 0.12 μM in MCF-7 cells after 6 days treatment. After optimization, lower IC50 values were obtained 
with smaller standard deviation between 24 to 72 hours’ time frame. Therefore, optimization of the 
acid phosphatase assay has positive effect on IC50 determination. 
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5.4. Conclusion 
 
A series of N-(ferrocenylmethylamino acid)-fluorinated benzene carboxamides have been prepared 
and evaluated for their biological activities. Compound 28, 86 and 87 were selected for optimization 
of the acid phosphatase assay. A few parameters were optimized and found: the effect time have a 
linear relationship between acid phosphatase activity and cell number; 0.25% DMSO had negligible 
effects on the cell viability. Therefore, 1000 cell per well and 0.25% DMSO were used for further in 
vitro proliferation investigation. All selected carboxamides were shown to exert an anti-proliferative 
effect against the MCF-7 cell line. Found that longer the breast cancer cells exposed to the test 
compounds, the lower the IC50 values obtained. After optimization, lower IC50 values with smaller 
standard deviation were obtained after 24, 48 and 72 hours. Therefore, optimization of the acid 
phosphatase assay has positive effect on IC50 determination. 
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Materials and Methods 
Cells and cell culture 
 
Cell culture media, supplements and related solutions were purchased from Sigma-Aldrich (Dublin, 
Ireland) unless otherwise stated. The MCF-7 breast cancer cell line was obtained from the Health 
Protection Agency. The cells were grown in modified eagles’ medium with 5 % foetal bovine serum 
(FBS). Cell lines were grown as a monolayer culture at 37 °C, under a humidified atmosphere of 95 % 
O2, and 5 % CO2 in 75 cm2 flasks. All cell culture work was carried out in a class II laminar airflow 
cabinet (Holten LaminAir). All experiments involving cytotoxic compounds were conducted in a 
cytoguard laminar airflow cabinet (Holten LaminAir Maxisafe). Before and after use the laminar 
airflow cabinet was cleaned with 70 % industrial methylated spirits (IMS). Any items brought to the 
airflow cabinet were swabbed using IMS. At any one time, only one cell line was used in the laminar 
airflow cabinet and after completion of work with the cell line, the laminar airflow cabinet was 
allowed stand for 15 minutes before use. This was to eliminate any possibility of cross contamination 
between cell lines. The Laminar Airflow was cleaned daily with industrial disinfectants (Virkon or 
Tego) and also with IMS. These disinfectants were alternated fortnightly. Cells were fed with fresh 
media or subcultured when confluency reached 70 % in order to maintain active cell growth. 
 
 
Subculture techniques of cell lines 
 
Media and Trypsin/EDTA solution (0.25 % trypsin (Gibco), 0.01 % EDTA (Sigma Aldrich) solution 
in PBS) were incubated at 37 °C for 20 min in a water bath. The cell culture medium was removed 
from the tissue culture flask and discarded into a sterile bottle. The flask was rinsed with PBS (7 ml) 
to ensure the removal of any residual media. Once removed to a sterile waste bottle, fresh 
trypsin/EDTA solution (4 ml) was added and incubated at 37 °C until all the cells were detached 
from the inside surface of the tissue culture flask. The trypsin was deactivated by adding PBS (6 ml). 
The cell suspension was removed from the flask and placed in a sterile universal container and 
centrifuged at 2000 rpm for 5 minutes. The supernatant was removed and discarded from the 
universal container and the pellet was suspended in complete medium. A cell count was performed. 
Depending on number of tests, an aliquot of cells was used to reseed a flask at the required density, 
topping up the flask with fresh medium. 
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Assessment of cell number 
 
Cells were trypsinised, pelleted and resuspended in media. An aliquot (10 μL) of the cell suspension 
was applied to a universal vial and dye was added. This was applied to the chamber of a glass cover 
slip enclosed haemocytometer. Cells in the 16 squares of the four grids of the chamber were counted. 
The average cell number, per 16 squares, was multiplied by a factor of 104 and the relevant dilution 
factor to determine the number of cells per ml in the original cell suspension. 
 
 
In vitro proliferation assays 
 
Confluent cells in the exponential growth phase were harvested by trypsination and a cell suspension 
of 5 x 104 cells/ml was prepared in fresh culture medium. The cell suspension (40 μL) was added to 
a flat bottom 96 well plate (Costar 3599), followed by culture medium (60 μL). The plate was slightly 
agitated in order to ensure complete dispersion of the cells. The cells were incubated for an initial 24 
hours in a 37 °C, 5 % CO2 incubator to allow the adhesion of cells to flat bottom wells. The 
compounds for testing were prepared in 1 μM stocks. The different concentrations used for IC50 data 
studies were made up accordingly by adding the desired amount of compound stock solution to fresh 
culture media. Once the compounds and media were added to the 96 well flat bottom plates, the plate 
was gently agitated and incubated at 37 °C, 5 % CO2. Following an incubation period of 24, 48 and 
72 hours, drug media was removed from the 96-well plate and each well was washed with 100 μL of 
PBS. This was removed and 100 μL of freshly prepared phosphatase substrate (10 mM p-nitrophenol 
phosphate in 0.1M sodium acetate, 0.1% triton X-100, pH 5.5) was added to each well. The plate 
was incubated at 37 °C for 2 hours. The enzymatic reaction was stopped upon addition of 1M NaOH 
(50 μL) to each well. The absorbance of each well was read in a dual beam reader (Synergy HT, Bio- 
Tek, USA) at 405 nm with a reference wavelength of 620 nm. 
 
Assessment of cell survival in the presence of test sample was determined by the acid phosphatase 
assay. For the IC50 data studies, the concentration of drug that causes 50 % growth inhibition was 
determined by plotting the percentage (%) survival of cells (relative to control cells) against the 
concentration of the test sample. In relation to IC50 data studies, IC50 values were calculated using 
Calcusyn software (Biosoft, UK). 
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Statistical Analysis 
 
IC50 values were calculated using CalcuSyn Software (BioSoft). Student t-test (two tailed with 
unequal variances) was used to compare the activity of test compounds to their corresponding control 
group, and p-value < 0.05 was considered. 
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